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Die Fehldiagnose der Borreliose bleibt noch immer ein relevantes Problem. Große 
Auseinandersetzungen über die Definition und Ursachen des chronischen Verlaufs der Krankheit sind 
noch immer aktuell. Die nur geringe Anzahl an Borrelien in Patientenproben erschwert den direkten 
Nachweis des Krankheitserregers. Aus diesem Grund basieren diagnostische Tests auf indirekten 
Nachweismethoden. Der beste und einzig offiziell anerkannte Test zur Unterstützung der Diagnose 
der Borreliose bleibt der Nachweis von spezifischen Antikörpern. Obwohl heutige Versionen sehr 
gut optimiert wurden und ziemlich zuverlässig sind, ermöglichen es diese Tests nicht, eine akute von 
einer geheilten Krankheit zu unterscheiden. Wegen ihrer Spezifität für Antigene sind B Zellen sehr 
interessante Kandidaten für neue Biomarker. Im Gegensatz zu den Antikörpern, die noch lange nach 
dem Immunkontakt nachweislich bleiben können, sollten die B Zellen nur während einer akuten 
Infektion erhöht sein. Das Ziel dieser Studie war es zu zeigen, dass durch Borrelien hervorgerufene 
B Zellen im peripheren Blut von akuten Patienten nachweislich sind, und zu testen, inwiefern 
ähnliche Zellen in verschiedenen Patienten vorkommen. Unsere Resultate stimmen mit denen von 
anderen Studien überein und zeigen, dass im Vergleich zu zufällig gewählten Individuen eine größere 
Wahrscheinlichkeit besteht, überlappende B Zell Klone zwischen Patienten, die dem gleichen Immun 
Stimulus ausgesetzt waren, zu finden. Obwohl wir die Patienten an unterschiedlichen Zeitpunkten 
untersucht haben, konnten wir eine größere Überlappung zwischen unseren Patienten feststellen. 
Unsere Daten zeigen allerdings, dass die überlappenden Klone in sehr unterschiedlichem Ausmaß in 
den verschiedenen Patienten vorkommen. Die Klone, die in den einzelnen Proben dominierten, waren 
eher Patienten spezifisch. Dies stimmt ganz gut mit der dynamischen Natur der B Zell Immunantwort 
überein. Da das Auftreten von identischen B Zell Rezeptor Sequenzen in verschiedenen Patienten 
eher selten war, wollten wir testen, ob weniger restriktive Gruppierungskriterien es ermöglichen, 
Sequenzen in Kategorien nach der gleichen Epitop Reaktivität einzuteilen. Es stellte sich heraus, dass 
die Sequenzen wahrscheinlich zu unterschiedlich sind, als dass Sie in Gruppen mit der gleichen 
Epitop Reaktivität eingeteilt werden können. Um dies zu erreichen müssen ausgefeiltere 
bioinformatische Skripte entwickelt werden. Diese müssten Mutationen an Schlüsselstellen in der 
Antikörpersequenz sowie die dreidimensionale Struktur des Antikörpermoleküls mit einbeziehen. 




erwartet. Es wird wahrscheinlich nicht möglich sein, ein paar Schlüssel CDR3 Aminosäure 
Sequenzen zu isolieren. Wir erwarten uns eher eine Liste an verschiedenen Borrelia-spezifischen B 
Zell Klonen, die durch Einzelmutationen an Schlüsselstellen von Klonen anderer Reaktivität 
unterscheidbar sind. Wegen der Polyspezifität und der dynamischen Natur der B Zell Immunantwort 
wird wahrscheinlich eine Kombination von verschiedenen Klonen gleichzeitig nachgewiesen werden 
müssen. Das Matchen von B Zell Klonen mit ihren jeweiligen Antigenen, zusammen mit der Analyse 
vorkommender Mutationen und des B Zell Rezeptor Isotyps, sowie die phylogenetische 
Verwandtschaft der einzelnen Sequenzen dieser Klone hat das Potenzial, laufende (primäre und 
sekundäre) von vergangenen oder autoimmun Reaktionen zu unterscheiden. Dies könnte sehr 









Misdiagnosis of acute Lyme disease still remains a huge problem. Also many debates are going on 
about the definition and underlying causes of the chronic course of this disease. Due to the scarcity 
of Borrelia in patient samples, direct detection of the pathogen is challenging. Diagnostic laboratories 
need to work with indirect approaches to prove the presence of Borrelia inside patients. The best and 
currently only accepted test to support the diagnosis of acute Lyme disease infection is the detection 
of Borrelia-reactive antibodies. Although extensive optimization has led to the development of 
specific and quite reliable tests to prove the presence of these molecules, they have the limitation that 
they do not enable to directly distinguish an ongoing from a previous infection. Since B cells are the 
cells of our immune system that react most specifically to immune challenges, they are very 
interesting candidates to be explored for biomarker research. As opposed to the antibodies, which can 
stay in peripheral blood for prolonged times even after clearance of the infection, Borrelia-reactive 
B cells should only be elevated when the pathogen is present. The main goal of this study was to 
prove the presence of Borrelia-reactive B cells in peripheral blood of acute Lyme disease patients 
and to assess to what extent expanded clones overlap between patients. Our results are in line with 
other B cell repertoire studies, indicating that individuals that have been challenged with the same 
immune stimulus have a higher chance to present overlapping clones as compared to other randomly 
selected donors. Since we were not able to use precise timepoints in the case of acute disease, it was 
quite surprising to find an increased overlap of B cell clones in our patients. Our data indicate, that 
overlapping clones appear at heterogeneous levels between donors. Rather patient unique B cell 
clones are predominating individual repertoires. This is in accordance with the rather dynamic nature 
of B cell immune responses. Since the occurrence of identical B cell receptor sequences in different 
patients was a rare event, we explored whether sequence clustering using less stringent parameters 
would allow to extract B cell clones reacting towards the same epitope. Differences in sequences 
between clones were however too large to allow reliable grouping of sequences according to epitope-
reactivity. For this purpose, more sophisticated bioinformatics clustering tools need to be developed. 
Those need to take mutations at key residues and three dimensional structures of antibody molecules 
into account. From our findings, we conclude, that B cell repertoire signatures might be more complex 




candidates, but we will end up with a rather large list of Borrelia-reactive B cell clones that can be 
distinguished from B cells reactive towards other antigens by the presence of single key mutations. 
The polyspecific and dynamic nature of the B cell immune response will probably require to prove 
the presence of certain combinations of clones. Matching of B cell clones with their corresponding 
antigens and analysis of mutation levels, isotypes and phylogenetic relationships among sequences 
from these clones has the potential to allow to distinguish ongoing (primary and secondary) from past 
immune responses and autoimmune diseases. This might help to solve some of the controversies 









1.1 The B cell immune response 
 
As opposed to T cells, which only indirectly recognize processed antigens presented on MHC 
molecules, B cells recognize antigens directly through their B cell receptor. In the course of the 
immune response, B cells even further optimize their unique B cell receptor for antigen binding. 
These properties make B cells highly interesting candidates to explore as new biomarkers of acute 
infections [4]. Their usefulness in this regard has already been demonstrated by the frequent use of 
antibodies to support the diagnosis of diseases [5]. 
 
1.1.1 Diversification and selection of B cell receptors during B cell development 
 
Each B cell expresses a more or less unique B cell receptor on its surface, which allows for specific 
recognition of virtually any non-self structure. The B cell receptor is composed of heavy (H) and light 
(L) chain, each one containing three variable complementarity determining regions (CDRs) [6,7]. 
Those are the major sites of antigen recognition. Mature naïve B cells are generated throughout life 
from hematopoietic stem cells in the bone marrow [8,9]. The great diversity of their B cell receptors 
is generated during development by genetic recombination of variable (V), diversity (D) and joining 
(J) gene segments [10] (Figure 1). Imprecise joining between the segments as well as nucleotide 
insertions at the junctions of mainly the heavy chain further increase diversity of the receptor [10]. 
The CDR1 and CDR2 regions of both heavy and light chains are encoded within the V genes, while 
the CDR3s form the combination sites between VDJ on the heavy chain and VJ on the light chain. 
The CDR3 of the heavy chain (CDRH3) is the most variable part of the antibody and therefore most 
likely responsible for the specificity of antigen recognition [11]. For this reason many studies focus 






Figure 1: Recombination of gene segments during B cell development allows to generate the 
great diversity of B cell receptors that form the naïve repertoire. 
 
V(D)J recombination is not a totally stochastic process, as a similar bias in gene segment usage can 
be observed between individuals and at different timepoints [12,13]. Genetic factors seem to 
influence gene segment frequencies within the final naïve B cell repertoire, as V and D segment-use 
profiles are shared to a greater extent between twins than among unrelated individuals [14]. The 
CDRH3 sequence composition of B cell repertoires is however rather personal, even for individuals 
with identical genetic background [14]. Although they did not cover the whole B cell repertoire with 
their technique, the authors from this study conclude, that the system is able to generate a greater 
diversity than can be represented by the actual circulating B cells [14]. This would indicate, that even 
individuals with the same genetic background might react differently to common antigenic challenges 
[14]. Although V and D segment usage is biased, the joining of V, D and J gene segments [14] as 
well as heavy and light chain pairing [15,16] seem to follow a stochastic linkage according to their 
abundance in the final repertoire.  
 
Not all the rearrangements are retained within the final naïve B cell repertoire. From deep sequencing 
data it could be inferred, that 69% of the initially rearranged IgH sequences are deleted from the 
repertoire of the final naïve B cells, with a selection against sequences containing long CDRH3s and 
hydrophobic patches [17]. These characteristics have been associated with autoantibodies but broadly 
neutralizing HIV antibodies containing such features have also been found [17]. This could be an 





As for many other body functions, also the human B cell immune response is affected by ageing 
[18,19]. The frequency of autoantibodies increases with age [19]. Furthermore, a poor health status 
of elderly could be associated with a reduction in B cell repertoire diversity [20]. Since peripheral 
blood is composed of several different B cell subsets, a deeper analysis is required to completely 
understand this phenomenon [21,22]. 
 
1.1.2 Different B cell subsets with specialized functions 
 
Several studies estimated the number of B cells that are circulating within the human body with 
varying numbers [23-25]. These slight discrepancies between studies are probably due to the 
biological differences between individuals. It is estimated that of the 1011 B cells in the human body 
[26], on average 2x109 [24,25] with a median of 3.1x108 [23] are circulating within the peripheral 
blood. Furthermore it has been estimated, that the latter B cell subpopulation is composed of 2-9x106 
different CDRH3 sequences [27]. The naïve B cells (CD27-IgM+IgD+), which have never 
encountered an antigen, make up 60-70% of the peripheral blood B cells [22]. In the absence of 
antigenic stimulation they die after several days of circulation between blood and lymphoid tissues, 
so that they need to be continuously replenished from the bone marrow with a considerable turnover 
over time [22]. The remaining B cells that are patrolling our body can be subdivided into several 
experienced and/or specialized B cell subsets [28].  
 
Based on findings from mouse studies, B cell antigens have initially been subdivided into T cell 
dependent (TD) and T cell independent (TI), with a corresponding subdivision of mature B cells into 
three major subsets [29,30]. Follicular B cells - which can also respond to TI antigens - are giving 
rise to long-term memory B cells and antibody secreting plasma cells in response to protein antigens 
that elicit strong TD germinal center responses. Marginal zone B cells and B1 cells on the other hand 
respond more rapidly to TI antigens and are thought to give a first line of defence until the more 
specific germinal center response is taking over. TI antibody responses have further been subdivided 
into TI type 1 and TI type 2, with the former being induced by B cells that have been activated through 
Toll-like receptor (TLR) signaling. The latter are induced by antigens containing highly repetitive 
elements, which activate B cells through extensive crosslinking of their B cell receptor. This shows, 




and differentiation pathways, which can be influenced by the nature, the concentration and the 
location of the antigen [30,31]. Both innate and adaptive immune cells can influence the outcome of 
B cell immune responses [30,32,33], but also the B cells themselves can take over regulatory 
functions [34,35]. For this reason, this rather simple classification of B cells into these different 
subsets has recently been challenged [30]. Since pathogens are composed of a mixture of antigens of 
different natures, the B cell response towards these immune stimuli is very likely composed of a 
mixture of different pathways.  
 
Important to consider are also differences between the B cell immune systems of mice and humans, 
which means that findings in the mouse model always need validation before being considered also 
true for the human situation [36]. As opposed to mouse B cells, human B cells for example do not 
respond directly to lipopolysaccharides (LPS) [37]. All attempts to find the human counterpart to 
mouse B1 cells - which are thought to arise from a different origin than marginal zone and follicular 
B cells (collectively also referred to as B2 cells) and are mainly found in peritoneal and pleural 
cavities from which they secrete natural antibodies in the absence of antigen - failed so far [38-41]. 
There is evidence, that the most recently proposed human counterpart (CD20+CD27+CD43+CD70-) 
[38] actually represents B cells that are in a pre-plasmablast stage rather than B1 cells[41], however 
the debate about these cells is still ongoing [42]. Although CD27 was found to be a good marker for 
memory B cells in humans [43], the mouse field had more difficulties to find mouse markers that 
clearly distinguish mutated from unmutated B cells [44]. For splenic marginal zone B cells (sMZcs) 
– which play a major role in the response to blood-borne pathogens – the human counterpart is also 
still not clearly defined and controversially discussed. As opposed to the mouse, these cells harbour 
mutated V genes and recirculate between blood and the spleen [24,28,45]. Currently it is 
hypothesized, that the human sMZcs arising early in life are probably generated in an antigen-
independent manner to form the pre-immune B cell repertoire, but that later in life, these cells 
predominantly arise from antigen specific germinal center responses [28,45]. 
 







Table 1: List of important B cell markers used in this study to analyze B cell subpopulations. 
Marker Description 
CD19 Pan-B cell marker [22,46] 
CD20 Pan-B cell marker not expressed on plasmablasts/plasma cells [22] 
CD27 Memory B cell marker highly expressed on plasmablasts/plasma cells [46] 
IgD 
Together with CD27 allows to distinguish naïve B cells and non-switched 
memory B cells from classical memory B cells[46,47]; an association was 
made between CD27-IgD- B cell numbers and systemic autoimmunity as well 
as chronic infections [47] 
IgM/ IgG Allow to determine isotype expressed on memory B cells [46] 
CD38 Expressed at high levels on plasmablasts and plasma cells [46] 
CD138 Marker for plasma cells [46] 
CD23 Activation marker; involved in T-B cell interactions [22,48] 
CD5 Initially thought to be the marker for the human counterparts of mouse B1 
cells, it is now known that this marker is expressed on a wide number of 
different B cell populations [49]; CD5 is also expressed on malignant B cells 
[50] 
CD10 Marker that is expressed on transitional B cells [51] and on germinal center 
(founder) B cells [52] 
CD24 Combined with CD38 this marker allows to distinguish transitional B cells 
from mature naïve B cells [47]  
CD43 This marker was shown to be expressed on the human counterpart to mouse 
B1 cells [38,49] but more recently this view was challenged and it was 
proposed that CD43+ cells are rather B cells that entered a pre-plasmablast 
stage [41] 
CD21 It was found that CD21lowCD38low B cells might play a role in autoimmune 
diseases and immunodeficiencies [47] 
 





Proteins capable of activating both T helper cells and B cells elicit highly specific germinal center 
responses [53,54] which allow the generation of long term protective memory (Figure 2). While it is 
important to keep in mind that other pathways exist [30,55], due to their optimization for binding to 
the antigen, B cells generated by germinal center responses are most interesting for biomarker 
research. Inside these structures, selected B cells undergo several rounds of B cell receptor somatic 
hypermutation (103 per base pair per generation versus 106 under normal conditions with cell cycle 
times of 6-12 hours) and affinity selection to modify their receptor for a better recognition of the 
antigen[54]. These processes are responsible for the increase in serum antibody affinities that have 
been observed to occur over the course of immune responses [56-58]. Although B cell receptor 
mutations can be found all over the sequences, they seem to be targeted to hot-spot motifs (cold-spot 
motifs also exist) [59], an information that can be very useful for the interpretation of B cell receptor 
sequencing results [60]. Due to easier accessibility of lymphoid tissues and the possibility of genetic 
manipulations, a detailed understanding of germinal center responses could be obtained mainly 
through animal experiments.  
 
Since the generation of highly specific antibodies is rather a slow process – requiring the 
establishment of germinal center structures in which several rounds of somatic hypermutation and 
selection occur -, at initial stages of the immune response a large fraction of activated B cells directly 
differentiates into short lived extrafollicular plasma cells [61-65]. Both a higher affinity of the B cell 
receptor for the antigen but also a higher epitope abundance preferentially induce B cells to undertake 
this initial short-term plasma cell pathway [64,65]. Within the first week of the response, these 
unmutated cells expand in the lymphoid tissues and give rise to a first line of defence until the more 
specific and long-lived plasma cells generated in the germinal center responses can take over 
[56,61,63,66]. From the large amount of initially formed plasma cells, only those with the highest 
affinity for the antigen survive as long-lived antibody producing cells in the bone marrow [56]. 
Interestingly in human studies it was observed, that besides antibody secreting plasmablasts specific 
for the immunizing antigen, a second antibody secreting plasma cell subpopulation of unknown 
specificity appeared in peripheral blood [67]. This indicates, that as a result of limited space inside 
the bone marrow, newly formed plasma cells might induce resident cells to leave their niche. Since 
long-lived plasma cells are the cells of the B cell immune response that are most specific for the 
antigen, their main role is to protect the body against the same pathogen through the action of their 





A second product of germinal center responses are long-lived memory B cells, which allow our body 
to elicit much faster and more efficient B cell immune responses upon reencounter of a similar 
immune stimulus [28]. These cells seem to be less affine for the antigen [56,69], meaning that they 
probably have a greater polyspecificity allowing also protection against related or mutated variants 
of the same pathogen [68,70]. From a biological point of view, it makes sense to first generate the 
antibodies that confer protection against the pathogen that invaded the body and only later produce 
memory B cells that can also confer protection upon reinfection with a similar pathogen [56,70]. This 
does however not exclude the possibility, that some early memory B cells could be formed outside 
of germinal center responses [71]. Generally the many discrepant results in the field regarding clear 
separation of B cells into subsets and determining their fate indicates that there is some degree of 
stochasticity in the system. Since so many factors are involved, certain B cell types might have a 
higher intrinsic preference to undergo a certain pathway, but this does not necessarily mean that they 
cannot or will never also use another one. Since not being perfect is a prerequisite for the evolution 
and survival of biological systems, it only makes sense to consider this assumption.  
 
In vitro culture experiments using human B cells revealed, that IgM memory B cells more likely re-
eneter the germinal center reaction, while IgG memory B cells have a tendency to rather differentiate 
directly into antibody secreting plasma cells [72]. Although it is still under debate whether this is true 
for all human IgM expressing memory B cells, current data favour the view, that IgM memory B cells 
are the early products of germinal center responses, while isotype switched memory B cells are rather 
generated at later timepoints [28]. This would be in line with the uniform switching that was observed 
in early mouse experiments [61] and the general switching pattern from IgM to IgG isotype of 
antibodies appearing over the course of immune responses [58].  
 
Although it is accepted, that human memory B cells only expressing IgM or IgG isotypes are 
generated in germinal center responses, the origin of those IgM memory B cells that did not 
downregulate IgD is still under debate [28]. Current data indicate however, that at least a large 
fraction of the CD27+IgM+IgD+ memory B cells are the products of early T cell dependent responses 
[21,24,60,72-78]. A germinal center independent origin of these cells was proposed based on the 
finding, that these cells express B cell receptors and harbour mutations that are different from 
germinal center derived B cell subsets present at the same timepoint [21,24,73,74]. Since B cell 




preferentially used to mediate contacts with antigens [79-84], a germinal center independent pathway 
needs to be confirmed by more direct approaches. Analysis of the evolution of these clones between 
different timepoints and sequencing of repertoires at greater depth [60,77] are required to completely 
solve this issue. It should also be considered here, that maybe not all the B cells entering the germinal 
centers at initial stages of the response will survive and enter the B cell subpopulations generated 
later during the response as mutated and class-switched versions. Transcriptome analysis combined 
with in vitro functional assays [72] and epigenetic data [78] indicate that CD27+IgM+IgD+ B cells 
share more features with real memory B cells than with naïve B cells and are in line with the idea of 
these cells being generated early in T cell dependent immune responses. Furthermore, the increase in 
mutation frequencies from IgM+IgD+ to IgM+IgD- and IgG+IgD- B cells [24,74,77,78] is in line with 












Figure 2: Diversification of B cell receptors during the immune response occurs in 
germinal centers. Several rounds of somatic hypermutation and affinity selection result in 
the production of cells that have a high affinity for the antigen. In a first step B cells have to 
compete for access to signals from T helper cells before they vie with each other to get access 
to antigen presented by dendritic cells. Depending on the signals they get from these two cell 





In summary, T cell dependent B cell responses induce germinal centers in which B cells expressing 
receptors recognizing the pathogen are continuously selected to be optimized for binding and to enter 
the long-lived memory B cell compartments. These structures allow to further diversify the B cell 
repertoire in order to be armed for a potential rechallenge with the same or a similar pathogen. The 
idea that besides their role as inducers of highly specific and long-term antibody responses, germinal 
centers are also enlarging the B cell repertoire diversity in order to protect against mutated versions 
of the same pathogen [68,70], is an important consideration when analyzing B cell repertoire data 
after immunization or infection with the aim to identify specific B cell repertoire signatures. It appears 
that over the course of the immune response, germinal centers precisely switch their output [85] to 
send the cells of different affinities to the different B cell compartments fulfilling precise functions. 
Similar to the effect seen when combining different drugs to target the same pathogen, the generation 
of a diverse antigen-reactive repertoire [70] might also prevent the occurrence of escape mutants. It 
is interesting to mention in this context, that more diverse B cell repertoire responses could be 
associated with better survival after infection with the influenza A (H7N9) virus [86]. 
 
1.1.4 B cell receptor selection at different stages of the B cell immune response 
 
Competition between B cells possessing different antigen affinities is dictating the different stages of 
antibody affinity maturation and selection [64,65,87,88]. This means, that whether a B cell with a 
particular B cell receptor is responding or not can depend on the presence or absence (both with 
regard to time and location) of other B cells expressing B cell receptors with a different specificity 
for the antigen. In the absence of B cells with high affinity, the less affine ones will take over, while 
in a system where more affine ones are present, the same B cell might not respond.  
 
germinal centers or they differentiate either into long-lived plasma cells or memory B cells. 
B cells which do not get any survival signals will die. Only B cells with the highest affinity 
for the antigen will be selected to enter the bone marrow as long-lived cells that secrete 
antibodies to protect the organism against the pathogen that elicited the immune response. 
Memory B cells are generally less specific for the antigen and thereby allow to mount strong 
and fast immune responses also to related pathogens. Since the germinal center response is 
rather a slow process, a large part of B cells directly differentiates into short-lived plasma 
cells to provide a first line of defense until the more specific cells generated in germinal 




Germinal centers have been shown to be open and dynamic structures [89,90], meaning that new B 
cells can constantly enter and influence the outcome of pre-established germinal center responses. 
This is very important, when considering complex antigens [91,92] or pathogens like Borrelia 
burgdorferi that can even change antigen expression in the course of immune responses. This means, 
that not only the presence or absence of a certain B cell receptor but also of epitopes can influence 
the outcome of the B cell response at the B cell receptor level. This also means, that initial responses 
are probably dominated by B cell receptor sequences that are highly abundant in the pre-immune 
repertoire but that these might later be exchanged by other more rarely occurring ones allowing higher 
affinity binding [93,94].  
 
Mouse studies have revealed, that although the naïve B cell repertoire composition is largely 
influenced by genetic factors, the selection of B cell clones into the plasma cell pool is rather 
occurring stochastically [95]. This rather stochastic selection does however not seem to prevent a 
higher clonal overlap among plasma cells from individuals that have been challenged with the same 
immune stimulus [95]. 
 
To avoid uncontrollable spreading of pathogens within the body, the speed at which immune 
responses happen is crucial and explains the need for the above described efficiency of the system. 
In order to allow for a quick recognition of the antigen, the naïve B cell repertoire is composed of 
highly polyspecific B cell receptors (Figure 3). Experiments using phage display libraries, were able 
to show, that individual germline antibodies can not only recognize a very large number of different 
epitopes [96], but that also a very large number of different germline antibodies (>1000) can 
recognize the same antigen [97]. The recruitment of B and T cells to special anatomical sites like the 
lymph nodes increases their chances to meet, thereby also speeding up the process [98]. Previous 
generation of an expanded and diverse memory B cell pool largely located to these sites might also 
contribute to a quicker response. Besides these strategies, it was proposed that B cells and T cells 
must undergo already some degree of proliferation before cognate interactions so that they can find 
their interaction partner more easily [98]. The degree of polyspecificity of generated memory B cells 
needs (to my knowledge) still be determined. In mice it could however be shown, that infection can 
induce the production of memory B cells that are capable of recognizing mutant variants even better 
than the viral strain that was used for immunization [68]. The fact, that B cell immune responses 




polyreactive memory B cells are also very likely generated. For this reason, the possibility that some 
memory B cells might participate in the immune response needs to be considered especially when 
analyzing human B cell repertoire perturbations. 
 
 
Figure 3: Selection of B cells into and out of the B cell immune response. In order to allow for a 
quick B cell response, the naïve B cell repertoire is composed of B cells harboring polyreactive B cell 
receptors. These seem to be selected rather stochastically to enter the B cell immune response. As 
germinal centers are open and dynamic structures, new B cells can constantly enter and change the 
response and might lead to a switch in germinal center outcomes. Even if B cells are selected rather 
stochastically into the B cell immune response, some degree of convergence seems to occur. This 
means that  similar B cell receptors might be generated in different individuals. Especially in humans 
it is important to consider, that memory B cells generated in previous immune responses might 
participate in the B cell immune response of interest. The main question of this project: can we 
identify among the diverse repertoire that is expected to react with Borrelia a few B cell clones that 






Due to the isolation and use of monoclonal antibodies in biological assays that allow to even 
distinguish between proteins that only differ by one amino acid position (for example: Thy1.1/Thy1.2 
system [101]), biologists tend to have the reductionist view [102,103] of the antibody-antigen 
recognition process as being highly specific. In addition to that, the separation of protein sequences 
into defined antigenic regions [104] may lead to the wrong assumption, that different individuals 
recognize the same antigen in a similar manner. Even if a similar antigenic region is targeted, this 
does not necessarily mean, that this region is bound by the same mechanism [102]. Early studies 
already concluded, that immune stimuli induce the production of several different antibodies, which 
together render sera specific for that antigen but some of which might also be responsible for the 
frequently observed increase in cross-reactivity of sera with unrelated antigens [99,100]. Since only 
B cells harbouring the most specific antibodies are kept in the bone marrow to secrete antibodies, the 
timepoint of sampling might influence ELISA results. While one might find a large number of 
different antibodies reacting with the same antigen early in the response, later response sera might be 
predominated by only a few highly specific antibodies. Detailed investigation of the composition of 
human serum antibody repertoires by combining mass spectrometry with next generation sequencing 
is a new field that will allow to address these questions more thoroughly [105]. A first study using 
this approach was able to follow changes in serum antibody composition at different timepoints after 
tetanus vaccination [106]. Although a much larger plasmablast clone number was expanded in day 7 
PBMC samples, only a few of the corresponding antibodies could be found back in sera of these 
donors at later stages of the response [106]. For the two donors analyzed in this study, only three 
clonotypes were responsible for over 40% of the measured antibody response [106]. Taken together 
with the rather large number of memory B cells being generated, this means, that at the cellular level 
the B cell immune response is way more diverse than at the antibody level (the latter can be in the 
range of 100 clonotypes [106,107]).  
 
Antibodies generated in prior immune responses can also affect germinal center outcomes [108,109]. 
In the light zones of germinal centers, B cells first compete for uptake of antigen presented as 
antibody-antigen complexes by follicular dendritic cells and after that for helper signals from T cells 
which sense the amount of antigen presented. Antibodies that are produced in the course of the 
immune response shield epitopes on the antigens that are presented by follicular dendritic cells, 
thereby making sure, that only B cells with B cell receptors of higher affinity than that of already 




is a way of how germinal centers can communicate with each other by other means than via cell 
migration and explains why B cell responses can stay so diverse without polarizing to a specific 
antibody over time. It seems though, that antibody feedback is mainly mediated by antibodies of the 
IgM isotype. 
 
Although not all these studies directly selected for B cell clones reactive with the same antigen, 
sequencing of induced memory B cells or plasma cells from patients with the same disease conditions 
generally leads to the isolation of a rather broad repertoire composed of various different V-J gene 
combinations [110-116]. These studies are in line with a rather broad spectrum of B cell clones 
generated upon immune stimulation and also explain why many B cell repertoire studies showed, that 
overlapping clones between patients are very rare events [1,13,86,117-120]. Due to this great 
diversity, next generation sequencing techniques [121] are indispensable for the study of the B cell 
immune response at the B cell receptor level. Although this field matured extensively over the past 
years, even this technique only allows to analyze a small part of an individual’s whole B cell 
repertoire [122]. For this reason, future studies will need to combine next generation sequencing with 
single cell isolation approaches [123,124] to adequately characterize and determine the sizes of 
antigen-reactive B cell repertoires.  
 
1.1.5 The kinetics of B cell immune responses 
 
Although at the B cell receptor level, the response seems to be largely influenced by stochastic and 
environmental factors, general kinetics of the B cell immune response are surprisingly similar 
between different immune stimuli [4] suggesting the existence of some buffering mechanisms [125]. 
Generally it can be assumed, that around one week after vaccination or onset of symptoms, large 
numbers of plasma cells are released into the circulation. They are present there at elevated numbers 
however only during one day. It is interesting to mention in this context, that the peak of the 
extracellular plasma cells responsible for initial antibody production is occurring at exact this 
timepoint in mice [61]. Although these experiments showed, that a large fraction of these B cells are 
eliminated by undergoing apoptosis [63], this coincidence in time raises the question of whether this 
striking rise in peripheral plasma cells is the result of a rather polyspecific early first line plasma cell 
burst. Many human studies have focused on this early plama cell peak for the isolation of antigen-




lived serum antibody repertoire [106]. In humans, plasma cells at this stage already harbour a high 
number of mutations, which is why a large fraction is probably resulting from pre-existing memory 
B cells that can have been generated in previous responses to related or unrelated antigenic challenges 
[116,126-129].  
 
For long-term survival, antibody secreting plasma cells need to find a niche inside the bone marrow, 
from which they continue secreting antibodies that can be detected for prolonged times in the serum 
[130-134]. Upon immune stimulation, memory B cells also increase, although at a much slower and 
lower levels than the plasma cells [116,135-138]. The fact that for over one month period and only 
after immunization, PBMCs can be stimulated with the corresponding antigen to secrete antigen 
reactive antibodies [139-141], indicates that antigen activated and reactive B cells are circulating in 
peripheral blood over a longer period. Those cells are of particular interest for biomarker research. 
Furthermore older studies were able to show a slight increase in peripheral blood B cells upon acute 
infection [142,143], further indicating that they could be of use to support diagnosis [4]. As opposed 
to antibody secreting plasma cells – which home to the bone marrow -, memory B cells largely 
localize to secondary lymphoid tissues and although they largely decrease in numbers after clearance 
of the antigen, some continue circulating between these locations and peripheral blood for a lifetime 
[23,133,144,145]. The continuous evolution and increase in antibody affinities over time [56-58] 
suggests that also some plasma cells must be continuously generated. A low level of plasma cells is 
also present in peripheral blood in the absence of infection or vaccination. These cells were shown to 
be derived from constant immune responses going on at mucosal sites [146]. 
 
It is assumed, that a decrease in antigen towards the end of immune responses is leading to an increase 
in competition between germinal center B cells thereby allowing for the gradual selection of more 
and more specific clones [147]. The response is believed to stop, when the antigen has dropped below 
a certain concentration [125]. An interesting and important question to raise here is: what happens in 
the case of chronic antigenic stimulation? The finding, that a substantial number of reactive B cells 
can localize directly inside chronically inflamed tissues [117,148] raised the question of whether 
reactive B cells can be reliably isolated from peripheral blood samples. Examples describing elevated 
numbers in the periphery however also exist. In the autoimmune disease systemic lupus 
erythematosus  – in which the autoantigen is constantly present -, a correlation between disease 




peripheral blood samples from a chronic HIV infected individual allowed to follow the co-evolution 
of viruses and anti-HIV broadly neutralizing antibodies over a three years time period [151]. In 
multiple sclerosis shared clones between the central nervous system and peripheral blood could also 
be found [152]. These findings indicate, that antigen-reactive B cells should not only be found in 
peripheral blood upon acute but also upon chronic infection making them attractive candidates for 
biomarkers to indirectly show the presence of pathogens inside the body. It seems though, that the 
plasma cells generated under chronic auto-immune stimulation are of a different nature than the long-
lived plasma cells generally generated upon single booster immunizations [153,154]. In mouse 
models, it was found that chronic antigen stimulation and inflammation are inducing the generation 
of short-lived plasma cells [154]. A very interesting and important finding from this study was, that 
chronic inflammation seems to induce long-lived bone marrow plasma cell displacement and prevents 
entry of newly generated plasma cells into the long-term survival niches of the bone marrow [154]. 
If it can be confirmed, this means that chronic inflammation might affect protection against 
previously encountered immune stimuli. It could also be shown, that injection of soluble antigen into 
an ongoing germinal center response leads to apoptosis of antigen-reactive germinal center B cells, a 
strategy that might be exploited by some pathogens [155-157].  
 
1.1.6 B cell repertoire signatures 
 
As already mentioned above, the great diversity and polyspecificity of the naïve B cell repertoire in 
combination with the finding, that antigen reactive B cells are often composed of various different 
VJ gene combinations, suggests that B cells are rather stochastically selected from the primary 
repertoire to start the immune response. It seems though, that some degree of convergence is 
occurring especially at later timepoints during which germinal centers should have generated B cell 
receptors of high specificity. This suggests, that there are probably some optimal B cell receptors in 
the repertoire for each antigen, but since the body needs to respond very quickly, as a first line of 
defence at early timepoints, he is working with the best B cells available at that time. Later in the 
response more B cells have circulated the affected lymphoid tissues and - since germinal centers are 
open structures - might lead to the appearance of more similar sequences among individuals. In 
addition to that, their B cell receptor is optimized for binding in germinal centers, and the selection 
of similar amino acid changes might also lead to a higher convergence. This is what one expects to 






Haptens coupled to carrier proteins and hen egg lysozyme are two groups of antigens that were 
extensively studied in mouse models. Very early studies already addressed the question: how diverse 
is the antigen-reactive B cell repertoire, and their results are in line with more recent findings. In the 
1980ies a common signature characterizing B cell receptors of high affinity for the hapten NP was 
identified [158]. It was found, that one amino acid change in the V-gene (tryptophan to leucine 
exchange at codon 33 in the CDR1 region of the mouse V186.2 germline sequence) was repeatedly 
occurring and responsible for a 10 fold increase in antibody affinity for the antigen [158]. The 
identification of this signature allowed to analyze and follow the fate of germinal center B cells in 
great detail [56]. It seems though, that these clones are not the only ones generated in response to this 
vaccination. Especially secondary immune responses seem to induce a broader antigen-reactive 
repertoire composed of different V genes [94,159]. Analyzing the in vivo adaptation of the anti-henn 
egg lysosyme monoclonal antibody HyHEL10 to a mutated version of this antigen (HEL3x) also 
indicated that a key mutation (substitution of tyrosine at codon position 53 with aspartate) was 
responsible for the observed increase in antibody affinity (~85 fold) [66]. This mutation occurred in 
over 95% of the isolated high affinity clones [66]. 
 
Due to their great potential for the generation of universal vaccines, phylogenetic pathways leading 
to the generation of broadly neutralizing antibodies to HIV and influenza have been studied 
extensively and contributed significantly to a better understanding of antibody-antigen interactions 
and their co-evolution. Even if it is important to keep in mind that these are rather special cases, 
several interesting conclusions regarding B cell repertoire signatures can be drawn from these studies. 
Approximately 20% of individuals generate broadly-neutralizing antibodies upon HIV infection. In 
one fifth of these patients, antibodies of the VRCO1-class could be identified [160]. These antibodies 
are generated from a common germline V-gene (IGHV1-2*02) and harbour an exceptionally high 
number of mutations [118]. Even though these sequences only share less than 50% identity, they 
seem to bind to their target through similar mechanisms [160]. Also in this case, key mutations at two 
residues in the CDR2 region are the only globally shared features of isolated heavy chain sequences 
(glycine to alanine at position 56 and threonine to valine at position 57) [118]. Following the ontogeny 
of broadly influenza neutralizing antibodies showed how tremendously single amino acid 
substitutions can change binding to antibody targets [161]. This suggests, that antibodies with very 
different sequences can adopt very similar three dimensional antigen binding mechanisms and that 




repertoire data. This is also in line with more recent computational analysis, that lead to the 
conclusion, that only a few key residues are responsible for the majority of the difference in energy 
that occurs upon binding to the antigen [84]. It is important to emphasize in this context, that two 
different types of amino acid changes occur in antibody sequences. One part of these amino acids 
might directly interact with the antigen, while the other part only indirectly contributes to binding by 
affecting the overall antibody structure [6]. 
 
The fact, that only a subset of patients is capable of forming broadly neutralizing antibodies indicates, 
that the B cell immune response at the B cell receptor level can be highly personal. Broadly 
neutralizing antibodies have been shown to have a higher degree of autoreactivity, which is probably 
the reason why they are occurring rather sporadically [162]. As mentioned above, the convergent 
nature of these types of antibodies is thought to be rather an exceptional case [119]. Since viruses 
tend to mimic host proteins to avoid recognition by the immune system, it has been hypothesized, 
that the hydrophobic IGHV1-69 gene – which predominates influenza broadly neutralizing antibodies 
- has occurred during evolution because it allows to bind to important hydrophobic regions on viruses 
(including influenza, HIV and HCV) [119]. Due to their higher risk of generating auto-immune 
reactions, B cell receptors containing highly hydrophobic HCDR3s are however generally deleted 
from the repertoire [17]. This means, that usage of this particular V-gene might be the only possibility 
to generate such antibodies, which is why if they occur, they are highly similar in different 
individuals.  
 
In accordance with the above statements, pathogenicity in pemphigus patients was associated with 
the presence of one tryptophan in the CDR3 of the heavy chain of isolated Dsg-specific antibodies 
[163]. Another example for which a disease signature was identified by looking at the B cell repertoire 
is multiple sclerosis. In that case, an enrichment of VH4 expressing B cells harbouring replacement 
mutations at eight defined codons was found in cerebrospinal fluid [164]. 
 
Even if some signatures could be identified, the great diversity and polyspecificity of antigen reactive 
B cell repertoires suggests, that the B cell immune response is a highly personal process largely 
governed by stochastic and environmental factors. For this reason, the isolation of disease specific 
signatures that would allow to discriminate between different conditions was initially thought to be 




binding and is sufficient to confer specificity of an antibody for its antigen [11]. For this reason, one 
would expect convergent signatures to occur rather at this site. The only condition however for which 
a clear convergent CDR3 sequence could be associated with disease activity is dengue [165]. Since 
specificity of antibodies with this CDR3 for dengue was never proven experimentally, the question 
occurs of whether this high degree of convergence might be explained by the polyreactive natural B 
cell activation that was shown to occur in this disease [166]. On the other hand, the generation of a 
highly diverse antigen reactive repertoire does not exclude the possibility that some sequences 
nevertheless might be generated in common in different individuals. It might just be a matter of how 
deep one digs into the repertoire, a problem that can be overcome by using next generation sequencing 
to analyze B cell immune responses [167,168]. With this technique, several groups were able to show 
a higher convergence of repertoires among individuals exposed to the same antigenic challenge 
[127,169-171], meaning that overlapping clones should exist. If the occurrence of overlapping clones 
among different individuals suffering from the same disease condition can be confirmed, this would 
make B cells very attractive biomarkers for diagnosis. It remains to be investigated though, how 
specific these overlapping sequences are for each disease condition and how globally they are 
occurring among individuals. Other important considerations are their kinetics and levels in 
peripheral blood. Recent studies indicate, that the overlapping clones might predominantly occur at 
low levels during later stages of the immune response [171] raising doubts about their usefulness for 
diagnosis. Since every antibody-antigen interaction as well as every B cell immune response to a 
certain disease is rather unique, it might still be worth investigating each disease individually. Our 
current knowledge of the B cell repertoire is not big enough to draw global conclusions. It could very 
well be that for certain diseases, specific signatures can be isolated, while for other conditions this 
might not be possible. 
  
Even if B cell repertoire deep sequencing studies might not lead to the isolation of convergent 
signatures, these data contain a tremendous amount of other interesting information, which allows to 
better understand the B cell immune response to various conditions. Conclusions from such studies 
can be very valuable for the development of vaccines or to understand why certain patients are 
protected while others are not and why some are more prone to develop chronic courses or 
autoimmune diseases.  
 





1.2.1 Lyme disease and problems encountered with diagnosis 
 
With an estimated 65500 cases per year in Europe [172] and 300000 in the United States [173], Lyme 
disease is the most common tick transmitted disease in these two regions of the world. One needs to 
keep in mind though, that these numbers are just estimates and that real numbers might largely deviate 
from these estimations. The disease is caused by a bacteria, or more precisely a spirochete, that resides 
inside the midgut of ticks [174]. The latter are blood feeding ectoparasites that belong to the same 
arthropod class than spiders and mites (Arachnida) and that - similar to mosquitoes - can transmit 
various different diseases during blood feeding [175,176]. Although other tick species exist, the most 
important vector for Europe is Ixodes ricinus [174]. As opposed to mosquitoes, the blood meal of this 
tick generally takes longer. Ticks developed different mechanisms to overcome the host immune 
response which would otherwise attack them and prevent them from feeding [177-180]. 
 
Borrelia generally first need to migrate from the midgut of the ticks to their salivary glands, from 
which they are then secreted into the skin of the host [181-183]. For this reason, it is assumed, that 
they are usually only transmitted after 24-48 hours [184]. Differences between different Borrelia 
species were however observed, with some species being transmitted earlier [184,185]. Since no 
vaccine is currently available [186], avoidance of areas with high tick incidence and early correct 
removal of these parasites is the best prevention strategy of the disease for humans [174].  Although 
it was shown that disturbance of the tick – for example by adding nail polisher or by squeezing it - 
did not increase infection rate [185], it is still recommended to not harm the tick upon removal. 
Prophylactic antibiotics treatment [187-189] might be another option to prevent Borrelia 
dissemination inside the body, but this is not an optimal solution especially in the case of frequent 
tick bites. 
 
Due to their transmission route, Borrelia enter the body of the host through the skin. The helical shape 
of this bacterium allows it to migrate at a very high speed inside tissues [183,190]. After their 
deposition, the bacteria migrate away from the site of the tick bite and can invade the body. Motility 
of the bacteria is important to establish an infection [183]. In 60-80% of patients, migration through 
the skin leads to the characteristic early manifestation called erythema migrans [191]. This symptom 




immune response of the host following the migrating bacteria [190]. Not every patient develops this 
characteristic symptom [192-195] and also tick bites are frequently unnoticed [196]. Misdiagnosis of 
this early manifestation has also been observed [197]. In case the patient does not manage to combat 
the bacteria at early stages, they might disseminate to different parts of the body including other sites 
of the skin, the nervous system, the joints or even the heart [174,193,198-200]. A study performed in 
Northern Europe was able to show, that within three months after the tick bite 40% of infected 
individuals develop disease manifestations [192]. Since Borrelia are not known to produce toxins, 
the symptoms are probably a result of inflammation caused by the infection [174]. Lyme disease has 
many different faces [174,193,198-200] and many symptoms are similar to those observed in other 
diseases [201]. This can render diagnosis difficult, especially when no erythema migrans or tick bite 
was noticed. Even though the diagnosis might be easy for specialists in the field, it might be 
complicated for general practitioners which only rarely see Lyme disease cases [202]. For this reason 
the development of diagnostic tests allowing a clear yes or no result is highly important. Current 
diagnostic procedures predominantly rely on the correct identification of patient symptoms and 
exclusion of other possible diseases. In the absence of erythema migrans, serological tests should be 
used to confirm the diagnosis [173,203-207]. One needs to keep in mind though, that a positive 
serological result can only indicate whether the patient has once had contact with Borrelia but cannot 
give any indication whether the infection is still acute [173,208]. IgM antibody testing is only 
recommended to support diagnosis of early stage disease (first month after tick bite) in the absence 
of a clear erythema migrans [173,204,205,207]. Current improved versions of serological tests should 
detect IgG antibodies in the majority of later stage patients [203,205] and in their absence, other 
possible reasons for the symptoms should be considered. Although serological tests have been 
extensively optimized in the past [203,207], scientific studies often only focus on one specific aspect 
of a problem and therefore do not allow to reproduce the real situation occurring in practice. In current 
recommended tests, an ELISA followed by a more specific immunoblot are used to confirm 
seroconversion. Problems with correct interpretation of immunoblot results in practice have been 
observed [207,209,210], which is why a two ELISA test system with an automatic readout has been 
proposed to solve these practical issues [207]. Issues with different performances of different tests 
are also not solved yet [209,211,212], so that a universal test system still needs to be established. 
 
Since Lyme disease is caused by a bacteria, it can be treated with antibiotics and the majority of 
patients recover well from the disease [174,194]. In the majority of cases, the disease would even 




dissemination of the bacteria that could cause later stage complications [174,193]. There is a subset 
of patients that continues to have symptoms after treatment, a phenomenon that is more frequently 
observed in donors suffering from later stages of the disease in which the bacteria had time to largely 
disseminate inside the body [174,213-215]. Several explanations exist. On one hand, prolonged 
infection and tissue inflammation might have caused some irreversible damage inside the affected 
tissues and might prevent the patients from full recovery. It was also suggested, that persistent 
presumably antibiotics resistant Borrelia might be the reason for these continuous symptoms. Clinical 
studies from the United States indicate, that additional antibiotics treatment might alleviate chronic 
fatigue in some patients, but patient improvement might be associated with a high risk of side effects, 
which is why prolonged antibiotics treatment is currently not recommended [216]. Although it cannot 
be completely ruled out, that in individual cases antibiotics treatment might have failed to completely 
eradicate Borrelia, especially in cases where a wrong treatment schedule might have been followed, 
currently there exists no solid proof for the occurrence of resistant Borrelia in humans [193,214,217]. 
Real life situations might also be different from the well selected patient cohorts used for scientific 
studies. It was for example found, that patients with haematological malignancies might require more 
often retreatment than immunocompetent individuals but also in these cases the outcome was good 
after treatment [218]. Reoccurrence of Lyme disease manifestations is generally caused by a different 
Borrelia strain, indicating that reappearing symptoms are due to reinfection rather than a relapse of 
the disease [219-221]. Since Borrelia tend to only be present at very low numbers in accessible human 
samples, it is very difficult to prove or disprove the persistence of these bacteria inside the patients. 
For these reasons Borrelia culture and PCR approaches are only being used for research purposes but 
are not reliable enough to be used as diagnostic tests of acute infection [173,202,203,222]. Even if 
these methods have a low sensitivity, one would still expect a positive result in individual antibiotics 
resistant cases, which has not been observed [223]. Of course it is hard to prove that there are no 
Borrelia anymore inside less accessible tissues. Since the bacteria seem to be able to sense the 
presence of a feeding tick, lately xenodiagnosis was proposed to test for the presence of viable 
bacteria inside chronically infected humans [224,225]. In this approach, germ-free ticks are put onto 
patients to feed and these ticks are later screened for the presence of bacteria. Although individual 
ticks from one post-treatment Lyme disease patient were positive by PCR for Borrelia DNA, they 
failed to isolate viable spirochetes [224,226]. Some studies showed the presence of cystic structures 
that react with Borrelia antibodies in tissues from patients, but no clear correlation between the 
presence of these structures and persistent symptoms after treatment has been established[227]. In 




that confirmatory experiments other than immunological staining are required to confirm these 
findings [227]. A mouse study was able to demonstrate the persistence of Borrelia antigens after 
treatment, indicating that the body might have problems to eliminate all remnants of dead Borrelia 
and that this could potentially be the cause of the observed persistent inflammation [228]. Similar to 
this, the “amber theory” of chronic Lyme arthritis hypothesizes, that inclusion of Borrelia remnants 
into joint matrix could result in recurrent inflammation in case they are release into the joint space 
[229]. There is also evidence, that ongoing inflammation and autoimmune responses might be 
involved at least in a subset of patients. In some cases, autoantibody producing B cells could be 
isolated from affected tissues and the presence of autoantibodies in sera from patients have also been 
observed [230-247].The type of T cell help that B cells get might play a role in the chronic course of 
the disease. Patients developing higher levels of CXCL9 and CXCL10 chemokines are more prone 
to produce anti-Borrelia antibodies [248] and Borrelia are more difficult to isolate from these patients 
[223]. These Th1 cell responses seem to be important for efficient killing of spirochetes. An 
association was made between Th17 cell driven responses and the formation of autoantibodies [223]. 
This effect might not be directly visible, when simply comparing autoantibody levels between 
resolved and chronically evolved patients [249]. Over the course of the response to Borrelia, there 
seems to be however a shift in the Th17 immune response from a protective role early in the disease 
towards a detrimental one if not switched off at later stages (at least in the case of Lyme arthritis) 
[250]. It seems that a large part of patients develop transient autoantibodies, but only in a subset of 
these, these antibody titers remain high for prolonged times [237,249]. It could thus be, that 
depending on the signals that the B cells get, they might develop clinically important autoantibodies 
later in the disease [250]. The exact role these antibodies play in the different forms of post-treatment 
Lyme disease conditions remains to be more clearly investigated though[250]. General problems to 
clearly differentiate post-Lyme disease patients from resolved ones [249,251] indicate, that multiple 
and highly complex mechanisms might be responsible. Personalized medicine and systems biology 
approaches on very large patient cohorts will probably be required to solve these issues. 
 
The chronic manifestations observed after Lyme disease infection are actually not specific for Lyme 
disease, but similar symptoms have also been observed under many other conditions [252-256]. These 
manifestations are frequent among the general population [193,210,257,258]. Due to the increased 
awareness and popularity of Lyme disease, it is often used as explanation in case such symptoms 
appear. This very likely leads to frequent misdiagnosis of chronic Lyme disease [213,259]. Only 




having chronic Lyme disease [213]. A less confusing and more correct term to use in this case would 
be “Post-treatment Lyme disease syndrome” [214] or “Post-Lyme disease symptoms” [213]. In the 
absence of an indication of previous acute Lyme disease, other reasons should strongly be considered. 
 
1.2.2 Borrelia and important antigens they express 
 
The tick-transmitted spirochetes of the genus Borrelia can be divided into two groups. One is 
transmitted by soft ticks (Argasidae) and is causing tick-borne relapsing fever, while the other one is 
transmitted by hard ticks (Ixodidae) and causes Lyme disease [260,261]. Louse-borne relapsing fever 
also exists. Tick-borne relapsing fever occurs only rarely in Europe but needs to be considered under 
special cases, especially when the patient has travelled to endemic areas [262]. Recently it was 
however found, that Borrelia miyamotoi, a relapsing fever spirochete present in the most important 
tick species complex from Europe [260], can also cause relapsing fever [260,263]. Since this 
spirochete can be transmitted transovarially, its importance for public health needs to be strongly 
considered [260]. Furthermore, antibodies induced  by this group of Borrelia can cross-react with 
Lyme disease antigens, and might for this reason occasionally be important to consider for the correct 
interpretation of Lyme disease serological results [260]. 
 
Lyme disease causing Borrelia belong to the Borrelia burgdorferi sensu lato complex, which 
comprises over 20 different genospecies [264]. For simplicity, when I am referring to Borrelia here 
without any other indications, I mean this group of spirochetes. Not all the members of this group are 
human pathogenic. Pathogenicity could be confirmed for five species (Borrelia burgdorferi sensu 
stricto, Borrelia garinii, Borrelia afzelii, Borrelia bavariensis and Borrelia spielmanii) [193,264]. 
While in the United States, Borrelia burgdorferi sensu stricto is mainly responsible for human Lyme 
disease, the situation is more complicated in Europe. Here several different species can cause disease, 
Borrelia afzelii and Borrelia garinii being the most frequent ones [174,265]. Different Borrelia 
species could be preferentially associated with certain symptoms [266], which explains differences 
in disease manifestations observed between the two continents [193,201,267]. For this reason, when 
reading scientific articles, it is important to consider the area in which the study has been carried out.  
As opposed to other gram negative bacteria, Borrelia do not contain lipopolysaccharides on their 
surface [191]. They instead express a large number of different outer surface proteins, some of which 





The rather special genome of Borrelia is composed of one linear chromosome and several linear and 
circular plasmids [191,268] (Figure 4). Borrelia strains are very heterogeneous, which is mainly due 
to differences in plasmid content [191]. The majority of lipoproteins important for adaptation to their 
different environments are encoded by genes located on these plasmids [268,269]. When Borrelia are 
kept in culture, loss of plasmids encoding genes important for infection need to be considered 
[191,268] and complicated the isolation of antigens. In addition to that, Borrelia express different 
proteins under in vitro conditions than in the vertebrate host or in the tick environment. For this 
reason, ELISA assays often contain VlsE on top of Borrelia whole cell extracts [203]. 
 
Figure 4: Both the tick vector but also Borrelia themselves actively influence the B cell immune 
response of mice and probably also of humans. While the tick seems to inhibit only the local 
production of antibodies, Borrelia more extensively manipulate the B cell immune response in order 
to survive in their reservoir host. On one hand the great diversity of antigens (OspC) which are even 
actively changed in the course of the immune response (VlsE) prevents the host from being protected 
against different Borrelia strains. On the other hand Borrelia also directly affect the formation of 
long-lived plasma and memory B cells. Although the human immune response is also special – at 
least in some individual cases – it remains to be investigated more thoroughly what is going on at the 
cellular level in this case. The majority of housekeeping genes are expressed on the rather conserved 
linear chromosome of Borrelia, while many of the lipoproteins that are important for their 
transmission are expressed on the rather heterogeneous plasmids. 
Outer surface protein C (OspC) is a very important antigen used to support diagnosis. It is encoded 
on a circular plasmid and is one of the most diverse Borrelia proteins [203,268]. OspC is upregulated 




[191,268,269]. Mouse experiments demonstrated, that the strong early antibody response induced by 
this diverse antigen is protective against the same strain but not strains expressing a different variant 
[270,271]. In humans, certain OspC types could be associated more frequently with disseminated 
disease [272,273]. 
 
In the mammalian host, OspC is only expressed transiently at early stages of infection [269], while 
expression of another very interesting antigen - variable major protein-like sequence expressed (VlsE) 
- is thought to increase over time [274]. This protein is expressed on a linear plasmid [191,268] and 
it was hypothesized that it is used by Borrelia to distract the B cell immune response away from 
protective epitopes [274]. During infection, Borrelia use genetic recombination to constantly change 
the sequence of this protein [274]. It was estimated, that with the used system, Borrelia could 
potentially generate 1030 different protein variants [275], a diversity that exceeds by far the expected 
diversity of the human B cell repertoire [276]. Paradoxically though, in its inner core, this protein 
contains a highly conserved epitope – invariable region 6 (IR6) - that is hidden in intact Borrelia, but 
which seems to be largely exposed to the human immune system in vivo [276]. Since antibodies 
elicited towards this region cannot kill the bacteria, it was proposed that Borrelia use reactivity to 
this epitope – in addition to the variable regions on intact bacteria - as decoy to even further distract 
the immune response away from functionally more important epitopes [276]. IgM antibodies are 
preferentially generated to the intact VlsE protein that should be expressed on the surface of intact 
bacteria, while antibodies of the IgG isotype are generally generated against the C6 epitope, which is 
rather expected to be exposed in non-intact bacteria [277]. Although quite speculative, findings from 
this study might indicate that live Borrelia influence the IgM switching especially at early stages of 
the infection, while dead bacteria might no longer do that. Even if the mouse B cell repertoire might 
use different mechanisms to recognize this epitope region [278], animal experiments [279] allow to 
more precisely compare antibody cross-reactivities between different strains. In humans the infecting 
bacteria is often hard to isolate [173]. These experiments already indicated, that also with VlsE-C6, 
the outcome of ELISA results can be influenced by the combination of Borrelia strains used in the 
ELISA and those for infection [279]. Even though the VlsE-C6 region seemed quite well conserved, 
human serum panels from different regions showed differences in reactivities towards individual 
peptide epitopes from different strains, indicating that a mixture of epitopes from different strains is 
needed to detect all seropositive patient sera [280-283]. Although the IgG subclass distribution was 
not affected, patients with more disseminated and chronic disease manifestations were more likely to 




new epitopes in the course of prolonged infection [104,284]. Similar to the antibodies generated 
towards the IR6 region, also these antibodies were found to be unable to bind to intact bacteria [284]. 
 
While antibodies against OspC and VlsE-C6 appear already at very early stages of infection, those 
towards DbpA, BmpA, p58 and p83/100 – which are also frequently used in immunoblots - only 
appear later [285]. The presence of specific bands can be useful to support diagnosis of certain disease 
conditions (stages), their absence however should be interpreted with caution. A negative result can 
also mean that the infecting strain expressed a different variant that was not detected by the assay. 
 
The described antigenic proteins are just a few very well studied examples that allow to illustrate the 
complexity of the B cell immune response towards Borrelia. A much larger number of antigens is 
expected to be expressed inside the human host and many of them might still be unknown. As already 
mentioned before, because Borrelia express different proteins in different environments, it was very 
hard to isolate the antigens that are expressed in vivo. Poljak et al. chopped the genome of Borrelia 
into little pieces and expressed the corresponding amino acid sequences on the surface of bacteria 
[286]. Isolation of bacterial clones from these libraries with human Borrelia-reactive sera led to the 
identification of 122 different Borrelia afzelii antigenic regions [286]. Since these libraries are 
probably missing many discontinuous epitopes and largely focus on only those regions that show a 
high reactivity in common between different individuals, one can assume that the real number of 
antigenic regions largely exceeds this number. Taking also into account, that different Borrelia strains 
might express different variants of the same proteins, one can conclude that the Borrelia reactive B 
cell repertoire is probably highly complex and diverse among different individuals and timepoints. 
 
1.2.3 The B cell immune response in Lyme disease 
 
1.2.3.1 Findings from the mouse model 
 
Mouse experiments showed that both the tick [287,288] but also Borrelia [289-293] themselves 
actively influence the B cell immune response (Figure 4). The tick seems to inhibit the local 
production of antibodies secreted by plasma cells, not however the formation of memory B cells 




different mechanisms to interfere with host immune responses [177-180]. This could explain, why 
the B cell immune response to tick-transmitted Borrelia appears delayed as compared to that one 
against tissue-transplanted bacteria [290]. A B cell inhibitory protein could also be isolated from tick 
salivary glands extracts [294]. 
 
It could be shown that Borrelia actively migrate to the draining lymph nodes and influence germinal 
center responses [290]. Large expansions of extrafollicular B cells could be observed [290]. Many of 
these B cells are reacting with Borrelia antigens, indicating a specific response [290]. Although with 
a delay, normal germinal centers are initiated at early stages of infection [289]. They however 
deteriorate later on followed by an accumulation of mainly naive B cells [289,293]. Lymph node 
architectural changes seem to already occur prior to the accumulation of B cells, meaning that the 
excessive accumulation of cells is not the reason for the observed deterioration[293]. The 
architectural changes were shown to be accompanied by an only transient increase in antibody 
avidity, indicating a failure to produce robust protective antibodies [291]. For many months after the 
infection, the mice are not able to generate a robust memory response [292]. Although the excessive 
accumulation of B cells in the lymph nodes appeared rather T cell independent, the formation of 
antibody secreting plasma cells and their long-term survival in bone marrow niches that occurred 
only at very late stages of infection were affected in the absence of T cell help [289]. In the absence 
of T helper cells, Borrelia burden is increased in mice, indicating that these cells affect the quality of 
the response [291]. Ectopic germinal centers are thought to be responsible for the occurrence of the 
delayed long-lived plasma cells, however their existence still needs to be proven [289]. The B cell 
immune response to Borrelia in this model was largely predominated by cells expressing the IgM 
isotype, indicating that they might have problems to class-switch [289]. This is in line with human 
studies, that showed an unusually long persistent Borrelia-positive IgM antibody titer in a subset of 
patients [295]. 
 
Mice infected with Borrelia also failed to induce a robust protective and long-term immune response 
to a co-administered influenza vaccine [292]. This confirms a direct effect of Borrelia on the B cell 
immune response. The exact mechanism these bacteria use to do that is however not totally clear yet. 
T cells of infected mice seem to follow a normal activation and differentiation route without the 
appearance of exhausted or suppressive cells [291]. T cells from infected donor mice however 




cells to the plasma cell fate [296]. Congruently, they induced B cells to prematurely exit the 
proliferation phase and to more readily differentiate into antibody producing plasma cells [291]. 
Interestingly, this effect was antigen dependent, which is in line with the antigen-specificity of the 
extrafollicular B cell expansion described before [290,291]. It seems, that Borrelia try to prevent B 
cells from entering germinal center responses in which highly specific antibodies are usually 
generated. Like this, the body needs to protect himself with rather more polyspecific and suboptimal 
naïve B cell receptors of IgM isotype that are taken directly from the primary repertoire.  
 
Besides the described effects on T cell help, it was observed that the follicular dendritic cell network 
[292] is disrupted and it seems that MyD88- and TRIF-independent type I IFN signalling [293] is 
involved but not the only factor in the excessive accumulation of B cells in the lymph nodes. In the 
absence of type I IFN signalling, mice only showed a reduced B cell accumulation in lymph nodes, 
but this did not prevent disorganization of germinal centers upon Borrelia infection [293]. 
Interestingly in humans it was found, that strains with a higher tendency to disseminate induce higher 
levels of type I and type III interferons [297]. Since Borrelia can exert a strong mitogenic activity on 
B lymphocytes [298], one initially thought that this might be at the origin of the extensive expansion 
of B cells. Toll-like receptor signalling was however excluded as the cause of this effect [293,299]. 
Since Borrelia are known to affect the complement system which also plays a role in B cell activation, 
it might be worth investigating its role in future projects [98,300,301].  
 
Borrelia use two strategies to be transmitted from tick to tick. Either they are directly transferred to 
neighbour ticks that are sucking blood at the same time on the same animal (a process that is also 
known as “co-feeding”) [302]. In other cases, they manage to evade the host immune response thereby 
ensuring persistence until the next tick is feeding. Rodents belong to this class of natural reservoir 
hosts for Borrelia, meaning that the bacteria can persist without causing too much damage to the 
animal [303]. Incidental hosts like humans are not as well adapted to Borrelia [303], and it was found 
that in Northern Europe for example 40% of infected individuals develop symptoms upon infection 
[192]. This number might vary though depending on circulating Borrelia strains in the region of 
interest. One needs to be cautious when transferring conclusions gained from mouse experiments to 
the human situation. The used mouse model is however mimicking many phenomena also observed 





1.2.3.2 The situation in humans 
 
Early studies followed human antibody kinetics in the course of Borrelia infection and demonstrated 
a rather heterogeneous and slow response, which correlates with the duration of symptoms and 
spirochete dissemination prior to the start of antibiotic therapy [295,304-306]. It was found, that 
treatment with antibiotics largely affects the evolution of the B cell immune response to Lyme 
disease. Patients under treatment could be subdivided into different reactivity groups. Some 
developed persistent antibody titers, while others stayed seronegative and even others showed a 
decline in antibody titers over time [304]. Some patients had problems to induce robust long-lived 
IgG antibody responses even when antibiotics treatment was only started several months after onset 
of symptoms [304]. Discrepant results between different serological test systems [209,211,280,307] 
however make it difficult to draw general conclusions about the presence or absence of a B cell 
immune response in a certain patient. This indicates however, that differences in infecting Borrelia 
strains very likely affect the outcome of the B cell immune response. What can be concluded is, that 
the B cell immune response to Borrelia is highly diverse among patients. On one hand the infecting 
Borrelia strain but on the other hand also host genetic factors might contribute to the frequently 
observed discrepant results among different test systems.  
 
A decline in antibodies after antibiotics treatment is very frequently observed in Lyme disease 
[305,308,309]. Interestingly, a recent study showed more discrepant results among serological tests 
in treated as opposed to healthy or acute donors [212], implying that antibiotics might not affect all 
detected antibodies to the same extent. After treatment, many early stage patients remain seronegative 
[305]. Although it was not possible to test whether these individuals would have seroconverted at 
later timepoints, current optimized versions of serological tests indicate that the majority of patients 
generate detectable antibodies especially at later stages of the disease [173,206,207]. Due to the 
presence of a higher number of different Borrelia genospecies [265], the situation is more 
complicated in Europe than in the United States [310]. Since so many different Borrelia strains can 
cause infections, a seronegative result does not necessarily mean that there is nothing going on at the 
B cell level, but the used test might not contain the right Borrelia antigens or was simply not sensitive 





Some patients were shown to develop a long lasting IgM antibody titer that stayed detectable for up 
to 20 years after the infection [295]. This is rather unusual, as in other diseases antibodies of this 
isotype are only present at acute stages which is why they are frequently used for diagnosis [5]. 
Reinfection of early stage patients from endemic areas [219,220,311] is indicating a weak non-
protective antibody response and might further complicate the interpretation of serological tests. It 
needs to my knowledge however still be investigated more thoroughly how pre-existing antibodies 
influence the chance of getting reinfected. Absence of protection can be explained by different means. 
Similar to what has been found in the mouse model, Borrelia might actively influence the human B 
cell immune response and prevent the induction of protective antibodies especially at early stages of 
the disease. In accordance with that, sera from late stage patients more likely protected mice from 
infection than that of early stage subjects [312,313]. Although also other antibodies might have been 
involved, protection was largely attributed to antibodies generated against outer surface proteins 
(OspA and OspB) [312,313]. OspA is expressed inside the tick and downregulated as Borrelia enter 
the animal host. This protein can occur at the surface of bacteria again at later stages of infection, 
which is the reason why some patients generated these protective antibodies. In this example 
protection was dependent on the expression of the protein rather than the body not being able to 
generate antibodies. OspA ended up in a licensed vaccine, which was however withdrawn from the 
market due to low efficacy combined with complaints about adverse side effects [186]. New 
vaccination strategies based on this protein and a combination with OspC epitopes – a protein that is 
expressed in vivo - are current research topics [314-316]. Inclusion of OspA from only one Borrelia 
strain was not enough to elicit protection against all other circulating species. This means, that 
protection might also depend on the protein variants expressed by the infecting strains. In agreement 
with this are statistical analysis performed on ticks and erythema migrans patients from the same area, 
which indicate that even early stage patients might be protected for several years against the same but 
not a different Borrelia strain [221]. This assumption is based on the finding, that strains isolated 
from first infections are generally different from those of subsequent infections [220]. Mouse studies 
indicate that reinfection with the same Borrelia strain might however also be possible especially after 
antibiotics treatment [292]. To conclude, some patients might indeed be protected against certain 
Borrelia strains. However this might depend on which strains they catch (and caught before) as well 
as the list and nature of antigens expressed prior to their elimination. It seems, that the outcome of 
the B cell immune response is influenced by a complex interplay between host genetics and virulence 





Although many human studies focus on the antibody response, to my knowledge only a few studies 
have investigated the human B cell immune response to Borrelia at a phenotypic level. In contrast to 
some older studies that showed an increase in peripheral B-lymphocytes in other acute bacterial 
infections [142,143], Lyme disease does not seem to be associated with such changes [317,318]. 
Interestingly, in Neuroborreliosis [230,319,320] but also in Lyme arthritis [240,321,322], tissue 
localized ectopic Borrelia specific B cell immune responses have been observed. In the case of 
Neuroborreliosis, those were associated with low numbers of Borrelia-specific B cells in peripheral 
blood [319]. The strong response of synovial mononuclear cells from Lyme arthritis patients confirms 
a local immune reaction occurring within the joints [323].  
 
A recent RNAseq study of acute patient PBMCs found differences in the induction of B cell 
developmental pathways and calcium-induced T cell apoptosis by Borrelia as compared to other 
infectious agents [251]. Furthermore their data generated evidence for the involvement of a rather 
low proportion of B and T cells in peripheral blood in the acute Lyme disease condition as compared 
to other diseases. Although it still needs to be tested whether ectopic B cell immune responses are 
responsible for the effects observed in the aforementioned mouse model, their occurrence can be 
considered as rather confirmed in the human setting. The not necessarily but often transient nature of 
ectopic lymphoid follicles (ELFs) [324] would explain the patterns of reduction in antibody titers 
observed after antibiotics treatment [305,308,309]. The general absence of those structures from the 
skin[324], could explain the delayed antibody response that seems to correlate with the degree of 
Borrelia dissemination [308,309,323]. Recent studies that were able to associate Th17 responses 
[223,325] with post-Lyme disease symptoms and the development of autoantibodies at later stages 
of the disease, further support the idea, that inflammation driven ectopic B cell immune responses 
could play a role in the chronic course observed in a subset of patients.  Th17 cells seem to play a 
role in ectopic lymphoid follicle immune reactions in chronic inflammation and these structures have 
been shown to be a possible trigger in many autoimmune and chronic diseases [324]. In this context, 
the findings from the mouse study that showed, that chronic inflammatory conditions can prevent the 
homing of long-lived plasma cells to the bone marrow is also important to consider [154].  
 
Analysis of immune factor levels within peripheral blood was able to separate acute patients into two 
groups, one with higher levels of T cell recruiting chemokine and inflammatory marker expression 




in which B and T cell responses seem to be rather low [248], indicating heterogeneous responses 
among patients. This is in line with the rather heterogeneous nature also observed at the antibody 
level [295,304,305].  
 
1.3 Objectives of this study 
 
As outlined above, the human B cell immune response to Borrelia is very complex and far from being 
completely understood. Especially studies at the B cell receptor and cellular levels are missing. The 
main goal of this project was to explore whether signatures could be extracted from the bulk B cell 
repertoire of acute Lyme disease patients that might be useful to support diagnosis. Since B cells 
generally start to react with antigens already very early after contact [53], we expect to be able to 
detect an ongoing response at the cellular level already way before the antibody response is 
measurable. This is especially interesting in this case, as it was shown that ticks might inhibit the 
production of antibodies, but they don’t seem to interfere with the generation of memory B cells 
[287,288].  
Since B cells are the cells of our body that react most directly and specifically to immune challenges, 
we expect similar clones to appear in different individuals. Even if a very large amount of different 
B cell clones might be involved in the response, this does not exclude the possibility that some clones 
might nevertheless be generated in common. It is very likely though, that they only occur at very low 
levels. Recent studies indicate, that some degree of convergence is occurring 
[95,127,165,169,171,326], which looks highly promising and supports this hypothesis. One big 
problem though is the great diversity of the B cell repertoire. Even with next generation sequencing, 
we are very likely missing a large portion of important B cell clones [122]. For this reason, focusing 
on antigen-specific sequences is crucial. 
The IR6 domain of VlsE (VlsE-C6) is an epitope region, that is quite well conserved between different 
Borrelia strains [276]. Antibodies are already detectable very early and throughout all stages of 
infection probably as a result of it being expressed throughout the whole infection period [274,327]. 
For this reason, we decided to use this epitope as model antigen to test for the level and kinetics of 
Borrelia reactive B cells in peripheral blood of acute Lyme disease patients.  
Besides the potential presence of immune signatures, B cell repertoire next-generation sequencing 
data harbour a tremendous amount of different interesting information that might be valuable to better 




able to confirm some of the findings from the mouse model which clearly showed that Borrelia 
actively influence the B cell immune response [289-293]. We expect, that certain features (like 
mutation status, class-switching of clones, evolution of clones over different timepoints,…) might 
allow us to draw conclusions about the nature of the B cell immune response towards Borrelia and 
maybe even to separate different patients into reactivity groups. In the case of hepatitis C virus 
infection, differences in clonal evolutions could for example be found between resolving and 
chronically evolving patients [328]. It would be highly interesting to determine whether similar 










2.1 Chemicals and solutions used to amplify and purify nucleic acids 
 
Compound Company 
10x Dulbecco’s Phosphate buffered saline 
(DPBS) w/o Ca++, Mg++ 
Lonza 
1kb plus DNA ladder Thermo Fisher Scientific (Invitrogen) 
2-Propanol BioReagent for molecular biology Sigma-Aldrich 
Dimethyl sulfoxide, Hybri-Max™, sterile-
filtered, BioReagent, suitable for hybridoma, 
99.7% (DMSO) 
Sigma-Aldrich 
Dithiothreitol (DTT) (0.1M) Thermo Fisher Scientific (Invitrogen) 
Ethanol molecular biology grade VWR 
IGEPAL® CA-630 for molecular biology 
(Nonidet P-40/Igepal) 
Sigma-Aldrich 
Magnesium Chloride (MgCl2) Thermo Fisher Scientific (Invitrogen) 
Nucleotides (dNTPs) Thermo Fisher Scientific (Invitrogen) 
Oligonucleotides/Primers Eurogentec 
Orange DNA Loading Dye (6x) Thermo Fisher Scientific 
Random primers Thermo Fisher Scientific (Invitrogen) 
RNAse/DNase free water Thermo Fisher Scientific (Gibco) 
SeaKem® LE Agarose Lonza 






2.2 Chemicals used to prepare buffers, solutions and media 
 
Compound Company 
10x Dulbecco’s Phosphate buffered saline 
(DPBS) w/o Ca++, Mg++ 
Lonza 
2-Amino-2-methyle-1-propanole (AMP) Sigma-Aldrich 
Bovine Serum Albumin Sigma-Aldrich 
Carbonate-Bicarbonate Buffer capsules Sigma-Aldrich 
Dimethyl sulfoxide, Hybri-Max™, sterile-
filtered, BioReagent, suitable for hybridoma, 
99.7% (DMSO) 
Sigma-Aldrich 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich 
Fetal bovine serum (FBS), South American 
Origin, Low IgG, sterile filtered, for cell culture 
(Lot: 8SB0001): 
Lonza 
Ficoll-PaqueTM PLUS, endotoxin tested, sterile GE Healthcare Life Sciences 
HyClone™ Fetal Bovine Serum (U.S.), 
Standard (Lot: AAB199095) 




Thermo Fisher Scientific (Gibco) 
Phosphatase substrate 5mg tablets Sigma-Aldrich 
Potassium Chloride (KCl) Sigma-Aldrich 
RPMI 1640 with UltraGlutamine I and HEPES Lonza 
Sodium Acetate (CH3COONa) Merck Millipore 
Sodium azide (NaN3) Sigma-Aldrich 
Sodium Chloride (NaCl) Acros Organics 
Sodium pyruvate (100mM) Thermo Fisher Scientific (Gibco) 






Trizma® base Sigma-Aldrich 
TWEEN® 20 Sigma-Aldrich 
UltraGlutamine I Lonza 
 
From these reagents, the following buffers were prepared: 
 
Buffer / solution Reagent Volume /  
Concentration 
Experiment 
TAE buffer  

























































































































HotStarTaq® DNA Polymerase Qiagen 
Phusion® High-Fidelity DNA Polymerase New England Biolabs 
Platinum® Taq DNA polymerase Thermo Fisher Scientific (Invitrogen) 
Q5® Hot Start High-Fidelity DNA Polymerase New England Biolabs 
RNaseOUTTM Recombinant Ribonuclease 
Inhibitor 
Thermo Fisher Scientific (Invitrogen) 
RNasin® Ribonuclease Inhibitor Promega 
SuperScript® III Reverse Transcriptase Thermo Fisher Scientific (Invitrogen) 
 
2.4 Antibodies, and reagents used for flow cytometry 
 
Antibody / Chemical Company 
Goat Anti-Human IgG-AP Southern Biotech 
Hoechst Thermo Fisher Scientific (Invitrogen) 
Anti-Human IgA-APC Jackson ImmunoResearch Laboratories 
Anti-Human IgM-APC Jackson ImmunoResearch Laboratories 




Mouse Anti-Human CD138-APC Biolegend 
Mouse Anti-Human CD138-BV711 BD Horizon 
Mouse Anti-Human CD14-eFluor605NC eBioscience 
Mouse Anti-Human CD14-FITC Immunotools 
Mouse Anti-Human CD14-PE Immunotools 
Mouse Anti-Human CD16-PercPcy5.5 Biolegend 
Mouse Anti-Human CD19-BV605 BD Pharmingen 
Mouse Anti-Human CD20-AF488 Biolegend 
Mouse Anti-Human CD20-AF700 Biolegend 
Mouse Anti-Human CD20-Biotin Immunotools 
Mouse Anti-Human CD21-PE-Cy7 Biolegend 
Mouse Anti-Human CD23-APC-eFluor780 eBioscience 
Mouse Anti-Human CD24-BV421 BD Horizon 
Mouse Anti-Human CD24-eF450 eBioscience 
Mouse Anti-Human CD27-BV421 BD Biosciences 
Mouse Anti-Human CD27-PECF594 BD Horizon 
Mouse Anti-Human CD38-PerCP-Cy5.5 Biolegend 
Mouse Anti-Human CD3-FITC Immunotools 
Mouse Anti-Human CD3-PE Immunotools 
Mouse Anti-Human CD3-PE-Dy647 Immunotools 
Mouse Anti-Human CD43-APC eBioscience 
Mouse Anti-Human CD56-PeCP-Cy5.5 Biolegend 
Mouse Anti-Human CD5-FITC Immunotools 
Mouse Anti-Human IgD-BV421 BD Pharmingen 
Mouse Anti-Human IgD-PacBlue Biolegend 




Mouse Anti-Human IgG-PE BD Pharmingen 
Mouse Anti-Human IgM-BV570 Biolegend 
Neutravidin-DyLight650 Thermo Fisher Scientific 
 
2.5 Commercial kits 
 
Kit Company 
Agencourt® AMPure® XP beads Beckman Coulter 
Agilent High Sensitivity DNA Kit Agilent Genomics 
AllPrep DNA/RNA Mini Kit Qiagen 
Big Dye® Terminator v3.1 Cycle Sequencing 
Kit 
Thermo Fisher Scientific (Applied Biosystems) 
Borrelia afzelii + VlsE IgG Europe ELISA 
Testkit 
Genzyme Virotech 
Borrelia afzelii IgM ELISA Testkit Genzyme Virotech 
Borrelia Europe LINE IgM Immunoblot Genzyme Virotech 
Borrelia Europe Plus TpN17 LINE IgG 
Immunoblot 
Genzyme Virotech 
Dynabeads™ mRNA DIRECT™ Purification 
Kit 
Thermo Fisher Scientific (Invitrogen) 
EasySepTM Human B cell Enrichment Kit Stemcell Technologies 
Human B cell Isolation Kit II Miltenyi Biotec 
Human IgG total Ready-SET-Go!® ELISA eBioscience 
Ion 318TM Chip Kit v2 Thermo Fisher Scientific 
Ion PGMTM Enrichment Beads Thermo Fisher Scientific 
Ion PGMTM Wash 2 Bottle Kit Thermo Fisher Scientific 
Ion PGM™ Hi-Q™ Sequencing Kit Thermo Fisher Scientific 




Ion PGM™ Template OT2 400 Kit Thermo Fisher Scientific 
Ion Sphere™ Quality Control Kit Thermo Fisher Scientific 
Jet Quick PCR Purification Spin kit Genomed 
QIAamp® DNA Blood Mini kit Qiagen 




2.6.1 Primers used for amplification of Borrelia DNA 
 
Primer 5’-3’ Sequence PCR reaction Reference 
V1a GGGAATAGGTCTAATATTAGC First round PCR [329] 
V1b GGGGATAGGTCTAATATTAGC First round PCR [329] 
V3a GCCTTAATAGCATGTAAGC Second round PCR [329] 
V3b GCCTTAATAGCATGCAAGC Second round PCR [329] 
R1 CATAAATTCTCCTTATTTTAAAGC First & second round PCRs [329] 
R37 CCTTATTTTAAAGCGGC First & second round PCRs [329] 
 
2.6.2 Primers used for amplification of Rickettsia DNA 
 
Primer 5’-3’ Sequence PCR reaction Reference 
Rr17k.1p TTTACAAAATTCTAAAAACCAT First round PCR [330] 
Rr17k.539n TCAATTCACAACTTGCCATT First round PCR [330] 
Rr17k.90p GCTCTTGCAACTTCTATGTT Second round PCR [330] 





2.6.3 Primers used for amplification of immunoglobulin heavy chain genes from single cells 
 
Primer 5’-3’ Sequence PCR reaction Reference 
VHL-1 TCACCATGGACTGSACCTGGA First round PCR [331] 
VHL-2 CCATGGACACACTTTGYTCCAC First round PCR [331] 
VHL-3 TCACCATGGAGTTTGGGCTGAGC First round PCR [331] 
VHL-4 AGAACATGAAACAYCTGTGGTTCTT First round PCR [331] 
VHL-5 ATGGGGTCAACCGCCATCCT First round PCR [331] 
VHL-6 ACAATGTCTGTCTCCTTCCTCAT First round PCR [331] 
CμII CAGGAGACGAGGGGGAAAAG First round PCR [331] 
CγII GCCAGGGGGAAGACSGATG First round PCR [331] 
CαII GCTCAGCGGGAAGACCTT First round PCR [331] 
VH-1-nr CAGGTSCAGCTGGTRCAGTC Second round PCR [331,332] 
VH-2-nr CAGRTCACCTTGAAGGAGTC Second round PCR [331,332] 
VH-3-nr SAGGTGCAGCTGGTGGAGTC Second round PCR [331,332] 
VH-4-nr CAGGTGCAGCTGCAGGAGTC Second round PCR [331,332] 
VH-5-nr GARGTGCAGCTGGTGCAGTC Second round PCR [331,332] 
VH-6-nr CAGGTACAGCTGCAGCAGTC Second round PCR [331,332] 
CμIII-nr GAAAAGGGTTGGGGCGGATGC Second round PCR [331,332] 
CγIII-nr GACSGATGGGCCCTTGGTGGA Second round PCR [331,332] 
CαIII-nr GACCTTGGGGCTGGTCGGGGA Second round PCR [331,332] 
 
2.6.4 Primers used for amplification of immunoglobulin light chain genes from single cells 
 
Primer 5’-3’ Sequence PCR reaction Referenc
e 




VκL-2 CTGGGGCTGCTAATGCTCTGG First round PCR [331] 
VκL-3 TTCCTCCTGCTACTCTGGCTC First round PCR [331] 
VκL-4 CAGACCCAGGTCTTCATTTCT First round PCR [331] 
VλL-1 CCTCTCCTCCTCACCCTCCT First round PCR [331] 
VλL-2 CTCCTCACTCAGGGCACA First round PCR [331] 
VλL-3 ATGGCCTGGAYCSCTCTCC First round PCR [331] 
CκII TTTCAACTGCTCATCAGATGGCGG First round PCR [331] 
CλII AGCTCCTCAGAGGAGGGYGG First round PCR [331] 
Vκ-1-nr CGMCATCCRGWTGACCCAGT Second round κ PCR [331,332] 
Vκ-2-nr CGATRTTGTGATGACYCAG Second round κ PCR [331,332] 
Vκ-3-nr CGAAATWGTGWTGACRCAGTCT Second round κ PCR [331,332] 
Vκ-4-nr CGACATCGTGATGACCCAGT Second round κ PCR [331,332] 
CκIII-nr AAGATGAAGACAGATGGTGC Second round κ PCR [331,332] 
AgeI-Vλ-1 CTGCTACCGGTTCCTGGGCCCAGTC
TGTGCTGACKCAG 
Second round λ PCR [333,334] 
AgeI-Vλ-2 CTGCTACCGGTTCCTGGGCCCAGTC
TGCCCTGACTCAG 
Second round λ PCR [333,334] 
AgeI-Vλ-3 CTGCTACCGGTTCTGTGACCTCCTAT
GAGCTGACWCAG 
Second round λ PCR [333,334] 
AgeI-Vλ-4/5 CTGCTACCGGTTCTCTCTCSCAGCYT
GTGCTGACTCA 
Second round λ PCR [333,334] 
AgeI-Vλ-6 CTGCTACCGGTTCTTGGGCCAATTTT
ATGCTGACTCAG 
Second round λ PCR [333,334] 
AgeI-Vλ-7/8 CTGCTACCGGTTCCAATTCYCAGRC
TGTGGTGACYCAG 
Second round λ PCR [333,334] 
XhoI-Cλ CTCCTCACTCGAGGGYGGGAACAGA
GTG 
Second round λ PCR [333,334] 
 






















































































































































Amplification PCR  
amp_P1 
CCTCTCTATGGGCAGTCGGTGAT 





2100 Bioanalyzer Agilent Technologies 
ABI PRISM® 3130xl Genetic Analyzer Applied Biosystems 
CFX96TM Real-Time PCR Cycler Bio-Rad 
Electrophoresis Power Supply EV231 Consort 
FACSAria SORP BD Biosciences 
Gel tank combs and casting form Bioplastics 
Heating block Peqlab 
InGenius gel documentation system Syngene 
Ion OneTouchTM 2 System Thermo Fisher Scientific 




Leica M205C Stereomicroscope equipped with 
camera and incident LED source 
Leica 
Leitz DMIL Inverted Phase Contrast 
Microscope 
Leitz 
NanoDrop ND-1000 Spectrophotometer Thermo Fisher Scientific 
Precision balance Sartorius 
Purelab® flex water purifier ELGA LabWater 
Qubit® 2.0 Fluorometer Thermo Fisher Scientific (Invitrogen) 
Safe ImagerTM Tramsilluminator Thermo Fisher Scientific (Invitrogen) 
SL40R centrifuge Thermo Scientific 
SpectraMax Plus Microplate Reader Molecular devices 
Tissue Lyser II Qiagen 
UNO96 Thermal Cycler VWR 
 
2.8 Software and bioinformatics 
 
Software / Tool Company / Developer 
2100 Expert Software Agilent Genomics 
bcRep R package (bcRep_1.3.4) Bischof and Ibrahim [2] 
BioEdit Sequence Alignment Editor v7.2.5.0 Tom Hall 
Bio-Rad CFX Manager Bio-Rad 
Cd-hit-v4.6.7 Li et al. and Fu et al. [336,337] 
Change-o Gupta et al. [338] 
Fastx-Toolkit The Hannon Lab 
GeneSnap Syngene 
GraphPad Prism 5 GraphPad Software, Inc. 




IMGT®/HighV-QUEST Alamyar et al. [340] 
IMGT®/V-QUEST Brochet et al. [341] 
Kaluza Analysis Software Beckman Coulter 
PAGAN graph aligner Löytynoja et al. [342]  
Phylogeny.fr Laboratoire d’Informatique, de Robotique et de 
Microélectronique de Montpellier [343-346] 
Python 2.7.6 Python Software Foundation 
Python clustering script (cl_1.1.9) Galson et al. [126,127,171] 
R The R Foundation 
Rstudio Rstudio 
SeqTrace-0.9.0 Stucky [347] 
Torrent Suite Software and Torrent Server Thermo Fisher Scientific 
VDJtools-1.0.3 Shugay et al. [348] 
 
2.9 Blood tubes and other special lab materials 
 
Lab material Company 
Axygen® 0.2mL Maxymum Recovery® Thin 
Wall PCR Tubes 
Axygen Scientific 
BD Vacutainer® K2 EDTA tube (10ml) Thermo Fisher Scientific 
Cryo.s™ Cryogenic Storage Vials Greiner Bio One 
DynaMagTM-2 Magnet Thermo Fisher Scientific 
EasySepTM Magnet Stemcell Technologies 
Eppendorf® DNA LoBind microcentrifuge 
tubes 1,5 ml 
VWR 
LeucoSep® tube, polypropylen, 50ml, sterile Greiner Bio One 




MACS® Manual Separators (OctoMACS and 
QuadroMACS) 
Miltenyi Biotec 
Polyester films, non sterile VWR 
VACUETTE® RÖHRCHEN 8 ml Z Serum 
Separator 
Greiner Bio One 









3.1 Recruitment of patients 
 
For this study, patients for which Lyme borreliosis has been diagnosed by a medical doctor from 
Luxembourg have been recruited. A total of three blood draws were planned for each patient (Figure 
5). In general, the first blood draw was done as close as possible to the timepoint of diagnosis (average 
duration of symptoms before first blood draw: 8 ±13 weeks ranging from 2 days to 1 year) and start 
of therapy (average before first blood draw: 4±5 days  ranging from 0 to 17 days). A second blood 
draw was performed one week after and a third one, one month after the first visit. Due to the expected 
constant state of seropositive, seronegative and chronic Lyme disease patients, these donors were 
only sampled at a single timepoint. At each visit, the patients had to fill out a questionnaire asking 
them about their symptoms, diagnosis, treatment, tick exposure and previous Lyme disease infections 
(for more information, please refer to 8.1 Questionnaires). Only patients which reported at their last 
blood draw that antibiotics treatment reduced, changed or healed their symptoms or for which a clear 
picture of the erythema migrans was available were considered as clear acute cases and were included 
for the analysis of the B cell immune response against Borrelia. Since the overall number of 
participants was not high, we continued recruitment until the end of the study and therefore the data 
presented are not always consistently performed on the same patients. Since this study was rather 
exploratory in terms of getting first hints about the B cell immune response at the repertoire level, for 
subsequent analysis, we chose to study the most clear and interesting cases available at the time the 
assay was performed over the ones we started to explore already. Table 3, Table 4 and Table 5 give 
a general overview and more detailed information about relevant participants from this study. To 
keep groups comparable, age matched donors were used for each experiment. As control cohort, 
healthy individuals or donors with a recent tick bite were included. Ticks of these donors were 
screened for the presence of Borrelia and Rickettsia DNA [349]. Donors for which at least the back 
of the tick was still intact (adult female I. ricinus tick) and for which the Borrelia PCR was negative 
were included into the control group. These donors were selected based on their age to equalize acute 




group as compared to the controls. The current study has been accepted by Luxembourg’s ethics 
committee and data protection commission and each donor had to sign an informed consent before 
blood was taken. 
 
Figure 5: Overview of blood sampling and experiments performed on the samples. 
 
3.2 Estimation of tick feeding time 
 
To be able to estimate the time of feeding [350,351] and to assess intactness of the ticks after removal, 
a picture from the top and one from the bottom was taken using a microscope equipped with a camera. 
After that, ticks were stored in tubes at -80°C until used for DNA extraction. The length of the 
alloscutum (a) and the width of the scutum(b) were determined and the scutal index calculated from 
their ratio (a/b) [351]. In a second step the idiosoma length was determined once by looking at the 
tick from the top and once from the bottom (to see how reproducible this measuring is) (A) and the 
scutal width (B) as well as the coxal gap (C) were also determined. In this way, a second value for 
the scutal index (A/B) and coxal index (C/B) were calculated[350]. As described in (Figure 6), 
feeding time of individual ticks was estimated based on scutal and coxal indices using the formulas 





Figure 6: Schematic representation of method that was used to estimate tick feeding time. A = 
idosoma length, B = scutal width, C = coxal gap, a = alloscutum length, b = scutal width. As 
indicated, a different formula was used for adult female ticks than for nymphs. 
 
3.3 Screening of ticks for the presence of Borrelia and Rickettsia pathogens 
 
The PCR protocols used here have been setup by Anna L. Reye in the framework of a previous project 
from our laboratory[349]. Since ticks can harbour potentially dangerous pathogens, extraction of 
DNA was performed in a biosafety level 2 cabinet in our biosafety level 3 room. The QIAamp DNA 
Blood Mini kit (Qiagen) was used and the protocol of the manufacturer followed. Ticks were 
disrupted in 300ul AL buffer using the TissueLyser II (Qiagen). Amplification of Borrelia DNA 
(OspA gene) was performed in two consecutive steps using the primers from Michel et al. [329]. For 
the first round PCR, the following mastermix was prepared: 
 
Reagent Volume/reaction [ul] 
ddH2O 7.65 




MgCl2 (50 mM) 1 
dNTPs (10 mM) 0.5 
SyBr Green (10X) 0.25 
V1a primer (10 uM) 2 
V1b primer (10 uM) 2 
R1 primer (10 uM) 2 
R37 primer (10 uM) 2 
Platinum Taq® polymerase (5U/μl) (Invitrogen) 0.1 
DNA extracted from tick 5 
Total 25 
 
To avoid contaminations, all the mastermixes prepared in this study were strictly pipetted in our clean 
mastermix room. DNA for first round PCRs was added in our PCR1 room in which only samples 
with low DNA concentration can be handled. For the first round OspA PCR, the following protocol 
was used: 
 
Temperature [°C] Time [min:sec] Cycles 
94 3:00 1 
94 00:45  
50 00:45 40 
72 01:00  
72 10:00 1 
 
For the second round PCR the following mastermix was prepared: 
 





Buffer (10x) 2.5 
MgCl2 (50 mM) 1 
dNTPs (10 mM) 0.5 
SyBr Green (10X) 0.25 
V3a primer (10 uM) 2 
V3b primer (10 uM) 2 
R1 primer (10 uM) 2 
R37 primer (10 uM) 2 
Platinum Taq® polymerase (5U/μl) (Invitrogen) 0.1 
Product from first round PCR 1 
Total 25 
 
DNA for second round PCR was added in our PCR2 room, in which more concentrated DNA samples 
and extracted plasmids can be handled. The following temperature protocol was used: 
 
Temperature [°C] Time [min:sec] Cycles 
94 3:00 1 
94 00:45  
52 00:45 40 
72 01:00  
72 10:00 1 
 
Although this was not checked for in this case, this PCR should give a product of 850bps.  
Detection of Rickettsia DNA (17 kDa) was also done by two rounds of PCR using the primers from 





Reagent Volume/reaction [ul] 
ddH2O 11.65 
Buffer (10x) 2.5 
MgCl2 (50 mM) 1 
dNTPs (10 mM) 0.5 
SyBr Green (10X) 0.25 
Rr17k.1p primer (10 uM) 2 
Rr17k.539n primer(10 uM) 2 
Platinum Taq® polymerase (5U/μl) (Invitrogen) 0.1 
DNA extracted from tick 5 
Total 25 
 
The following temperature protocol was used: 
 
Temperature [°C] Time [min:sec] Cycles 
94 3:00 1 
94 00:30  
55 00:30 40 
72 00:45  
72 10:00 1 
 
The following mastermix was prepared for the second round PCR: 
 





Buffer (10x) 2.5 
MgCl2 (50 mM) 1 
dNTPs (10 mM) 0.5 
SyBr Green (10X) 0.25 
Rr17k.90p primer (10uM) 2 
Rr17k.539n primer (10uM) 2 
Platinum Taq® polymerase (5U/μl) (Invitrogen) 0.1 
Product from first round PCR 1 
Total 25 
 
The following temperature protocol was used: 
 
Temperature [°C] Time [min:sec] Cycles 
94 3:00 1 
94 00:30  
54 00:30 40 
72 00:45  
72 10:00 1 
 
This PCR should yield a PCR product of 450bps. All PCRs on tick DNA from this study were 
performed in a 96 well CFX real time PCR machine (Biorad). Real time PCR curves were analyzed 
with CFX Manager (Biorad). For Rickettsia PCRs, products were analyzed on an agarose gel. Positive 








3.4 Processing of patient blood samples and PBMC cryopreservation 
 
Manipulation of patient material was done under biosafety level 2 conditions. PBMCs were extracted 
from 30ml of blood collected in sodium heparin tubes. We made sure to process the blood tubes 
within 8 hours after the blood draw. Tubes were stored at room temperature (RT) until processing. 
For peripheral blood mononuclear cell (PBMC) isolation, 15ml Ficoll was added to each 50ml 
Leucosep tube and centrifuged for 30-60s at 1000xg at RT. 15ml of blood were diluted with 15 ml of 
PBS and transferred to the prepared Leucosep tubes. After centrifugation for 40min at 400xg at RT 
without brake, the PBMC layer was removed and washed twice in 50ml PBS (300xg for 10min at 
RT). Cells resuspended in 5ml PBS were counted manually using Trypan blue staining and Neubauer 
chamber before another centrifugation step. Freezing was done by resuspending the PBMCs in 2.5ml 
cold complete RPMI1640 medium, followed by slowly adding droplet by droplet 2.5ml cold FBS 
containing 20% of DMSO [1]. After that, 3-5 aliquots of cells (1ml/tube) were prepared in precooled 
(-20°C) cryotubes and immediately put on ice and frozen down as quickly as possible in -80°C using 
a Mr. frosty. For long-term storage, cryotubes were transferred to a cryotank. Approximately 8ml of 
blood have been taken in serum tubes. After incubation for at least 30min at 37°C to allow blood 
clotting, the tubes were spun down for 30min at 3000rpm. The serum was aliquoted and stored at -
80°C. Some of the blood samples used for PBMC extraction from seropositive and seronegative 
participants were collected in EDTA tubes. 
 
3.5 Screening of patient sera for the presence of Borrelia antibodies 
 
In general the last timepoint of each donor was tested for seropositivity against Borrelia using the 
commercially available kits for Europe from Sekisui Virotech. In case of a seropositive result, the 
first timepoint(s) was(were) also tested to check for a potential seroconversion. Besides this an in-
house Borrelia-VlsE-C6 peptide ELISA has been developed using the following peptides as antigen: 
C(Mal-PEG2-Biotin)MKKDDQIAAAIALRGMAKDGKFAVK (VlsE-C6 epitope from Borrelia 
bugdorferi s. s. strain B31), C(Mal-PEG2-Biotin)MKKDDQIAAAMVLRGMAKDGQFALK (VlsE-
C6 epitope from Borrelia garinii strain IP90) and C(Mal-PEG2-
Biotin)MKKRNDNIAAAIVLRGVAKDGQFALK (VlsE-C6 epitope from Borrelia afzelii strain 




originate from [280]. VlsE peptides for ELISAs were stored at -80°C as 1-2mg/ml solutions in 50% 
DMSO. ELISA plates were coated overnight at 4°C with 50ul of 1ng/ml peptide solution in carbonate 
buffer and plates washed three times with washing buffer. Plates were blocked for two hours at RT 
with 150ul blocking buffer. After another three washing steps, 50 ul of diluted serum samples (1:100) 
were incubated for one and half hours before washing three times. The secondary antibody (Goat 
Anti-Human IgG-AP) was diluted 1:700 in dilution buffer and 50ul were incubated in the wells for 
one and half hours. The plates were washed an additional three times before substrate was added. 
Readout of the ELISA plate was performed at 405nm after incubation for one hour at 37°C. For 
ELISAs performed in 384 well plates a slightly changed protocol (with an easier way to prepare the 
buffers) was used. 2ug/ml in 20ul were used to coat the 384 well plates. 
 
3.6 Multicolor flow cytometry 
 
Cells were thawed as described in the next section. 2x106 PBMCs were stained immediately after 
thawing in 100ul FACS buffer on ice. The samples were measured in three independent FACS 
experiments. One control sample was used for compensation controls and to test reproducibility 
between experiments. Compensation was done using a mix of cells and compensation beads. 
Antibodies were not titrated but the amount indicated on the vials was used. For multicolor staining, 
a mastermix containing all the antibodies was prepared. Control and acute samples were equally 
distributed among experiments. After addition of antibodies, cells were incubated on ice for 20-
30min. 4ml FACS buffer was added to wash and the cells were centrifuged for 10min at 300xg and 
4°C. Supernatant was removed by pouring and cells resuspended in 100ul FACS buffer. Hoechst was 
only added shortly prior to measuring on a FACSAria SORP (BD Biosciences) machine. Antibodies 
used in the panel: CD14-eFluor605NC, CD24-eF450, CD43-APC, CD23-APC-eFluor780 
(eBioscience), IgD-BV421, CD19-BV605, IgG-PE (BD Pharmingen), CD10-BV510, CD138-
BV711, CD27-PECF594 (BD Horizon), IgM-BV570, CD38-PerCP-Cy5.5, CD20-AF700, CD21-PE-
Cy7 (BioLegend), CD5-FITC, CD3-PE-Dy647 (Immunotools). For the first experiment no CD43 
staining was performed and the following antibodies were used instead in the corresponding channels: 
CD24-BV421 (BD Horizon), IgD-PacBlue and CD138-APC (BioLegend). Markers for this 





3.7 FACS staining for antigen-specific single cell sorting 
 
Cells were thawed up on the day before the FACS sorting and isolated B cells were kept overnight in 
complete RPMI1640 medium at 37°C and 5% CO2. For thawing, the cryovials were put into a water 
bath at 37°C until the outer layer of the ice crystal had melted. As soon as the ice crystal started 
melting, 1ml of prewarmed (37°C) complete RPMI1640 medium was added for complete thawing 
and cells were transferred into 8ml prewarmed (37°C) complete RPMI1640 medium. Cells were spun 
down at 300xg for 10min at room temperature, resuspended  in 1ml medium and counted with Trypan 
blue staining and Neubauer chamber. The cells were kept in the incubator at 37°C and 5% CO2 during 
the counting procedure. B cell isolation has been done by negative selection using the human B cell 
isolation kit II from Miltenyi. The separation of B cells was only suboptimal due to problems with 
cell clumping. This was probably a result of the long and too fast centrifugation after thawing. 
 
The next morning, as described in [352] the biotinylated peptides and Neutravidin were mixed and 
incubated at a ratio 4 to 1 (each Neutravidin has four biotin binding sites). For each reaction, 1ul 
Neutravidin was mixed with 6.7ul of 10uM biotinylated peptide. The same peptides were used as for 
the ELISAs, but they were resuspended in water. The tube was incubated in the dark on ice for 20-
30min followed by centrifugation for 10min at 4°C at maximum speed (to remove aggregates). Biotin 
was used as negative control as with the biotin binding sites blocked we saw less background than 
with untreated Neutravidin. In our hands, changing from Streptavidin [352] to Neutravidin reduced 
the background tremendously. During incubation, the isolated B cells from the previous day were 
spun down at 300xg for 10min and resuspended in cold 100ul FACS buffer. During the whole staining 
procedure, the cells were kept cold (either on ice or in the fridge). When the tetramers were ready, 
7ul of tetramer mix were added to the cells and incubated for 30min on ice. For staining with mixed 
tetramers, the tetramers with each peptide were prepared separately and 7ul from each tetramer-
peptide mix was added to each tube (meaning a total volume of 21ul was used also for the Biotin 
control tubes). After incubation, cells were washed twice (300xg, 10min) with 4ml of cold FACS 
buffer (keep FACS buffer all the time on ice or in the fridge). For first washing, 4ml FACS buffer 
were added to the 100ul of cells. For marker staining, an antibody mastermix was prepared and the 
appropriate amount (no titration was done, concentration indicated on antibody vials was used) was 
added to the washed cells after resuspending in 100ul FACS buffer. The following antibodies were 




and dead cells: CD14-FITC, CD3-FITC, CD20-Biotin (Immunotools), IgD-BV421, CD27-PECF594 
(BDHorizon), CD19-BV605 (BDPharmingen) and Hoechst (Invitrogen). CD20-Biotin was used for 
compensation control for Neutavidin. After 30min incubation on ice, the cells were washed with 4ml 
of FACS buffer and resuspended in a minimum of 70ul (usually 100-200ul) FACS buffer for sorting 
on a FACSAria SORP (BD Biosciences) machine. 
 
3.8 Single cell sorting 
 
96 well PCR plates (Eppendorf) containing 5ul of 0,5x PBS, 10mM DTT and 5U Recombinant 
RNasin® Ribonuclease Inhibitor per well (according to single cell protocol from Buelow and Osborn 
[353]) were prepared in our mastermix room the day before the FACS experiment and frozen at -
20°C for overnight storage. The plates were sealed with plastic foil. Before sorting the plates were 
taken out and put into the fridge for thawing. In order to make sure that the liquid is at the bottom of 
the wells and to avoid spilling due to removing the foil, a quick spin at 4°C has been done before 
putting them into the sorter. The plate holder of the sorter is kept at 4°C for the whole sorting 
procedure. Maximum speed at which cells were sorted was 3000events/second and maximum flow 
rate of 2 was used. Random or negative B cells were sorted into the first row of the plate and the rest 
of the wells were filled with peptide tetramer positive CD19+CD27+(CD14-, CD3-, Hoechst-) B cells. 
In case of seropositive and seronegative donors, the sorting gates were set stricter, excluding also 
IgD+ B cells. The plates were sealed with plastic foil immediately after the sorting tube was empty 
and were quickly spun down (maximum 2min at 300xg and 4°C) to make sure that cells sticking to 
the sides of the wall of the wells also come into the liquid. In order to ensure RNA integrity, after 
sorting, the plates were immediately put on dry ice. A fresh plate was taken for every sample, no 
matter if the plate was full or not. After the experiment, the plates were transferred from dry ice to a 
-80°C freezer for storage. 
 
3.9 Reverse transcription for single cell PCR 
 
The PCR plate containing the stored single cells (5ul/well) was taken out of the -80°C freezer and 




Eppendorf vapo.protect thermal cycler. In a first step, 9ul of cold reverse transcription buffer 1 was 
added to each well: 
 
Reagent Volume/reaction [ul] 
First Strand buffer (2x) 5 
Lysis buffer (5% Nonidet P-40/Igepal, Sigma) 3 
Random primers (150ng/ul) 1 
Total 9 
 
The content of the plate was mixed by vortexing. A short spin of the plate was performed before 
putting it into the PCR machine at 65°C for 10min followed by 25°C for 3min. After these two 
temperature steps, the cells were put on ice for at least one minute before pipetting 5.5ul of the second 
mastermix containing: 
 
Reagent Volume/reaction [ul] 
First Strand buffer (5x) 2 
DTT (0.1M) 2 
dNTPs (2.5mM) 1 
SuperScript® III Reverse Transcriptase (200U/ul) 0.5 
Total 5.5 
 
After mixing and a short spin down, the plates were incubated at 37°C for 1h in the PCR machine 
followed by an inactivation step of the enzyme at 70°C for 15min. 
 





The single cell PCR was done using the primer sets from Wang and Stollar [331] but the restriction 
sites were omitted [332] from the primers. First round and second round PCRs were all performed in 
a total volume of 50ul in a UNO96 Thermal Cycler. For the heavy chain first round PCR the following 
mastermix was prepared in our mastermix room: 
 
Reagent Volume/reaction [ul] 
PCR Buffer (10x) 5 
dNTPs (2.5mM) 2 
Primers (20pmol/ul) -> 0,4uM final 1(x9 different primers) 
ddH2O 25.75 
HotStarTaq DNA Polymerase (Qiagen) 0.25 
Single cell cDNA 8 
Total 50 
 
The single cell cDNA was added in our PCR1 room in which only low level DNA samples are 
allowed to be handeled. The following temperature protocol was used: 
 
Temperature [°C] Time [min:sec] Cycles 
95 15:00 1 
94 00:45  
45 00:45 3 
72 01:00  
94 00:45  
50 00:45 40 
72 01:00  





For the heavy chain second round PCR, the same mastermix containing the second round primers and 
adjusted water was prepared and 3ul from the first round PCR was added in our PCR2 room in which 
more concentrated DNA samples are allowed to be handeled: 
 
Reagent Volume/reaction [ul] 
PCR Buffer (10x) 5 
dNTPs (2.5mM) 2 
Primers (20pmol/ul) -> 0,4uM final 1(x9 different primers) 
ddH2O 30.75 
HotStarTaq DNA Polymerase (Qiagen) 0.25 
Product from first round PCR 3 
Total 50 
 
The following temperature protocol was used: 
 
Temperature [°C] Time [min:sec] Cycles 
95 15:00 1 
94 00:45  
50 00:45 30 
72 01:00  
72 10:00 1 
 
No cells were sorted into the last row of the plates and these “empty” wells were used as negative 
controls for the PCR. In case the plate was not fully sorted, the remaining unsorted wells of the last 






3.11 Single cell PCR for amplification of immunoglobulin light chain genes 
 
For the light chain first round PCR the mastermix composition had to be adjusted: 
 
Reagent Volume/reaction [ul] 
PCR Buffer (10x) 5 
dNTPs (2.5mM) 4 
Primers (20pmol/ul) -> 0,2uM final 0.5(x9 different primers) 
MgCl2 3 
ddH2O 25.25 
HotStarTaq DNA Polymerase (Qiagen) 0.25 
Single cell cDNA 8 
Total 50 
 
The same temperature conditions could be used as for the heavy chain first round PCR. For second 
round PCRs the kappa and lambda reactions were performed separately. The following mastermix 
was prepared for the amplification of kappa light chain sequences: 
 
Reagent Volume/reaction [ul] 
PCR Buffer (10x) 5 
dNTPs (2.5mM) 2 
Primers (20pmol/ul) -> 0,4uM final 1(x5 different primers) 
ddH2O 34.75 
HotStarTaq DNA Polymerase (Qiagen) 0.25 






The same temperature protocol was used than for the heavy chain second round PCR. For 
amplification of lambda light chain products, the following mastermix was prepared this time using 
the primers from Tiller et al. [333,334]: 
 
Reagent Volume/reaction [ul] 
PCR Buffer (10x) 5 
dNTPs (2.5mM) 1 
Forward primer mix (10uM) 1 
Reverse primer (10uM) 1 
ddH2O 38.5 
HotStarTaq DNA Polymerase (Qiagen) 0.5 
Product from first round PCR 3 
Total 50 
 
The following temperature protocol was used: 
 
Temperature [°C] Time [min:sec] Cycles 
95 15:00 1 
94 00:45  
57 00:45 40 
72 01:00  







3.12 Analysis of correct sequence sizes on agarose gel and purification of PCR 
products for Sanger sequencing 
 
In order to verify whether the PCR reactions were successful, 5ul of each PCR product were mixed 
with 1ul of 6x loading dye and loaded onto a 1.5% agarose gel. Depending on the number of samples, 
either a small or a large gel was prepared. 1.5g or 4.5g agarose were heated in 100ml or 300ml of 
TAE buffer and boiled in a microwave. From time to time the solution was mixed and boiling was 
stopped when the whole agarose was dissolved. The solution was cooled down to a temperature at 
which it was still liquid but which allowed to touch the bottle without any problems. To later visualize 
the DNA on the gel, 10ul or 30ul of SYBR®Safe DNA Gel Stain was added and the homogenized 
solution poured into the gel chamber. The solid and loaded gel was run at 130V for 30-45 minutes in 
a gel chamber containing TAE buffer. To visualize the DNA bands on the gel, it was illuminated in 
an inGenius gel documentation system and an image was saved with a GeneSnap image acquisition 
software. 1kb plus DNA ladderTM was used as reference marker to estimate the size of the PCR 
products. The latter were purified using Jetquick PCR Product Purification Spin kit (Genomed 
Gmbh). In case of multiple bands the QIAquick Gel Extraction kit (QIAGEN) had to be used. 
 
3.13 Sanger sequencing and analysis of single cell sequences  
 
Sanger sequencing was performed in house by the technicians from our laboratory using the BigDye 
Terminator v3.1 Cycle Sequencing kit following the manufacturer’s protocol on a 3130xl Genetic 
Analyzer. The same primers were used than the ones for the amplifying PCR. The raw sequences 
were analyzed and consensus sequences manually corrected by using SeqTrace [347]. IMGT/V-
QUEST [341] was used to characterize the different sequences in terms of V and J gene usage as well 
as for CDR3 region identification. Clustering of single cell sequences was done using the bcRep R 
package 1.3.4 developed by Julia Bischof et al. [2] with the following settings clones95.tab<-
clones(aaseqtab = aaseqtab, summarytab = summarytab, identity = 0.95, useJ = TRUE, dispCDR3aa 
= TRUE, dispFunctionality.ratio = TRUE, dispFunctionality.list = TRUE, dispSeqID = TRUE). In 
this example, the sequences having the same CDR3 length, V and J genes as well as a CDR3 identity 
threshold of 95% were grouped into clusters. This was repeated with several CDR3 identity 




similarity was performed using the Python script cl_1.1.9.py kindly provided by Jacob Galson 
[12,127] using the following settings python cl_1.1.9.py -l overview.txt -r $x -m 1 -t 1 -o output , 
where the following mismatches were allowed x=2 (50% CDR3 identity), x=3 (67% CDR3 identity), 
x=4 (75% CDR3 identity), x=5 (80% CDR3 identity), x=6 (83% CDR3 identity), x=12 (92% CDR3 
identity). 
 
3.14 RNA extraction from PBMC samples for library preparation 
 
For thawing, best results (most viability of cells) was obtained when using the following procedure. 
Hold the cryovials into a water bath at 37°C until the outer layer of the ice crystal had melted. As 
soon as the ice crystal started melting, pour content of the vial into a 50ml falcon tube containing a 
mix of prewarmed (37°C) PBS and 3ml FBS. Centrifuge cells for only 5min at 1200rpm and 
resuspend them in 1ml PBS and remove aliquots for cell counting using Trypan blue staining and 
Neubauer chamber. Each tube contained frozen PBMCs from 6ml of peripheral blood. Spin the cells 
down for another 5min at 1200rpm during counting and immediately continue with DNA/RNA 
extraction using AllPrep DNA/RNA extraction kit (QIAGEN) according to manufacturer’s 
description. Six extractions corresponding to the samples that were pooled on one Chip were 
performed at a time. RNA yield was quantified using a NanoDrop Spectrophotometer. 
 
3.15 Library preparation and deep sequencing of the B cell repertoire 
 
Next generation sequencing of patients’ B cell repertoires was performed on an in house PGM Ion 
Torrent machine (Life technologies). The library preparation protocol of Vollmers et al. [1] using 
unique molecular identifiers (UIDs) in combination with BIOMED-2 V-gene FR2 primers [335] was 
adapted to the Ion Torrent system (Figure 7). Jean-Philippe Buerckert was so kind to share his mouse 
B cell repertoire protocol with me, which allowed to speed up the adaptation process. Barcoded 
primers were purified by PAGE while standard SePOP desalted primers were used for second strand 
synthesis. In the mastermix room, 1ul of 10mM dNTP solution and 2ul of 10uM barcoded isotype 
primers were added to a 96 well PCR plate, separating PCR reactions from each sample by at least 
one empty well in each direction. In the library preparation room, 500ng RNA for IgM and 1000ng 




In case of low RNA concentration, some reactions were done in two wells. The PCR plate was put 
into the PCR machine (UNO96 Thermal Cycler) programmed for 65°C 5min, 55°C 80min, 70°C 
15min and a total volume of 20ul. When the PCR machine reached the 55°C step, 8ul of the following 
mastermix were added to each well without removing the plate from the PCR machine: 
 
Reagent Volume/reaction [ul] 
First Strand buffer (5x) 4 
DTT (0.1M) 2 
RNaseOUTTM Recombinant RNase inhibitor (40U/ul) 1 
SuperScript® III Reverse Transcriptase (200U7ul) 1 
Total 8 
 
The content was well mixed by pipetting up and down a few times. I designed the PCR plate layout 
in a way to have PCR reactions from the same sample (IgM and IgG samples from individual 
timepoints) in one row so that I could use the same capping strip for the same samples. This allows 
to minimize cross-sample contaminations to a maximum by always opening only wells together that 
contain the same sample. By preparing IgM and IgG samples in parallel, one has the option to control 
for how properly one has worked by checking how much IgM isotype sequences one can later find 
in the IgG samples and vice versa. After the reverse transcription, 30ul of the following second strand 
mix was added to each reverse transcription reaction: 
 
Reagent Volume/reaction [ul] 
Phusion® HF Buffer (5x) 10 
ddH2O 7 
V-region primer mix (10uM) 10 
dNTPs (10mM) 1 
DMSO 1.5 






For second strand synthesis, tubes were put into the PCR machine that was programmed in the 
following way: 98°C 2min, 63°C 2min, 72°C 10min. After this, two consecutive manual Agencourt® 
Ampure® PCR purification bead (Beckman Coulter) cleanups were done using 1:1 bead to sample 
ratio and otherwise adhering to the manufacturer’s instructions. In order not to lose any DNA, low 
DNA bind tubes (Eppendorf) were used for all the purification steps. The double stranded DNA was 
eluted in 21ul water from our water purifier of which 20ul were added to a new PCR plate. The 
following PCR reaction mix was subsequently added: 
 
Reagent Volume/reaction [ul] 
Q5® Reaction Buffer (5x) 10 
Q5® High GC Enhancer (5x) 10 
ddH2O 4.5 
IonTorrent adapter primer mix (10uM) 2.5 
dNTPs (10mM) 2 
Q5® Hot Start High-Fidelity DNA Polymerase 1 
Total 30 
 
The PCR was performed in the same PCR machine (UNO96 Thermal Cycler) as used before, this 
time using the following temperature protocol: 
 
Temperature [°C] Time [min:sec] Cycles 
98 5:00 1 
98 00:10  
65 00:20 19-20 




72 02:00 1 
 
After this, the libraries were purified once using Agencourt® Ampure® PCR purification beads again 
at a bead to sample ratio of 1:1 before analyzing the quality and the quantity on a 2100 Bioanalyzer 
Instrument (Agilent Technologies). Those libraries that passed the quality check were pooled and a 
second Agencourt® Ampure® PCR purification bead cleanup of the pools was usually performed to 
completely get rid of potentially disturbing primer dimers before quantifying the pool on the 2100 
Bioanalyzer Instrument. The pools were sequenced using Ion PGM™ Template OT2 400 Kit, Ion 
PGM™ Sequencing 400 Kit and ION 318 CHIP KIT V2 (Life technologies) according to the 
manufacturer’s instructions. Because the old kits were no longer available at that time, the last 
sequencing run was performed using the newer Sequencing kit version (Ion PGM™ Hi-Q™ 
Sequencing Kit). After setting up the first deep sequencing runs for this project, Regina Sinner was 




Figure 7: Schematic representation explaining library preparation method. In our protocol, each 
mRNA is labeled with a unique molecular identifier (UID) barcode (highlighted in pink) before PCR 
amplification, allowing to assess PCR bias and coverage of the B cell repertoire. By generating 




only uses specific primers in the first amplification cycle and allows to reduce the primer sets to only 
one primer pair for the actual PCR amplification. This allows to reduce PCR amplification bias by 
avoiding multiplexing of different primers. As the Ion Torrent system is mainly doing 
insertion/deletion errors, we assume that selection of sequences containing exact matches of MID- 
NNNNNNN-GACT-NNNNNNNN-primer at the beginning of their sequence enables us to select for 
the majority of error free UID sequences from our samples and allows to discard reads having 
insertion/deletion errors at this site. Because the error rate increases with sequence length, the 
barcode was put at the beginning of the sequence. We start the sequencing from the constant part of 
the immunoglobulin heavy chain, as like this the CDR3 region is the closest possible to the beginning 
of the sequence. This enables us to get the maximum quality possible at the region we are the most 
interested in. In total 6 different molecular identifier (MID) barcodes (highlighted in orange) have 
been used to distinguish samples that could thus be pooled on the same Chip (IonXpress MID09: 
TGAGCGGAAC, MID15: TCTAGAGGTC, MID21: TCGCAATTAC, MID22: TTCGAGACGC, 
MID23: TGCCACGAAC and MID25: CCTGAGATAC). 
 
3.16 Flow cytometry and deep sequencing data analysis 
 
Kaluza Flow Cytometry Analysis Software was used for multicolor flow cytometry data analysis. 
Graphs and figures of this study were made using Power point and Graphpad Prism 5 Software. Mean 
and Standard Error of the Mean are represented in the different graphs. Significane: ****: p < 0.0001; 
***: p = 0.0001-0.001, **: p = 0.001-0.01; *: p = 0.01-0.05. Pre-processing of deep sequencing 
rawdata was performed using an in house cleanup pipeline developed by labmates (please refer to 
papers and thesis of Jean-Philippe Buerckert and Axel R.S.X. Dubois from our laborartory for more 
details). William Faison was so kind to do the data cleanup for this project. Briefly, unaligned and 
untrimmed raw bam files were downloaded from the Ion Torrent server and converted to fastq and 
fasta formats. Only sequences with correct and good quality MID and UID regions were kept for 
further analysis. Those were selected by searching for the following pattern without allowing any 
mismatch or frameshift: MID sequence – UID1 sequence – GACT – UID2 sequence – primer. Only 
reads for which at least 80% of the bases contained a quality score above 20 were kept for further 
analysis. Any reads exceeding 420bps in length were cleaved off after this threshold and all reads 
smaller than 180bps were discarded. After that, consensus sequences were generated using a 
multithread python script in combination with IgBlast [339]. For each UID, sequences defined as 
unproductive by IgBlast were excluded from the alignments and a consensus sequence was 
subsequently built with only productive reads using PAGAN graph aligner [342]. Singlet sequences 
were discarded from the analysis. After that, IMGT/High V-QUEST [354] was used for selection of 
productive final consensus sequences, assignment of V, J and CDR3 sequences as well as 




different general repertoire parameters, including CDR3 length, V and J gene distributions as well as 
repertoire diversity. Spectratype distortion was calculated by determining standard deviation of 
CDR3 length distribution using popData in R as in [20]. Clustering of sequences was performed using 
Change-o [338] kindly provided to labmates by Steven Kleinsteins group and the Python script kindly 
provided by Jacob Galson (which was also used for single cell data analysis) [12,127,171]. William 
Faison performed clustering analysis using the Change-o pipeline for this project. Unless otherwise 
indicated, deep sequencing data analysis was performed on final uncollapsed productive consensus 
sequences. Only phylogenetic tree analysis were performed on collapsed data. Standard bash scripting 
commands in Biolinux were used to handle the large datasets and to extract the information of interest 
from output files of the analysis tools. Grep and agrep (in case mismatches were allowed) commands 
were used to check for the presence of sequences of interest in samples. Cd-hit [336,337] was used 
to cluster CDR3 sequences or UIDs according to different degrees of similarity.  
 
3.17 Phylogenetic tree analysis of individual B cell clones of interest 
 
After selecting all the sequences belonging to the clone of interest (extracted from Change-o output 
files), they were aligned manually using BioEdit and cleaved off at the correct position (please refer 
to Figure 42 in the results section). Remaining insertion and deletion errors were manually corrected 
(please refer to the second paragraph of the following discussion point: 5.2 Strengths and weaknesses 
of the approach used herein to identify Borrelia specific B cell repertoire signatures) before collapsing 
and counting nucleotide sequences. Phylogenetic trees were generated from the corresponding amino 
acid sequences (generated by IMGT-VQUEST [341]) using the one click approach from 
phylogeny.fr[343,344]. The germline sequences from phylogenetic trees in this study were 
determined manually by using the first V germline sequence determined by IMGT [341] until the V-
D-J junction. As junction, generally the sequence present within the majority of sequences from that 
clone was taken. Whenever the D gene was clearly identifiable, this one was used, but this was nearly 
never the case. After the junction, the sequence was continued with the germline J gene. This means, 
that the trees are mainly highlighting mutations that occurred within the V-gene but mutations within 








3.18 In vitro single cell stimulation 
 
The in vitro stimulation protocol was kindly provided by Elisabetta Traggiai and John Lindner 
(Department of Mechanistic Immunology, Novartis Institutes for BioMedical Research, Basel, 
Switzerland). Alessia Colone took over this part of the project and provided final ELISA results on 
positive wells from which B cell receptors could then be analyzed. Briefly, she first negatively 
selected B cells from an aliquot of frozen PBMCs with the Easy Sep Human B cell enrichment 
cocktail kit (Stemcell Techonologies). After that, IgG expressing memory B cells were negatively 
selected using FACS sorting on a FACSAria Sorp machine (BD Bioscences). The following 
antibodies were used to gate on CD3-CD14-CD16-CD56-CD27+CD20+IgD-IgA-IgM-.B cells: anti-
CD3 PE, anti-CD14 PE (Immunotools), anti-CD16 PercPcy5.5 and anti-CD56 PecPcy5.5 
(Biolegend), anti-CD20 Alexa Fuor 488 (Biolegend), anti-CD27 BV421, anti-IgD PE (BD 
Biosciences), anti-IgA and anti-IgM (Jackson Immuno Research). After the sorting, cells were 
resuspended in supplemented RMPI 1640 and seeded in 384 wells plates at 1 cell/well mixed with 
2,5x105/ml of irradiated CD40L EL-4-B5 cells at 50 Gy and incubated in a stimulation cocktail 
similar to [355] allowing the production of antibodies. Cells were incubated at 37°C and 5% CO2. 
Supernatants were collected after 12-13 days for ELISA screening. At the same time cells were lysed 
in a homemade lysis buffer that has the same composition than the one from the Dynabeads Oligo 
(dT)25 kit (Life technologies) and stored at -80 0C. Besides the above described Borrelia VlsE-C6 
peptide antigens, Tetanus toxoid (TT) (Serum Institute of India), Cytomegalovirus Grade 2 (CMV), 
Varicella Zoster grade 2 (VZ), Measles Grade 2 (MV), Rubella K1S (K1S), Mumps Grade 2, Epstein-
Barr-Virus Viral Capsid Purified (EBV), Toxoplasma gondii (TG) antigens (Microbix Biosystems 
Inc.) were also tested for reactivity by ELISA: ELISAs were performed in 384 well plates as described 
above, using  2 μg/ml antigen concentration for all the antigens, except for EBV from which 30 ng/ml 
was sufficient. To isolate RNA only from wanted wells, lysis buffer from the Dynabeads Oligo 
(dT)25 kit (Life technologies) was heated up to 95°C and was added in volumes of 30-90ul (the 
volume is dependent on how cold the plate still was) to thaw up the content of the well of interest by 
pipetting up and down. This was repeated until everything from the well could be transferred into a 
low DNA bind tube (Eppendorf). The tube was filled up to 300ul of lysis buffer and RNA extracted 




attached were washed with 20ul 1x First Strand Buffer. They were kept in First Strand Buffer on ice 
until the following maxtermix was ready to be added: 
 
Reagent Volume/reaction [ul] 
dNTPs (10mM) 1 
5x First-strand buffer 4 
rRNasin RNase inhibitor (40U/ul) 0.5 
DTT (0.1M) 1 
ddH2O 13 
SuperScript® III Reverse Transcriptase (200U/ul) 0.5 
Total 20 
 
The First Strand Buffer was removed from the beads before they were resuspended in this 20ul 
mixture and incubated for 45 min at 50°C in a heating block. On completion of the reverse 
transcription, the beads were washed with 20 µl of 1x First Strand Buffer. Since the cDNA is attached 
to the beads, thorough homogenization of the solution prior to PCR amplification is required. 
Immunoglobulin PCRs were carried out immediately after cDNA synthesis as described above, with 
the exception that for the first round PCR only 3ul input material were used instead of 8ul. Beads 









4.1 Antibody responses in selected patients 
A detailed description of the donors that have been selected for closer analysis of the B cell immune 
response to Borrelia can be found in Table 3 (acute donors), Table 4 (tick bite donors) and Table 5 
(chronic patients). Seropositivity and seronegativity of the participants was determined in two ways. 
Besides the recommended two-tier method, for which we used commercial ELISAs and Immunoblots 
adapted for Europe, we also used an in house IgG VlsE-C6 peptide ELISA. In the latter, reactivity 
against peptides from three different Borrelia strains (B31, IP90, PT7) was assessed. We were able 
to confirm a strong correlation between reactivity of sera against the VlsE-mix on the commercial 
immunoblots and our in house ELISAs (Figure 8). Although the latter seems less sensitive, we were 
able to confirm, that all but one (95%) of the donors that strongly reacted with the immunoblot were 
also positive for at least one of the three peptides analyzed with the in house ELISA, confirming the 
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Figure 8: Correlation between VlsE reactivity in the commercial IgG immunoblot and in our 
in house VlsE-C6 IgG peptide ELISA. Peptides from three Borrelia strains (IP90, PT7, B31) were 
tested. Samples were grouped according to their reactivity in the commercial immunoblot (negative 
to highly positive: VlsE-, VlsE+, VlsE++, VlsE+++) and the corresponding values obtained with the in 
house ELISAs plotted on the y axis. ELISA values were normalized to two negative control samples 
(Ctrl) measured on each plate. ELISA results were kindly provided by Alessia Colone. 
 
Interestingly, we saw a general trend towards a higher reactivity for the peptide originating from the 
american Borrelia burgdorferi sensu stricto strain B31 (Figure 9), a result that was confirmed in 
several experiments. Eight (50%) of the sixteen analyzed acute Lyme disease patients showed IgG 
reactivity with at least two of the three Borrelia VlsE-C6 peptides tested (Table 2). Five of the patients 























































Figure 9: One example of the in house VlsE-C6 peptide ELISA assay used to test the serostatus 
of acute patients and controls. Two donors showed a striking increase (Lyme8) or decrease (Lyme4) 
in antibody titers during the observation period. T0-T2: different timepoints, HC: healthy controls, 
SN: seronegative donors, SP: seropositive donors, PC: positive controls, NC: negative controls. 
 
Table 2: Overview of VlsE-C6 peptide ELISA results of individual Lyme disease patients. 
Green: increase in antibody titer over time, Red: decrease in antibody titer over time, Blue: 
fluctuations in ELISA results but not really seropositive, Grey: stably seropositive donors, White: 
seronegative samples, Black: not determined. Numbers in brackets: fold change of antibody titer as 




In the two-tier testings, where we tested for both IgM and IgG reactivity against Borrelia, a 
seropositive result was obtained for 13 (81%) of the acute Lyme disease patients. In six (38%) of the 
acute patients, a change in antibody reactivity was observed, determined either by a change in 
intensity of single bands in the two-tier test done in house or by comparing our results to previous 
diagnostic tests done outside by different laboratories. Seronegativity of control donors were 
confirmed before sequencing antigen-specific B cells or the bulk B cell repertoire. For phenotypic 
analysis, healthy status was considered for both seropositive and seronegative otherwise healthy 
donors. 
Patient T0 T1 T2 T0 T1 T2 T0 T1 T2
Lyme1 Neg(1.0) Neg(0.54) Pos(1.68) Neg(1.0) Pos(3.05) Pos(2.50) Neg(1.0) Neg(0.27) Neg(0.80)
Lyme2 Pos(1.0) Pos(1.27) Pos(1.28) Pos Pos Pos Pos(1.0) Pos(1.64) Pos(1.66)
Lyme3 Neg Neg Neg Neg Neg Neg
Lyme4 Pos(1.0) Pos(0.83) Pos(0.52) Pos(1.0) Pos(0.80) Pos(0.49) Neg Neg Neg
Lyme5 Neg Neg Neg Neg Neg Neg Neg Neg Neg
Lyme6 Neg Neg Neg Neg Neg Neg Neg Neg Neg
Lyme7 Neg Neg Neg Neg Neg Neg Neg Neg Neg
Lyme8 Pos(1.0) Pos(1.71) Pos(2.23) Pos(1.0) Pos(1.74) Pos(2.38) Pos(1.0) Pos(1.77) Pos(2.32)
Lyme9 Neg Neg Neg Neg Neg Neg Neg Neg Neg
Lyme10 Neg Neg Neg Neg Neg Neg Neg Neg Neg
Lyme11 Pos Pos Pos Pos Pos Pos Pos Pos Pos
Lyme12 Pos Pos Pos Neg Neg Neg Pos Pos Pos
Lyme13 Pos(1.0) Pos(0.82) Pos(0.69) Pos Pos Pos Neg Neg Neg
Lyme14 Pos Pos Pos Pos Pos Pos Pos Pos Pos
Lyme15 Neg Neg Neg Neg Neg Neg Neg Neg Neg
Lyme16 Neg Neg Neg Neg Neg Neg Neg Neg Neg
B31 PT7 IP90






































































































































































































































































































































































































Twenty-nine ticks from participants were screened [349] for Borrelia and Rickettsia, the two most 
prevalent pathogens previously detected [349] in ticks from Luxembourg. Four (14%) ticks turned 
out to be positive for Borrelia (Figure 10) and two (7%) for Rickettsia DNA (Figure 11), values that 
closely match with previous findings (which were 16.3% and 6.7% respectively).  
Table 5: Patients for which chronic Lyme disease has been diagnosed and 
which were included into the multicolor flow cytometry analysis. 
Table 4: Donors which participated because of a recent tick bite. B cell repertoire deep 
sequencing analysis was performed on Tick 1-3, while Tick 3-5 were included into the multicolor 





Figure 10: Results from OspA real-time PCR that was used to test for the presence of Borrelia 
DNA in ticks. On the left, the results from the five donors used as controls in the deep sequencing 
and flow cytometry assays are depticted together with the positive and negative controls. On the right, 
the results obtained from all tested samples are depicted. 
 
Figure 11: Results from 17-kDa PCR that was used to test for the presence of Rickettsia DNA 
in ticks. Many side bands were obtained and the highlighted PCR products were sequenced. Only 
the green bands which also have the correct size can be considered as real positive for Rickettsia 
DNA. 
4.2 Analysis of patient’s peripheral B cell subset composition with multicolor 
flow cytometry 
 
To test whether acute Lyme disease affects peripheral B cell subsets, we developed a multicolor B 
cell panel (Figure 12). When analyzing the first six patients, we observed a rather constant donor 
specific peripheral B cell subset composition over time. No substantial changes, that would allow to 
distinguish acute Lyme disease condition from a healthy status could be determined from this low 
number of patients, indicating that occurring changes are rather of low level or very heterogeneous. 
In most cases, B cell subset composition was relatively stable throughout the one month observation 
period, confirming the reproducibility of our approach. After Borrelia infection, the time curve in 




variable. The comparison of acute Lyme disease patients with controls revealed a significant increase 
in double-negative (Figure 13A) and IgG expressing memory B cells (Figure 13F). There was also a 
tendency towards higher levels of plasmablasts (Figure 13E) and activated naïve B cells expressing 
CD23 (Figure 13H) especially when comparing only to healthy controls. Interestingly in one of the 
donors with a recent tick bite, we observed a particularly skewed peripheral B cell subset composition. 
This donor had highly expanded non-switched memory B cells (Figure 13D) as well as 
CD21lowCD38low autoreactive B cells (Figure 13I) combined with relatively high levels of 





Figure 12: Gating strategy 
used for multicolor flow 
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Figure 13: Results from multicolor flow cytometry experiment. Comp ctrl: Sample used for 
compensation control and to assess reproducibility between the three experiments (each dot 
represents one experiment). Healthy: healthy individuals sampled at a single timepoint. Tick bite and 
Acute: Individuals with a recent tick bite and acute Lyme disease patients respectively sampled 3 
times over one month. Chronic: patients for which chronic Lyme disease has been diagnosed. MS: 
patient for which at the initial visit Lyme disease has been diagnosed, but which was later found to 
suffer from multiple sclerosis. An unpaired two tailed t test with 95% confidence interval was used to 
determine statistically significant differences between samples of the two groups of main interest 






Figure 14: Description of a chronic lymphocytic leukemia (CLL) clone identified with 
multicolor flow cytometry. In one acute Lyme disease patient (Lyme11) we detected a 
CD19dimCD20dimIgDdimCD27posCD38negCD43posCD5posCD21dimCD138negCD23negCD24posIgMnegIg
GnegCD10neg subpopulation. After verification with the patient, it was confirmed that she suffered 
from a subclinical form of chronic lymphocytic leukemia. Blue: CD19posCD20pos B cells. Violet: 
CD19dimCD20dim CLL clone. Black: other measured cells (PBMCs). 
 
In one of the acute Lyme disease patients, an unusual high number of CD5+ B cells was observed. 
After closer analysis of this clone, it could be defined as a chronic lymphocytic leukemia (CLL) case. 
Another patient entered our study as acute Lyme disease patient, but in the course of the study it 
turned out to be rather a multiple sclerosis case. This patient is a good example for difficulties that 
can occur in the diagnosis of these complex diseases. For our multicolor flow cytometry panel it was 
a nice additional control. As peripheral B cell numbers and especially plasmablasts have been shown 




in the peripheral blood of this patient (Figure 13E). Also other B cell subsets that are indicative of a 
rather active immune response were present at elevated levels in this donor. Activated naïve B cell 
(Figure 13H), but also doublenegative B cell (Figure 13A) and IgM expressing memory B cell (Figure 
13G) percentages were relatively high in this donor. 
 
To better understand changes in peripheral B cell subsets, we plotted the fold change of each subset 
compared to the general average on radar charts (Figure 15). This allows to represent the 
heterogeneous peripheral B cell subset compositions that we observed with our B cell panel. Half of 
the healthy individuals (Figure 15D-F) showed expansions of various B cell subsets (including 
activated naïve, transitional, doublenegative, non-switched memory B cells and plasmablasts) as 
compared to the average of all samples analyzed. The other three (Figure 15G-I) showed almost no 
levels of expansions of the different B cell subsets. The patient at a very early stage of the disease, 
similar to half of the control samples showed rather no B cell expansions (Figure 15J). Somewhat 
later, IgM+ memory B cells and double-negative B cells were expanded (Figure 15K). In patients with 
an erythema migrans for 1-2 months, plasmablasts (Figure 15L) and IgG+ memory B cell frequency 
(Figure 15M) was increased in combination with activation of naïve B cells. At later stages of the 
infection as facial palsy (Figure 15N) and erythema migrans since one year (Figure 15O) more 









Figure 15: Global analysis of changes in peripheral blood B cell subset composition using radar 
charts. The fold change of each subset was normalized to the average of all the samples (highlighted 
as yellow line). Individuals with a recent tick bite are represented at the top (A-C). Healthy donors 
and acute Lyme disease patient samples are shown in the middle (D-I) and at the bottom (J-O) 
respectively. For both acute patients and donors with a recent tick bite average values of the three 
timepoints were calculated. 
 
4.3 Isolation of VlsE-C6 peptide reactive B cells with tetramer staining 
 
Borrelia-reactive memory B cells were directly labeled and sorted using a peptide tetramer staining 
approach [352] with the immunodominant VlsE-C6 epitopes derived from the three most important 
Borrelia species [280]. To setup the staining, we started generating peptide tetramers using 
Streptavidin [352], but changed to Neutravidin which allowed us to solve problems with an initial 
high background noise. The peptide staining approach was validated by confirming an increased 
staining of switched memory B cells in seropositive as compared to seronegative donors in the 
absence of staining of naïve B cells (Figure 16). Also in acute Lyme disease patients, the memory B 
cells showed an increased reactivity (Figure 17). The staining pattern was similar to the one of 
seropositive donors, with only a subset of samples showing a detectable reactivity towards the peptide 
tetramers. We did not observe any correlation between reactivity towards the individual Borrelia 

































Figure 16: Labelling of memory (CD27+IgD-) and naïve (CD27-IgD+) B cells from seropositive 
and seronegative donors with VlsE-C6-Neutravidin tetramers to confirm staining specificity. 
Background staining observed with biotin tetramers was subtracted to obtain the represented values. 
Reactivity of the samples from the different groups was compared with One-way Analysis of Variance 
test followed by Tukey's Multiple Comparison test. Represented are the results from five independent 
experiments including data from nine seropositive and five seronegative donors. Donor’s samples 
were subdivided onto four (including biotin control) tubes and stained separately with tetramers 
containing peptides from three different Borrelia strains (B31, IP90, PT7). We don’t distinguish 
values obtained with the different peptides in this figure as the same trend towards an increased 














































































































































Figure 17: Labelling of VlsE-C6 peptide reactive B cells in acute Lyme disease patients. 
Tetramers containing peptides from the three Borrelia strains (B31, PT7, IP90) were pooled and 
antigen reactive B cell numbers otherwise determined as in Figure 16. Only part of the healthy 
controls and all of the acute Lyme disease patients were sampled at different timepoints over one 
month period indicated as T0, T1 and T2. Samples from the two groups were compared using an 
Unpaired t test with Welch's correction. The observed difference was still significant when removing 
the outlying CLL patient for A (*) but no longer for B (n.s.). As described below, this high level could 
















































































































Figure 18: Reactivity of seropositive donors towards the VlsE-C6 epitopes originating from 
three different Borrelia species at the memory B cell (A) and antibody (B-C) levels. Due to 
differences in overall OD values, the results from the 96 well ELISA (B) assay are represented 
separately from those of the 384 well assay (B). The same control samples were used in both ELISA 
assays. The donor SP2 was only slightly reactive against the VlsE-mix on the more sensitive 
commercial immunoblot. This donor reported to have had a tick bite with a red skin lesion 5 weeks 
before blood draw. EQ1 was seronegative for VlsE-mix on the commercial immunoblot, but turned 
out to be seopositive by our in house VlsE-C6 peptide ELISA. B31: Borrelia burgdorferi sensu stricto; 
PT7: Borrelia afzelii; IP90: Borrelia garinii. SP avg: average of values from seropositive donors. 
SN: average values from seronegative donors. SP ctrl: average value from two seropositive donors. 
SN: average value from two seronegative donors. The green lines in each graph highlight the cut-off 
values, which were manually set.  
 
In one of the ten analyzed acute Lyme disease patients (Lyme11), we found a particularly large 
antigen-labeled B cell subpopulation. When analyzing the sequences from these cells, we found 
several different predominating expanded B cell clones. In addition to that, we found that these cells 
colocalized (meaning, they were CD27+IgDdimCD20low) with the CD5+ CLL B cell subpopulation 
that we previously detected in the same donor with our multicolor B cell panel (Figure 19). In order 
to test whether the CLL cells are indeed peptide reactive and to compare reactivity of the isolated B 
cell clones with the individual Borrelia epitopes, we labeled PBMCs separately with the three peptide 
tetramers in combination with the CD5 marker. As opposed to previous findings on MACS separated 
B cells for which around 10% of the memory B cells from Lyme11 were peptide positive (Figure 17), 
we were not able to reproduce this finding when using untouched whole PBMCs. Under these 
conditions, the CD5+ B cells were also not positive for peptide staining. Although labeling in this 
experiment was overall very low, we still saw a higher staining of memory B cells as compared to 
the naïve subset (Figure 20), confirming that a few peptide positive sequences should still be among 
the previously sorted B cells. When comparing the percentage labeled memory B cells we obtained 
when using the different epitopes, we found that the memory B cells of this patient most strongly 
reacted with the epitopes originating from Borrelia burgdorferi sensu stricto (B31) and Borrelia 
afzelii (PT7) (for memory B cells IP90: 0.03%, PT7: 0.09%, B31: 0.09% and for non-switched 
memory B cells: IP90: 0.02%, PT7: 0.05%, B31:0.07% staining difference as compared to naïve B 
cells) (Figure 20). At the serum level, this donor showed reactivity towards all three peptides (Figure 
9). Interestingly, (even when leaving out the outlying Lyme11 sample) we observed a correlation 








Figure 19: Peptide positive B cells in outlying donor (Figure 17, Lyme11). The large 
subpopulation of peptide positive memory B cells measured in Lyme11 could be found at the same 
position (being CD27dimIgDdim) as the CLL clone previously characterized in the same donor (Figure 
14). 
 











































Figure 20: Repetition of tetramer staining with individual peptides on a sample from Lyme11. 
This donor was highly positive for VlsE-C6 peptides in the first tetramer staining experiment. Staining 






                                
VlsE-C6 staining in relation






























Figure 21: VlsE-C6- tetramer staining of total memory B cells (CD27+) and switched memory 
B cells (CD27+IgD-) versus the time that has elapsed from onset of symptoms are represented. 
Spearman’s Rank Correlation Hypothesis Testing was done manually in Excel. 
 
4.4 Single cell immunoglobulin heavy chain sequence cluster analysis 
 
In order to characterize the antibody receptors from peptide positive B cells, single cells from 10 
acute Lyme disease patients were sorted into 96 well plates and their heavy chains sequenced 
[331,333,334]. In total, we were able to get 628 sequences from peptide positive B cells and 362 
sequences from control cells (including randomly sorted B cells, peptide negative and Neutravidin 
positive B cells) (Figure 22, Table 6). To compare the peptide reactive heavy chain sequences 
obtained from Lyme11 after MACS separation with the CLL cells, we also sorted and sequenced 52 
single CD5+ B cells from this donor (Table 6). When comparing these sequences, we found that they 
are the same clones and concluded, that these clones have nothing directly to do with Lyme disease, 
but have probably been sorted due to non-specific binding of the tetramers to CD43+ CLL cells that 
have not been completely removed using MACS. Overall in this experiment MACS separation was 
not efficient, because of a large amount of cell death and clumping after thawing and centrifugations. 
We assume, that not all four biotin binding positions were occupied in our tetramers and that they 




MACS kit. This would also explain the large amount of staining of cells other than CD19+ B cells 
(Figure 22). 
 
Figure 22: Gatings for measurement and sorting of VlsE-C6 peptide reactive 




Table 6: Overview of number of single cells sequenced per donor. 
 
 
In order to distinguish between truly peptide reactive B cells and background noise, sequence 
clustering at different degrees of CDR3 amino acid sequence similarity was performed on either the 
full V-J gene sequence (Figure 23) or the CDR3 only (Figure 28). Four different types of clusters 
were defined. By “Peptide” clusters, we refer to clusters containing sequences originating from 
peptide positive cells only. “Control” clusters are composed of sequences from control cells only. 
“Mixed” clusters on the other hand contain a mixture of sequences derived from peptide positive and 
control cells. “CLL” clusters contain at least one of the sequences from the sorted CD5+ CLL cells. 
Considering also V and J genes (Figure 23), the “Peptide” clusters did not substantially intermix with 
“Control” sequences. Even with more strict CDR3 identity thresholds, only a few peptide positive 
sequences clustered together, indicating that they originate from B cells with unique VJ pairings and 
CDR3 lengths. “Control” clusters were generally rare but became more frequent at lower CDR3 
identity thresholds. The number of sequences belonging to mixed clusters increased most drastically 
under less stringent clustering conditions. The CLL sequences clustered stably together with no 
significant increase in members at lower CDR3 identity thresholds, indicating that they are unique 
and do not share similar sequences with other sorted cells. They clustered however with a subset of 
peptide sorted single B cell sequences from the same donor, confirming our previous suspicion of 
non-specific binding of peptide tetramers to the CLL cells. We found, that lowering the CDR3 
identity threshold to below 85% was necessary to cluster single cell sequences into meaningful 
clones. Only when allowing this degree of mismatch were all the sequences belonging to CLL clones 
included into these clusters (explains transient mixed clusters at 100%-95% thresholds). Exclusion 
of some sequences at stricter thresholds is probably due to PCR and sequencing errors or alternatively 
could originate from biological variability.  
 
Patient ID Status Random Negative B31 Negative IP90 Negative PT7 Neutravidin Peptide mix B31 IP90 PT7 CLL
SN1 seronegative 8 19
EQ1 equivocal 37 30 12
SP1 seropositive 7 4 8 4 4 5
SP2 seropositive 22 26 30 18 15 20
Lyme3 acute LB 19 107
Lyme4 acute LB 19 81
Lyme5 acute LB 20 11
Lyme6 acute LB 27 101
Lyme7 acute LB 28 24
Lyme8 acute LB 9 2
Lyme9 acute LB 24 74
Lyme10 acute LB 19 19
Lyme11 acute LB 17 91 52




                                 
Single cell sequence cluster assignment




















































Figure 23: B cell receptor heavy chain sequences from peptide reactive and control cells were 
clustered according to same VJ gene usages and different CDR3 amino acid identities using the 





Figure 24: Representation of the evolution of individual 
“Peptide” clusters obtained with the BcRep R package [2] over 
different CDR3 identity thresholds. Each row represents one 
“Peptide” cluster. Each box represents the composition of a cluster 
at the corresponding CDR3 identity threshold indicated at the top 
of each column. For this analysis, sequences sharing the same VJ 
gene assignments and the same CDR3 amino acid sequences were 
collapsed. Each dot represents a unique clustered sequence. This 
means, that one dot can be composed of several individual 
sequences. Several dots in one box means that sequences with 
different CDR3 amino acid sequences were assigned to belong to 
the same cluster. Clusters are only highlighted when they are solely 
composed of sequences from peptide reactive sorted B cells. An 
empty box means, that either sequences did not cluster together yet 
because of a too strict CDR3 identity threshold or that the cluster 
started to intermix with control sequences and therefore 
“disappeared” from the “Peptide” cluster pool. In the column on 
the left, clone identity numbers are represented. In the top row, the 
used CDR3 identity thresholds are indicated (100%, 85%, 65%, 




Next, we followed the evolution of individual “Peptide” clusters when reducing CDR3 identity 
thresholds (Figure 24). In this case, a “Peptide” cluster (n=64) is a cluster, that at least at one of the 
tested identity thresholds is composed of only peptide positive sequences. 16% (10/64) of the 
“Peptide” clusters were stable with no detectable intermixing with control sequences even at a CDR3 
identity threshold of 0%. These clusters contained mostly two sequences with identical CDR3s. 5% 
(3/64) already clustered at 100% CDR3 identity but disappeared from the “Peptide” cluster pool, as 
they started to intermix with control sequences at CDR3 identity thresholds below 65% (1/64) or 25% 
(2/64). The vast majority of sequences (63%, 40/64) from “Peptide” clusters started clustering 
together at lower CDR3 identity (1/64 <100%, 2/64 <85%, 7/64 <65%, 23/64 <65%, 7/64 < 25%). 
Only 17% (11/64) of the “Peptide” clusters mixed with control sequences. This all confirms that 
peptide reactive B cells have heterogeneous and thus highly unique sequences. 
 
At 65% CDR3 identity, 7% (44/626) of sequences from tetramer positive cells clustered together, but 
only 1% (4/353) of the randomly sorted cells (Figure 25). Sequences from cells of both groups 
intermixed to a similar extent, which occurred at 0.8% (Figure 25). These results indicate, that with 
our tetramer approach we are enriching for cells of a certain specificity.  Sequences from clusters 
(65% CDR3 amino acid identity threshold) of seropositive donors were generally more distant from 
the germline (Figure 26) and from each other (Figure 27) as compared to the sequences – 





                                  




















Figure 25: Percentage of single cell immunoglobulin heavy chain sequences that clustered with 
sequences from the same or the different group (control or peptide positive). 
 
                          






















Figure 27: Representation of single cell sequence clusters. Clusters obtained with the BcRep R 
package [2] at the 65% CDR3 identity threshold are depicted. CDR3 amino acid sequences including 
mismatched positions are indicated next to the corresponding cluster. Different timepoints are 
highlighted in different colors. Isotypes are depicted in different shapes. N.D.: isotype not determined 
because of incomplete sequence, STP: single timepoint measured only, mut: number of mutations 
separating the linked sequences. The length of each bar is proportional to the number of mutations 
between the sequences. In mixed clusters, sequences from peptide positive cells are marked with §. 
Some sequences were isolated from cells that were present in the wells next to each other (highlighted 
with *), which should be interpreted with caution. 
 
We also performed clustering based on CDR3 similarity alone, allowing a mismatch in every second 
(50% identity), third (67% identity), fourth (75% identity), fifth (80% identity), sixth (83% identity) 
or twelfth (92% identity) CDR3 amino acid (Figure 28). With this analysis, an overall higher 
clustering of sequences was observed, especially when allowing an increased number of CDR3 
mismatches. Also in this case, sequences from peptide positive clusters stayed separated from control 
or CLL sequences and the majority of clusters responsible for an increased clustering at lower CDR3 





                                
































Figure 28: B cell receptor heavy chain sequences from peptide reactive and control cells were 
clustered considering only the CDR3 amino acid sequence using the python script from Galson 
et al. [12,127,171]. The same color code as for Figure 23 was used. 
 
4.5 Closer analysis of mutations in immunoglobulin heavy chain sequences 
from CD5+ B cell subpopulation of Lyme11 
 
42 of the sorted single CD5+ B cells from Lyme11 could be assigned to three different clones. Two 
of those were quite distant from the germline (clone1: 91% and clone2: 90% V-region identity) 
indicating that they might have participated in germinal center responses. The third and less 
prominent clone was less mutated (clone3: 96% V-region identity). The sequences of these three 







Figure 29: Closer analysis of mutations occuring in dominant clones from single sorted CD5+ B 
cells from Lyme11. 
 
4.6 B cell repertoire analysis with next generation sequencing 
 
Next we investigated changes in the bulk B cell repertoire induced by Borrelia and the tick bite. We 
applied a barcoding technique similar to the one from Vollmers et al. [1] which we adapted to the Ion 
Torrent next generation sequencing platform (Figure 30, Figure 31A). First, we compared sequencing 
replicates, library replicates and biological replicates (Figure 31B). 97±1% of CDR3 sequences 
overlapped between IgG sequencing replicates. IgG library replicates still overlapped by 74±24%. 
Biological replicates overlapped by 32±11% for IgG and 17±10% for IgM. After data cleaning and 
consensus sequence building with an in-house pipeline developed by colleagues, an average number 
of 24012±39051 (median: 9470; min: 594, max: 218302) productive sequences were obtained for 




randomly sorted single cells described above, the most abundant V and J genes were IGHV3-23, 
IGHV3-30, IGHV3-7, IGHJ4 and IGHJ6 (Figure 32, Figure 33). A considerable (on average 8-30% 
ranging from 0.31-59% for IgM and 6-12% ranging from 0-35% for IgG) CDR3 amino acid sequence 
overlap was observed between the different timepoints of the same individuals (Figure 31C,D). 
Interestingly the IgM overlap was on average two to three times higher in acute patients and tick bite 
donors compared to healthy individuals (Figure 31C). The high overlap in the tick bite group was 
only present in two of the three donors analyzed. In Tick1 we observed one largely expanded clone 
that predominated all three samples (14%(T0), 10%(T1), 13%(T2) of the IgM repertoire) while in 
Tick2 three such largely expanded clones (17%, 6%, 5% (T0), 13%, 9%, 4% (T1), 11%, 11%, 3% 
(T2) IgM repertoire) have been observed. For IgG, the average sequence overlap between different 
timepoints was also higher in acute patients than in the case of tick bite and healthy controls (Figure 
31D). As expected [12,14], interdonor overlap was very small (Figure 31E,F), indicating that each 
donor has a fairly unique B cell receptor repertoire. IgM CDR3 amino acid sequence overlap occurred 
~1.5 times more often in healthy individuals than in the other groups (Figure 31E). There was 
eventually no overlap between IgG samples from different donors (Figure 31F). We observed a 
tendency towards a higher concentration of final IgG libraries and number of IgG reads for acute 
Lyme disease samples (Figure 34F,H). 
Figure 30: Representative quality scores (y axis) at the different positions within the 
sequences (x axis). Due to sequence quality drop off at the end of Ion Torrent reads, we decided 
to change from the double sided UID method described by Vollmers et al [1] for the Illumina 
platform to a single sided UID method. In this way a high quality of barcodes could be guaranteed 
by placing them at the beginning of the sequences. After correct assignment of UIDs into groups, 













































































































































































































Figure 31: Setup of the deep sequencing method to analyze patients’ B cell repertoires. (A) The 
percentage of reads containing forward and reverse primer sequences demonstrates the extensive 
loss of reads due to quality drop off at the end of sequences described in Figure 30. (B) The extent of 




repl) and biological replicates (biol repl) are represented as percentage of final consensus sequences. 
CDR3 amino acid sequence overlap was also determined between samples from different timepoints 
(C,D) and donors (E,F). Groups were compared with One-way Analysis of Variance test followed by 









































































































































































































































































































































































































































































































































































Figure 32: V-gene distribution of next generation sequencing samples compared to that one of 
sequences from randomly sorted single cells. Two Way ANOVA followed by Bonferroni Multiple 





































































Figure 33: J-gene distribution of next generation sequencing samples compared to that one of 
sequences from randomly sorted single cells. Two Way ANOVA followed by Bonferroni Multiple 



































































































































































































































































Figure 34: Control for equal library preparation between samples from different groups. 
Comparison of PBMC (A) and RNA (B) extractions, RNA input (C,D), DNA concentrations of final 
libraries (E,F), final number of consensus sequences (G,H) and the percentage thereof that was 
productive (I,J) between groups using a One-way Analysis of Variance test followed by Tukey's 
Multiple Comparison test. 
 
Because of the uniqueness of the repertoire sequences of each donor, inter-individual sample overlap 
was also assessed using a less stringent approach. Sequences from the two groups (controls and acute 
patients) were clustered separately using the python script from Galson et al. [12,127,171]. Different 
CDR3 identity thresholds once taking V and J gene information into account (Figure 35A) and once 
only considering CDR3 sequences (Figure 35B) were tested. Similar trends were observed at all the 
tested conditions. Also with this approach, a slightly higher IgM CDR3 sequence overlap could be 
observed among healthy individuals as compared to the two other groups (Figure 31E,Figure 35B). 
Furthermore an increased overlap between acute Lyme disease patients’ IgG repertoires was 
apparent. At 83% CDR3 identity including V and J gene information (Figure 35A) we observed that 
one largely expanded clone detected in all samples from Tick1 overlapped with all the other samples 
from another tick bite donor (Tick3). This high overlap was most striking under these clustering 
conditions. Under the same conditions we also observed a larger number of acute patient samples that 
shared an unusual high frequency of reads with other samples from that same group. In that case it 
was samples from different donors that shared such a high fraction of sequences with one of the other 
samples from the group. When we calculated the median from these individual values for each donor, 
a significant difference between acute Lyme disease patients and controls was observed only for IgG 


































































































































































































































































































































































































































































Figure 35: Cluster overlap between samples at different CDR3 identity thresholds. Sequences 
from acute donors’ and control samples were clustered separately with the python script from Galson 
et al [12,127,171] once taking V and J gene information into account (A) and once only considering 
CDR3 sequences (B). Groups were compared using a One-Way Analysis of Variance followed by 
Tukey's Multiple Comparison Test. Tick1(Tick3): One large cluster from Tick1 that was present in 
all three timepoints was found to cluster together with a few sequences from Tick3. Diff. patients: 










































Figure 36: Assessment of sequence cluster overlap between different donors. Sequences were clustered 
based on whether they contain the same V and J genes as well as similar CDR3 amino acid sequences 
(one in six mismatches) using the python script from Galson et al. [12,127,171]. For each donor, the 
percentage sequence overlap between each sample from that donor with individual samples from all 
the other donors of that group was determined (Figure 35) and the median from all these values 
calculated. Data points corresponding to the three controls with a recent tick bite are highlighted 
with rhombi colored as in the other graphs. A Two-tailed Unpaired t-test was used to compare values 
from the two groups. 
 
Since a recent immune response should affect both, the IgM and IgG levels, we tested whether these 
parameters for IgM and IgG correlate with each other. When assessing the percentage of the repertoire 
(with all samples from the same participant pooled) that clusters containing a mix of IgM and IgG 
isotypes are making up, only 20% (1 of 5) of healthy donors but 67% (8 of 12) of acute Lyme disease 
patients showed elevated levels (Figure 37A). Interestingly two of the three tick bite donors that also 
showed largely skewed IgM repertoires (Figure 31C) also contained very high levels of sequences 
belonging to mixed clusters indicating that there is something going on at both IgG and IgM levels. 
When plotting IgM versus IgG sequence overlap between samples from different timepoints, a weak 
but positive correlation was seen in the patient group while a negative correlation was observed for 
controls (Figure 37B). The latter was mainly due to a strong perturbation at the IgM level in the 
absence of a strong effect on the IgG repertoire in the two tick bite donors. The four donors for which 
we observed a change in VlsE-C6 IgG titers over the sampling period with our in-house peptide 
ELISA (Lyme8 & Lyme2↑, Lyme 4 and Lyme13↓, Lyme1↑↓, Table 2) also showed the highest IgG 
CDR3 amino acid sequence overlap between the different analyzed timepoints. When assessing the 
degree of correlation between sequence overlap among timepoints and interdonor sequence clustering 




that expanded clones probably have a lower chance to overlap between donors as compared to smaller 
ones. 
 
In order to exclude, that the differences in clustering between groups (Figure 36B) were due to 
different numbers of samples (the higher the number of patients compared, the higher the probability 
that sequences overlap), we clustered IgG samples from all donors and as in Figure 36 assessed for 
each donor the degree of overlap with donors from all the other groups. This showed, that acute 
patients have higher overlaps only with members of their own group (Figure 37D). However, both in 
the patient and control group, the majority of clusters overlapped only between two donors (Figure 
37E) and the majority of clusters overlapping between a higher number of acute patients was also 
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Figure 37: Closer analysis of sequence clustering. (A) Clusters obtained using Change-o [338] 
that contained sequences of both IgM and IgG isotypes were selected and the percentage total 
repertoire (pooled samples as before) they make up is represented. (B) Correlation between average  
IgM and IgG CDR3 amino acid sequence overlap between timepoints. (C) Correlation between IgG 
CDR3 amino acid sequence overlap between timepoints (average) and clustering between donors 
(median) [12,127,171] is represented. Spearman’s Rank Correlation Hypothesis Testing was done 
manually in Excel. Sequence clustering between all donors was determined using the python script 
from Galson et al. [12,127,171]. Median values were calculated as before (Figure 36) but this time 
also assessing sequence overlap between samples belonging to different groups. Lines connect values 
from the same donor. (E,F) Distribution of overlapping clusters among donors. 
 
4.7 Comparison of different B cell repertoire parameters among groups 
 
In order to determine the degree of repertoire distortion induced by Borrelia infection, we first 
compared CDR3 amino acid length distribution (spectratypes) between samples from the different 
groups (Figure 38). The strong perturbations observed in the tick bite group could be explained by 
expansions in repertoires from individual donors rather than common changes observed in all the 
samples from that group. Since at this level of analysis, expansions of different clones (having 
different CDR3 lengths) in different patients could mask a potential distortion of repertoires, we also 
determined diversity based on nucleotide or amino acid sequences (Figure 39). Surprisingly, with 
different indices we repeatedly observed a slight increase in repertoire diversity in acute Lyme disease 
patient IgG samples as compared to the controls (Figure 39B,F&H). Overall differences between 
biological replicates were however large. Even when performing hierarchical clustering using 
diversity profiles of individual samples [3] (which should be less dependent on sequencing depth) 



























































Figure 38: CDR3 amino acid spectratype analysis. VDJtools [348] was used to extract CDR3 
amino acid length distributions from deep sequencing data. Two-way RM ANOVA followed by 
Bonferroni multiple comparisons test was used to compare the groups. The tick bite donors (yellow: 
Tick1; orange: Tick2) responsible for the observed distortions are highlighted above the expanded 




























































































































































































































































































































































































Figure 39: Changes in B cell repertoire diversity upon Borrelia infection. Different diversity 
indices were compared. (A-B) Shannon-diversity indices were calculated manually using uncollapsed 
CDR3 amino acid sequences (C-D) Spectratype distortions were determined from deep sequencing 
data as in [20]. (E-G) Inverse-Simpson and Shannon-Wiener diversity indices were calculated with 
VDJtools [348]. Samples from controls and acute patients were pooled and differences between these 





Figure 40: Hierarchical clustering of diversity profiles[3]. (A-B) Diversity profiles of 
individual samples belonging to the highlighted clusters are represented in the graphs. Blue 
curves: tick bite donors. Grey curves: healthy donors. Black curves: acute donors. y axis: 
Diversity (αD). x axis: α. (C) Clustering was reperformed this time also including biological 
replicates. Biological replicates belonging to the same donor are highlighted in the same color 




Since recent mouse studies suggested that Borrelia actively influence the B cell immune response 
[289-293,303], we tested whether a similar effect also occurs in humans. To understand whether 
germinal center responses might be affected in acute Lyme disease patients, we assessed mutation 
frequencies of B cells. We were able to confirm, that sequences from IgM repertoires are less mutated 
as compared to those from IgG samples (Figure 41). Differences between the three groups (Acute, 
Healthy and Tick bite) could be observed at the 94% germline identity peak in IgM. When looking 
at the profile of the curves, healthy individuals’ sequences were the least mutated, acute Lyme disease 
patients’ repertoires showed an intermediate mutation frequency, while the tick bite individuals 
contained most mutated sequences within their “distorted” IgM repertoire (Figure 41, top). 
Interestingly, in acute Lyme disease patients, we found a higher number of IgG sequences with lower 
mutation frequencies as compared to control repertoires, while the opposite was true for individuals 
which were stung by Borrelia negative ticks (Figure 41, bottom). 
 
It was a bit surprising to see that with our improved UID barcoding technique (that should remove 
the majority of sequencing errors) the major germline IgM peak lies at 94% instead of 100% V-region 
identity. Also when comparing the V-identity distribution with other samples from our laboratory for 
which no UID barcoding technique was used, we observed that the curves from these samples were 
less distant from the germline than those of the samples from the Lyme disease study. In order to 
understand what happened, we picked out a few sequences from the largely mutated peak from Tick2 
for closer analysis and found out, that sequences still contained the P adapter and some nucleotides 
hat were probably added by the Ion Torrent machine at the end of the sequencing runs. Although the 
V-gene seemed to be correctly assigned, the V-identity values are not correct as IMGT/High V-
QUEST [354] seemed to have included this non-V-gene sequence into the calculations. Since similar 
nucleotides seem to be added at the end of each sequence, we expect a simple shift of the whole curve 
without individual sequences being affected too much. In order to verify that we are indeed removing 
errors with our approach, we compared V-identity distribution and productive reads before and after 
consensus sequence building. For this, we randomly chose two Chips (one IgM and one IgG) and 
extracted the sequence with the best quality from each UID to compare this dataset to the final 
analyzed reads of the same samples. These data are indicative of a substantial reduction in mutations 
and increase in quality of the reads after sequence cleanup (V-identity before cleanup: 83.22±0.40 
(IgM), 79.24±0.83 (IgG), after cleanup: 89.97±2.90 (IgM), 84.38±0.82 (IgG); Number of productive 








































































































































































































































Figure 41: V-identity distribution. IMGT/High V-QUEST [354] was used to determine distance of 
reads from the closest germline gene for IgM (top) and IgG (bottom) repertoire data. The highly 




(orange: Tick2) while the other less mutated peaks were mainly due to the sample from the second 
timepoint (T1 in IgM) or the third timepoint (T2 in IgG) from another individual with a recent tick 
bite (yellow: Tick1). Groups were compared with Two-way Analysis of Variance followed by 
Bonferroni Multiple Comparisons Tests. On the top right of each graph the calculations of areas 
under the curve of the highlighted (in grey) regions are depicted. Values of samples were compared 
using a One-way Analysis of Variance followed by Turkey’s Multiple Comparisons test. Differences 
between groups are hardy detectable with this method. Individual sequences from the unusually high 





4.8 Closer analysis of largely distorted IgM repertoires of two donors with a 
recent tick bite 
 
When analyzing samples with our multicolor flow cytometry panel (Figure 13), one donor with a 
recent tick bite strongly deviated from the others. Perturbations were mainly observed in non-
switched B cell subsets but were very constant over the three timepoints. Furthermore, the participants 
generally recognized and removed the tick early, which was only attached between 0-3 days. For 
these reasons, we initially thought that this rather special B cell subset composition is specific for that 
donor and has nothing to do with the tick bite. When we observed a largely skewed B cell repertoire 
Figure 42: Closer analysis of individual sequences from highly mutated IgM peak observed in 
Tick2 indicates that this exceptionally high mutation load is not biological. This effect is probably 
due to the fact that conensus sequences have not been trimmed after the V-primer sequence. 
Alignments of next generation sequencing reads at the V-region side with the V3-region primer and 




in two other donors with a recent tick bite with our next generation sequencing approach however, 
we thought it might be worth further investigating this phenomenon. In accordance with the 
multicolor flow cytometry data (Figure 13C), that indicated a very high percentage of naïve B cells 
in the peripheral blood of this donor (84% versus an average of 63% for all samples), the final IgM 
libraries from this donor were very concentrated (Figure 43E) and the raw reads contained a high 
percentage of singlet or doublet UIDs (Figure 43D) but also gave a high number of consensus 
sequences (Figure 43B). The two donors with a skewed IgM repertoire (from which we unfortunately 
don’t have FACS data) on the other hand showed only a very low percentage of reads occurring as 
singlet or doublet UIDs (Figure 43D), plus their final IgM libraries were not very concentrated (Figure 
43E). The final concentrations of the IgG libraries were however similar to other samples (Figure 
43F), indicating that it was not a general problem with the sample (like integrity of the RNA). In case 
of very low input material, one could imagine that errors occurring during PCR amplification might 
artificially induce clonal expansions. In order to exclude this, we had a look at the UID distributions 
of the samples from the sequencing Chips of the tick bite donors and saw that they were not 
particularly different from the other samples that were run on the same Chip (Figure 44A). In fact, 
the UID distributions of the largely expanded clones nicely reflected the distribution of the rest of the 
sample (Figure 44B). Also the UIDs of these individual sequences were very different from each 
other (Figure 44C), indicating that the final consensus reads really originated from different mRNA 
molecules. The mutation status of these sequences indicated that they are quite distant from the 
germline, while this was generally not true for related sequences found in other donors (Figure 45), 
indicating that these mutations are probably true mutations and were not solely present due to 
difficulties of the Ion Torrent to sequence reads of that particular composition. In accordance with 
the high number of sequences belonging to isotype mixed clusters in these two donors with a recent 
tick bite (Figure 37A), in both we found (although at very low levels) IgG sequences related to these 
large clones and which showed the same distance from the germline as their IgM counterparts. In the 
expanded clone from Tick2, replacement mutations were mainly concentrated in the CDR2 region 
(Figure 46), which would make biologically sense. We focused here on the CDR2 as the large 
difference between CDR3 regions and their original germline D genes generally makes it difficult to 
assess mutation rates in this region. In Tick1 some amino acid changes in the CDR2 were also found, 






















































































































































Figure 43: Exclusion of sample preparation or sequencing biases as reason for outlying tick bite 
samples. Comparison of RNA extraction (A), final consensus sequences (B), raw sequences (C), 
percentage reads that showed up as singlet or doublet UIDs (D) and DNA concentration of final 
libraries (E) between IgM samples of donors with a recent tick bite and either all the other samples 
(A, B, E, F) or samples sequenced in the same sequencing run (C,D). (F) DNA concentration of final 
IgG libraries. As the aim was to see whether the tick bite samples are outliers as compared to the rest 
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Figure 44: Exclusion that low input material might have generated artificial clones due to PCR 
errors in UID barcodes. (A) Percentage of UIDs occurring at the indicated copy numbers for 
samples from tick bite donors (top) and corresponding acute patient samples that were sequenced on 
the same Chip (bottom). (B) Comparison of UID distribution from large clusters detected in Tick1 
and Tick2 with those from the whole sample. (C) Cd-hit [336,337] was used to cluster UIDs from 
sequences of the large clusters from Tick1 and Tick2 into groups using different degrees of similarity. 
To test whether the UID distributions deviate from those of other samples, the same number of UIDs 
was randomly selected (using shuf command in bash) from the other samples sequenced on the same 
Chip (Other) and clustering compared to that one of the tick bite samples (Tick). 
 






































































Figure 45: Mutation levels of large clusters identified in the IgM repertoires of Tick1 and Tick2. 
Mutation levels in sequences related [12,127,171] (Figure 35) to the large clusters were assessed by 
determining V-identities using IMGT/High V-QUEST [354]. For each sample, sequences were 
manually cleaved off with the BioEdit Sequence Alignment Editor until the V-region primer sequence 
and collapsed before determining V-identity distributions. Triangles: IgM isotype. Circles: IgG 
isotype. Tick1-l and Tick2-l: only considering sequences present at very high copy numbers. 
Sequences related to the largely expanded clone from Tick1 were also found in Tick3 as well as in 
acute and healthy donor samples. V-identities of these related sequences are also represented (Tick3, 
Healthy, Acute). Replacement mutations depicted in Figure 46 were determined from the sequences 






Figure 46: Analysis of replacement mutations occurring in the clones from Tick1 and Tick2 
that predominate their IgM repertoires. Replacement mutations (highlighted in red) were 
determined manually by comparison of the sequences present at high copy numbers to the germline 
at the amino acid level using BioEdit Sequence Alignment Editor. Lyme11 T3: a long term follow up 
sample from Lyme 11 (donor with a CLL clone) was available and a related sequence was found in 
that sample. 
 
4.9 Determination of VlsE-C6 memory B cell levels in deep sequencing data 
 
We tested whether the peptide tetramer reactive single cell CDR3 sequences can be retrieved in the 
deep sequencing data. Again, the vast majority (81%, 130/160) of the single cell sequences that could 
be found in the NGS data clustered with sequences of repertoires from the same donor (Peptide 
positive same donor: 96, Control same donor: 34) while only a few clustered with sequences from 
another donor (Peptide positive different donor: 15, Control different donor: 15). In acute donors, 
sequences belonging to peptide positive clusters did not exceed 1.5% of the total (meaning pooled 
IgM and IgG data) repertoire (Figure 47A). Clusters belonging to peptide positive sequences from 
different individuals made up less than 0.1% of the pooled repertoire samples (Figure 47A). This 
further indicates that the repertoire is very “private”. The clusters related to sequences from the 
peptide enriched B cells were generally not among the top clusters of the acute patients. Although 
more sequences from the bulk B cell repertoire clustered together with peptide associated sequences 
compared to control sequences, this difference may be partially explained by differences in sequence 
numbers. When we randomly select the same number of peptide and control sequences per timepoint, 
the observed effect is gone. Since in that case the number of sequences left to analyze is very low, a 




average cluster frequency of individual clusters however, clones related to peptide reactive B cells 
have a tendency to make up a larger proportion of repertoire sequences as compared to randomly 
sorted control cells (Figure 47B), indicating some degree of selection. A slightly larger fraction of 
peptide positive single cell sequences clustered with deep sequencing data as compared to randomly 
sorted cells (Figure 47C). When excluding all the single cell sequences related to the CLL clone, only 
4% of the peptide positive single cells were found to cluster among each other and could also be 
found in the NGS data (Figure 47D). Phylogenetic tree analysis was performed on clones for which 
a large number of related sequences was found in the NGS data (Figure 48). Generally clones were 
composed either of IgM or of IgG isotypes and correlated well with the isotypes of the single cells. 
Only in two of the six donors analyzed in that way could we find isotype mixed clusters (Lyme3 and 
Lyme8). As for the two largely expanded clones from the tick bite individuals (Figure 45), the clones 
were predominated by IgM sequences and contained only very few IgG counterparts. In two donors 
we found only IgM clusters (Lyme4 and Lyme 7). In the last third of these patients we were able to 
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Figure 47: Clustering of single cell sequences with deep sequencing data. (A) Change-o [338] 
was used to cluster pooled NGS sequences (referred here to as “repertoire”, including pooled IgM 
and IgG sequences from all sequenced timepoints) from each donor with those originating from the 
isolated single cells. The percentage repertoire that is related to the isolated single cells is 
represented. Values were separated according to whether the sequences were found back in the same 
donor from which they were isolated or in a different donor. Open circles: Control samples. Black 
circles: acute patient samples. (B) Average frequencies of individual single cell clusters found in the 
NGS data from the same donor were determined. Values obtained for randomly sorted control 
(Control) and VlsE-C6 epitope (Peptide) positive cells are depicted separately. Values obtained from 
the same donors are connected by lines. The cluster size from one VlsE-C6 reactive sequence isolated 
with in vitro single cell stimulation (please refer to section 4.10 Confirmation of findings with in vitro 
single cell stimulation) that was found back in the deep sequencing data is also represented 
(Stimulation). (C) Percentage of single cell sequences that cluster with deep sequencing data. (D) 
Percentage of peptide positive single cell sequences clustering with next generation sequencing data 










Figure 48: Phylogenetic tree analysis of clones releated to VlsE-C6-tetramer positive B cells. 
The isotypes of the single cells are indicated either as black circle (IgG),  triangle (IgM) or square 
(IgA). IgG sequences found in IgM clusters are highlighted with red arrows. 
 
4.10 Confirmation of findings with in vitro single cell stimulation 
 
In order to validate the isolated VlsE-C6 reactive B cell receptor sequences with a second method, 
IgG+ B cells were sorted by negative selection and single cells stimulated for antibody production in 
384 well plates. The in vitro stimulation experiments were carried out by Alessia Colone. On average 
10 plates (~3800 cells) per patient have been seeded. Lyme8 and Lyme4 were selected for this 
experiment, because they showed changes in antibody titers over time (Table 2), indicating an 




patients in which we found most single cell sequences back in the IgG deep sequencing data (Figure 
48), indicating that they might have expanded clones of interest in their repertoire. In addition to that, 
Lyme3 also showed a large cluster of IgM peptide sorted B cells.  
Supernatants of stimulated B cells from these four donors were screened for reactivity against the 
three Borrelia VlsE-C6 epitopes and the B cell receptor of cells from positive wells were sequenced. 
To confirm specificity of these cells for Borrelia, the supernatants were also screened for a whole 
panel of other antigens to which patients very likely have been exposed to in the past (Figure 49). All 
the wells except one were confirmed to be negative for the other tested antigens. Only one well 
reacted with both Borrelia and measles virus (CDR3-IMGT: ARADDSPSYYVNAFDL). With this 
approach, we were able to extract another 8 sequences from VlsE-C6 reactive B cells, with one of 
them occuring in two different wells from the same donor (Table 7). When comparing the frequency 
of VlsE-C6 reactive B cells to that of cells reacting with antigens from past infections or vaccinations 
(Figure 49A), the percentage of VlsE-C6 reactive wells was similar or even lower, confirming the 
low frequency of these cells among PBMCs. On average 0.07% of wells reacted with VlsE-C6 
(Lyme8: 0.142% (IP90,PT7,B31); Lyme4: 0.071% (IP90), 0.047% (PT7,B31); Lyme6: 0.032% 
(IP90,PT7), 0.095% (B31); Lyme3: 0.028% (IP90,B31), 0.057% (PT7)). Borrelia reactive B cells 
harboured a similar amount of mutations in their immunoglobulin heavy chain sequences as 
compared to those that reacted with the other antigens tested (Figure 49B). When analyzing their 
sequences, we were able to confirm the heterogeneous nature of VlsE-C6 reactive B cell clones (Table 
7). Only one of these sequences - the same sequence that was present in two different VlsE-C6-
reactive wells – was related (1 mismacthes within CDR3 was allowed) to a cluster (0.0292% 
repertoire) from the deep sequencing data of the same donor (Figure 50), further confirming that 
sequences from Borrelia reactive B cells are patient specific and generally not present among the 
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Figure 49: Frequency of antigen specific single B cells and mutation levels in their 
immunoglobulin heavy chain sequences. (A) Percentage wells from single cell stimulation that 
were positive in ELISAs for the indicated antigens or pathogens. Borr peptides: Borrelia VlsE-C6 
peptides from either B31, PT7 or IP90 strain [280]; MV: measles virus; Rub: Rubella; TT: Tetanus 
toxoid; VZ: Varicella-Zooster virus; EBV: Epstein Barr virus; CMV: Cytomegalovirus; TG: 
Toxoplasma Gondii. Filled black circles: Borrelia peptides; Open circles: other antigens or 
pathogens. These results were kindly provided by Alessia Colone. (B) V-identity of the single cell 
sequences obtained as determined by IMGT/HighV-QUEST [341]. 
 




CDR3 Stimulated sample # Sequences Related clone NGS V-gene J-gene
ARVVCTGGT Lyme8 (T1) 1 no IGHV4-34  IGHJ5
ARGTRDGQ Lyme8 (T1) 1 no IGHV3-33 IGHJ1
ARGTRDGQNPEFDY Lyme8 (T1) 2 Lyme8 IGHV3-33 IGHJ4
ARADDSPSYYVNAFDL Lyme4 (T1) 1 no IGHV5-51 IGHJ3
AILWGGLGVVTPDYYYFEMDV Lyme3 (T1 & T2) 1 no IGHV1-69 IGHJ6
TRNEIQLDD Lyme6 (T0 & T1 & T2) 1 no IGHV3-49  IGHJ4
VRNHTVYVGGNCNSNPGVFDI Lyme6 (T0 & T1 & T2) 1 no IGHV3-48 IGHJ3





Figure 50: Closer analysis of Borrelia VlsE-C6 reactive B cell clone found back in the deep 
sequencing data from Lyme 8. Top left: Phylogenetic tree highlighting the mutations (with 
concerned positions in brackets) occurring at each branch of the tree. Top right: Number of 
nucleotide sequences that made up each amino acid sequence represented in the phylogenetic tree as 
well as the timepoint at which they were present. Sequences have the same order than in the 
phylogenetic tree. Bottom: VDJ sequence of the germline and the isolated single cell sequences with 
amino acid substitutions from that clone highlighted in red. 
 
4.11 Clustering of isolated IgG+ memory B cell receptor sequences of different 
specificities with next generation sequencing data 
 
In order to get a first impression on the level of the CDR3s isolated with in vitro single cell stimulation 
in our next generation sequencing data we used a simple agrep command allowing one mismatch to 
screen for similar CDR3 amino acid sequences. In accordance with what we found with this approach 
for VlsE-C6 reactive B cells (Table 7, Figure 50), when searching for clones with CDR3 sequences 
related to single cells reactive towards the other antigens, we also hardly found any sequences back 
in the NGS data. These results confirm, that our deep sequencing approach is focusing on expanded 
or activated clones but is missing a large portion of the memory B cell repertoire. In one patient 
(Lyme 4), we however observed an expanded TT reactive B cell clone. This single cell sequence has 




TT reactive B cell clones in Lyme 4, we searched our NGS data for published CDR3 sequences from 
TT reactive B cells [326] and also found higher levels in the dataset from that same acute donor as 
compared to the rest of the samples. In order to generate evidence for an ongoing TT specific immune 
response, we analyzed the mutation status and isotypes of the extracted sequences (Figure 51). 
Although TT related NGS sequences could be found in the majority of our samples, they were rather 
composed of unmutated sequences of IgM isotype as would be expected by naïve B cells potentially 
able to start an immune response towards TT. Interestingly, two related sequences of IgG isotype 
could be extracted, which showed a mutation level similar to other isotype switched cells. Although 
one expanded clone related to published CDR3s could be identified in Lyme 4, this clone was of IgM 
isotype and only slightly mutated. The clone that was related to the isotype switched B cell isolated 
with in vitro stimulation on the other hand showed a higher mutation level that was similar to the 
sequence from the single cell and also the Borrelia reactive clone extracted from Lyme 8 (which 
showed the highest mutation level of all the clones).  
 
                         


























































Figure 51: V-identities and isotypes of sequences from next generation sequencing data that are 
related to isolated single cell sequences. TT-pub-other: TT-related sequences found in other donors 
than Lyme 4 using the published CDR3 dataset [326], TT-pub-Lyme 4-s: small TT related clones 
found back in the deep sequencing data from Lyme 4 using the published CDR3 dataset; TT-pub-




published CDR3 dataset; TT-stim-Lyme4: Clone related to the CDR3 sequence isolated in this study 
from Lyme4 by in vitro single cell stimulation; EBV-Lyme4 and MV-Lyme4: clones related to the 
single cells reactive with EBV and MV isolated by in vitro single cell stimulation from Lyme 4. Borr-
Lyme8: Clone related to Borrelia VlsE-C6 reactive single cell sequence found in Lyme 8. Triangles: 
IgM isotype, Circles: IgG isotype, Filled circles: Borrelia peptide reactive IgG clone, Open circles 
or triangles: clones related to other antigens or pathogens. 
 
Phylogenetic tree analysis was performed on the clones for which we could find related sequences in 
the next generation sequencing data (Figure 52). The phylogenetic tree related to the stimulated cell 
shows sequences going into different directions from the germline, which is indicative of an ongoing 
immune response (Figure 52A). A closer mutation analysis confirmed, that the majority of mutations 
within the TT related clone were occurring in the CDR2. This region was very different between the 
isolated single cell sequence and the assigned germline V gene (Figure 52B). This confirms, that the 






Figure 52: Closer analysis of clones from deep sequencing data related to B cells that are 
reactive against antigens other than the Borrelia VlsE-C6 epitope. (A) Phylogenetic trees showing 




of nucleotide sequences are indicated in the name of each amino acid sequence from the phylogenetic 
trees. (B) VDJ germline and single cell sequences with amino acid substitutions highlighted in red.  
 
Since this was a rather rough approach to search for related CDR3 sequences, we used Cd-hit-2d 
[336,337] to cluster CDR3s according to different CDR3 amino acid identity thresholds (Figure 53). 
At lower thresholds, the extent of clustering with deep sequencing data was different between CDR3s 
but for each individual CDR3, the level was similar among the different donors (Figure 53A-C). At 
these levels of identities, CDR3s containing stretches of Tyrosines seem to cluster generally with 
more sequences from each repertoire than other CDR3s. At the highest CDR3 identity thresholds 
(Figure 53E-F), the CDR3s already found with the simpler agrep command were sticking out also 
when analyzing with this method (Borrelia CDR3: ARGTRDGQNPEFDY; MV CDR3: 






Clustering 50% CDR3 identity





























































































































































































































































































































































































































































































































Clustering 60% CDR3 identity






























































































































































































































































































































































































































































































































Clustering 70% CDR3 identity





































































































































































































































































































































































































































































































































Clustering 80% CDR3 identity






























































































































































































































































































































































































































































































































Clustering 90% CDR3 identity

































































































































































































































































































































































































































































































































Clustering 100% CDR3 identity









































































































































































































































































































































































































































































































































Figure 53: Clustering of single cell CDR3 amino acid sequences with next generation 
sequencing data using Cd-hit-2d [336,337]. Different CDR3 amino acid identity thresholds were 
used to cluster single cell sequences with next generation sequencing data (pooled IgM and IgG 
samples). For every CDR3 analyzed, each dot corresponds to the clustering value of one donor. 
 
Since at lower CDR3 amino acid identity thresholds we observed a similar increase in clustering of 
sequences from the repertoires of the different donors, it was difficult to determine a clustering 
threshold that would allow to separate truly related sequences from randomly clustering ones. Only 
for the CDR3s reactive with Borrelia peptides could we try to set a threshold by testing whether there 
is a difference in clustering between the two groups at a certain value. At the ideal threshold, we 
would expect a maximum difference between the two groups. When doing this analysis with three 
different Borrelia related CDR3s (Figure 54), we observed no clear difference in clustering at the 
lower identity thresholds between the groups, indicating that the majority of these sequences are 
probably not truly related to each other. Individual acute Lyme disease donors stood out at the 
different thresholds, but no general difference between the two groups could be found. At higher 
identity thresholds, only the CDR3 that clustered before with the NGS data from Lyme8 showed a 
clear difference in Lyme8 as compared to all the other samples. No increased clustering was observed 
with any of the other CDR3s or identity thresholds tested, indicating that these CDR3s have been 
rather uniquely produced in the donor from which they were isolated and that sequences that were 
not found back at higher identity thresholds can also not be detected as common to the acute Lyme 






















































































































































































































































































































Figure 54: Comparison of clustering of CDR3 amino acid sequences from VlsE-C6 reactive 
single B cells with next generation sequencing data between acute and control subjects. Different 









5.1 A heterogeneous B cell immune response associated with low numbers of 
antigen-reactive B cells of interest in peripheral blood complicates the 
extraction of Lyme disease specific B cell repertoire signatures 
 
Our data indicate, that the human B cell immune response to Borrelia might be very heterogeneous 
when comparing different donors. By analyzing peripheral blood B cell subsets with multicolor flow 
cytometry, we hoped to identify a B cell subset that would be uniquely expanded in the acute Lyme 
disease condition but not in control samples. This would have allowed us to focus on a B cell subset 
of interest thereby avoiding sequencing of B cell receptors that are not of direct interest. A subset of 
the analyzed acute Lyme disease patients showed slightly elevated levels of plasmablasts, CD23 
expressing naïve B cells and IgG positive memory B cells, which are indicative of an ongoing B cell 
immune response. The rather unique B cell subset compositions of the individual donors made it 
however difficult to reliably extract one subpopulation that is clearly expanded upon Borrelia 
infection. 
 
The absence of detectable distortions in B cell subpopulations could be explained by a combination 
of the low number of patients analyzed and either a general low level of B cell activation [251] or 
heterogeneous responses between patients [304]. Considering the possibility that a robust B cell 
activation occurs in only a subset of Lyme disease patients is legitimate, as previous studies on human 
antibody responses classified patients into three different categories of responders [304]. Our analysis 
enabled us to get some insights into the peripheral blood plasmablast cell numbers to be expected in 
our samples. Using conventional gating strategies based on CD27 and CD38 as markers, their 
numbers were generally very low (between 0-0.64% of B cells). This is in accordance with previous 
studies that showed an unstable cell surface marker expression on these cells after cryopreservation 
[363]. An extensive amount of gating and back-gating needed to be done in order to find this cell 




this cell subset from our patient samples. Since only surface marker expression seems to be affected, 
frozen PBMCs can still be used to study B cell repertoire perturbations induced by immune stimuli 
[1]. 
 
When comparing the IgM heavy chain B cell repertoires of acute Lyme disease patients to healthy 
controls, we identified an increased CDR3 amino acid overlap between different timepoints. 
Interestingly, healthy individuals showed the highest interdonor IgM CDR3 amino acid overlap. This 
would be in line with the hypothesis, that the expanded clones in acute and tick bite individuals are 
rather patient unique. In healthy individuals we expect more naïve B cells, which are less mutated 
and might therefore have a higher chance to overlap between individuals. Generally interdonor 
overlap was much higher for IgM as compared to IgG samples. Furthermore, closer analysis of 
individual IgM clones indicated, that related naïve sequences can be found in the repertoires of other 
donors. For a cluster to be included into the group of overlapping sequences it is sufficient that only 
one related naïve B cell sequence is present in the repertoire of the other donor. This might explain 
why we don’t see any difference between the groups. Sorting of CD27+ memory B cells will be 
required to correctly address this issue. 
 
In accordance with a slight increase of IgG expressing memory B cells, we detected an increased 
diversity and interdonor cluster overlap of acute patients’ IgG repertoires. Also when assessing CDR3 
amino acid overlap between samples from different timepoints, we observed an increased overlap 
between acute patients’ samples as compared to the controls. Final IgG libraries prepared from acute 
patient samples also showed a tendency towards a higher DNA concentration, further indicating 
expanded IgG expressing B cell clones. Since the observed differences were hardly detectable and 
diversity seemed to rather have increased, we came to the conclusion, that Borrelia induced clones 
might not necessarily predominate the repertoires. 
 
In the present study, we did not normalize for the same number of reads per sample. For several 
reasons, we concluded that it might be important to include all the obtained reads into the analysis. 
First, 86% (32/37) of the sequences from single memory B cells isolated by in vitro single cell 
stimulation in this study could not be found back in the next generation sequencing data. From this, 
we concluded that we are far from covering the whole memory B cell repertoire. Recent studies 




As the same library preparation protocol (starting from PBMCs from the same amount of blood and 
using the same RNA input concentration) was used for all the samples, differences in final 
concentrations of libraries are likely due to real biological differences. Correct normalization is 
important for a reliable interpretation of the results, but is rather difficult due to the complex nature 
of the B cell repertoire. The repertoire is composed of a mixture of B cells, some of which could still 
be expanded from previous infections or be induced by other ongoing immune responses. Different 
donors also might react with different magnitudes or kinetics to the same stimulus [4,169]. Clones 
induced by other infections can largely influence the results of both normalized but also non-
normalized samples. Imagine, that there is a largely expanded clone form another infection still in the 
repertoire, this influences the percentage and rank of a Borrelia reactive clone. Even the number of 
expressed Borrelia proteins could influence these parameters. When working with whole PBMC 
samples, the presence of other immune cells and the relative abundances of IgM and IgG expressing 
B cells are also influencing the results. Since at this time the specificity of the expanded clones cannot 
be directly inferred from the deep sequencing data, it remains to be investigated, whether the clones 
that are predominating the individual repertoires have been induced by Borrelia or by some other 
immune stimulus. The most expanded clusters of each IgG repertoire did not show any overlap with 
other acute Lyme disease patient samples. When focusing on the top 50 clusters of each sample 58 
of 1700 (34 samples; 3.4%) were overlapping with sequences from another acute donor. 
Corresponding sequences from the other repertoires were however generally not belonging to the top 
50 clusters. When doing this analysis, two clusters particularly stood out. The first interesting cluster 
(CDR3aa: X-K(R)-W-R-X-X-Q-S-E-X-D(E)-X;  IGHV3-7; IGHJ4) was found in 5 different donors 
(Top50: Lyme7(T2), Lyme12(T1); Top200: Lyme4(T2), Lyme11(T0); low level: Lyme1(T0,T1,T2), 
Lyme4(T1), Lyme12(T0,T2), Lyme7(T0)) and the second one (CDR3aa: A-K-X-X-X-X-X-C-S-X-
X-X-C-Y-X-F-D-X, IGHV3-23; IGHJ4) was found to overlap even between 6 different donors 
(Top50: Lyme3 (T2), Lyme9 (T2); Top200: Lyme9(T0), Lyme 8 (T0), Lyme12(T0); low level: 
Lyme2(T1); Lyme7(T0,T1)). Both these clusters could not be found in any of the control samples. 
These clusters have been isolated by a rather rough manual approach and more sophisticated 
statistical analysis taking the occurrences and levels of individual clusters as well as general clonal 
repertoire distributions into account will be required to provide more reliable results. Isolation of 
antigen reactive single B cells and confirmation of their B cell receptor specificity is a more direct 
method that is crucial to solve these issues. Unfortunately we did not have the time to perform 
confirmatory expression experiments anymore, but when isolating VlsE-C6 reactive B cells we found 




single cell approaches is one possible explanation for the observed absence of clustering among 
peptide reactive sequences. Since next generation sequencing allows to analyze a much larger 
proportion of the repertoire, we tested to what extent we could find sequences related to the peptide 
enriched B cells in our deep sequencing data. Also with this approach, the vast majority of the single 
cell sequences clustered with sequences of repertoires from the same donor (86%, 96 of the 111 that 
were found back in the deep sequencing data). Overall our data indicate, that the B cell repertoire is 
rather “personal”, showing little overlap between individuals. These findings do however not exclude 
the possibility that Borrelia reactive B cell repertoire signatures might exist. Our data just indicate, 
that these signatures are more complex than initially imagined and that one might need to dig deeper 
into the repertoires in order to identify them. Specificity of extracted candidate signatures needs to be 
confirmed by different experiments. Quantitative PCR approaches allowing the amplification of the 
individual clones of interest from samples might be more sensitive than sequencing of bulk B cell 
repertoires. 
 
Since there cannot be an indefinite number of possibilities to bind to the same epitope, it is probably 
just a matter of how many sequences and patients will be analyzed before finding clones overlapping 
between individuals that were challenged with the same antigen. This has in fact been nicely 
demonstrated by recent next generation sequencing studies, which were able to show that elevated 
levels of antigen related sequences indeed occur after corresponding immune stimuli [169,171,326]. 
Although a rather clear immune signature could be isolated from a large acute Dengue patient cohort 
based on NGS data alone [165], the specificity of this sequence for this disease still needs to be 
confirmed, as it was proposed that the Dengue virus activates natural IgG B cells with polyreactive 
properties [166]. It would make sense, that evolution has designed these types of antibodies in a way 
that they share more common features between donors as compared to other more specific antibodies. 
The possibility of polyreactive sequences being included into vaccine induced clusters has already 
been proposed previously and should be considered as possible part of any antigen specific B cell 
immune response [126]. Interestingly very old mouse studies already indicated, that thousands of 
different B cell clones might be capable of reacting with an antigen and that B cell immune responses 
should rather be seen as being composed of a mixture of antibodies with antigen- and poly-specific 
reactivities [100]. Given, that such a mechanism would provide a broader range of protection, it would 
only make biologically sense to induce an immune response that is at the same time specific but that 
can also confer protection against related (possibly mutated versions of the same) pathogens. 




chance to overlap, it remains open whether this degree of overlap is sufficient and specific enough 
for repertoire sequences to be useful to support diagnosis or to say something about the 
immunological history of patients. Plasma cells isolated after meningococcal vaccination for example 
only shared 0.17-2.2% CDR3 sequences between donors, indicating that the vast majority of 
generated clones are rather patient unique [127]. Furthermore, when analyzing the presence of 
hepatitis B virus reactive antibody sequences in immunized individuals, a large fraction was already 
present in the switched repertoire before the immune challenge, showing the existence of cross-
reactive sequences in the memory repertoire of individuals [126]. In the present study, we also found 
that sequences overlapping between a higher number of donors were generally found in both groups 
(those with acute Lyme disease but also in the control group), raising the question of whether 
clustering approaches and overlap analysis in combination with such low numbers of patients are 
rather enriching for polyreactive B cell repertoire sequences. Overlapping sequences between acute 
patients and controls could be explained in that case by a subclinical infection or still expanded clones 
from previous infections in the repertoires of healthy donors [12]. Our multicolor flow cytometry data 
indicate, that indeed a subset of healthy donors might have expanded clones and an ongoing B cell 
immune response. This might be another explanation for why we hardly detected any difference 
between acute Lyme disease patients and healthy individuals when assessing repertoire diversity. 
Similar to other studies, our results are indicating, that cluster overlap is rather occurring at the lower 
level memory B cell subpopulation [171]. Although a closer analysis of the individual overlapping 
clusters is required to completely confirm this statement, our data showed rather an anticorrelation 
between CDR3 amino acid overlap among different timepoints as compared to overlap between 
different donors. As antigen-specific memory B cells can remain in the repertoire for even a lifetime 
[144], it remains to be investigated, whether the expansion of these cells upon acute infection is large 
enough for them to be useful for diagnosis. Furthermore - coming back to the problem with 
polyspecificity - since the major role of memory B cells is to elicit a quicker response to reinfection, 
which can occur by related but not identical pathogens, they have been shown to be less specific for 
the antigen as compared to the antibody secreting cells which have the main role to confer protection 
against the same pathogen [56,68-70]. On the other hand polyreactive memory B cell clones capable 
of recognizing different mutant variants of the same pathogen might be advantageous for diagnosis, 
because only one clone would need to be identified for an acute infection caused by the different 
variants. The kinetics of memory B cells is rather slow and thereby maybe not suitable for diagnosis 
[116]. Given all these considerations, the challenges of future studies will be to isolate those rare 




of specificity for the antigen. From this and previous studies, we can only conclude that the number 
of possible ways of our B cell repertoire to recognize an antigen is probably very large. Mathematical 
modelling and deeper statistical analysis will be required to successfully address this issue but is out 
of the scope of the present study. To reliably determine the sizes of B cell repertoires reactive towards 
different antigens or epitopes, single cell isolation techniques will need to be combined with next 
generation sequencing approaches [123,124] allowing to screen larger numbers of cells and to 
perform robust statistical analysis. 
 
Our deep sequencing data suggest that the switched memory and plasma cells generated in response 
to Borrelia infection might be less mutated than those generated in response to other infections or 
vaccinations. Low mutation frequencies - and hence low specificity - could be one explanation for 
the high level of crossreactivity of acute Lyme disease patient sera [285], which renders the 
development of specific serological tests difficult. On the other hand, direct comparison to other 
primary immune responses is crucial to be able to make such a statement. Since the majority of the 
patients form our study encountered Lyme disease for the first time, it is also possible that the low 
mutation frequency is due to the nature of a primary immune response rather than problems to 
undergo efficient germinal center reactions. As these sequences coincide with the major IgG peak 
and are more mutated than the ones from the IgM repertoire, they have probably undergone some 
degree of selection in germinal centers or similar structures. For VlsE-C6 reactive memory B cells 
we observed a similar or even increased mutation level as compared to memory B cells of other 
specificities, indicating that at least B cell clones reacting towards this epitope harbour “normal” 
mutation levels. 
 
In accordance with previous studies [3,126] which already indicated, that the effect of immune stimuli 
on the B cell repertoire is expected to be small and not easily detectable, we were not able to observe 
drastic changes in repertoire diversities upon Borrelia infection. The number of final sequences can 
influence diversity indices and differences observed between biological replicates were in a similar 
range than differences observed between samples, indicating that the effect of Borrelia on the B cell 
repertoire might be smaller than inherent fluctuations of the data. Also when performing hierarchical 
clustering using diversity profiles of individual samples [3], which should be less dependent on 
sequencing depth, biological replicates did generally not cluster together. This is in line with previous 




patients) allow separation according to immune status, while samples from immunized cohorts were 
not skewed enough and rather clustered according to library preparation protocol or sequencing 
machine than according to immunological status. 
 
The B cell immune response to Borrelia  is far from being completely understood. Even if our patients 
were diagnosed with acute infection, the level of VlsE-C6 reactive switched B cells were generally 
low. They showed even slightly lower or similar levels than cells induced by commonly encountered 
previous infections or vaccinations. Although the level of reactive B cells towards a single epitope 
(VlsE-C6) might not be directly comparable to the one towards whole pathogens or antigens, previous 
studies from the Lyme disease field have indicated that we might not expect drastic changes in 
peripheral B cell numbers upon acute infection [317,318]. Not only in mouse studies was it shown 
that Borrelia can actively influence the B cell immune response [289-292,303], but also in humans 
the B cell immune response seems to be rather of low level and different compared to other diseases 
[251]. 
 
5.2 Strengths and weaknesses of the approach used herein to identify Borrelia 
specific B cell repertoire signatures 
 
Initial library preparation protocols were based on multiplex PCR using BIOMED2 primers [335] 
followed by adapter ligation. These were the standard Ion Torrent library preparation protocols at that 
time and had several disadvantages, which we tried to overcome by adapting the protocols to newer 
versions. The adapter ligation method required separation of the final library from unwanted side 
products by using E-gel. Because of differences in sizes of the individual molecules, retrieval of the 
complete library turned out to be rather problematic. Besides this, the standard reverse transcription 
protocol in combination with the high number of cycles (35) used in our multiplex PCR gave a 
disturbing side band, which had to be removed using Gel-extraction. This is enhancing the risk of 
sample cross contaminations, which we absolutely wanted to avoid when studying sequence overlap 
between samples. In order to make sure that each primer is working equally well in the PCR reaction, 
concentration of each primer would have needed to be optimized and internal controls should have 
been used for quantification of individual V-genes after amplification. This would have been a 




one cannot exclude that even after such extensive optimizations and especially at later PCR 
amplification steps the presence of certain V-genes might still influence amplification of others. Due 
to our own and other studies on barcoding techniques [364], we now know, that even when using 
only one primer pair, the PCR process is still a stochastic and heterogeneous process. Different 
strategies (including 5’-template switching [365], synthetic immune receptor repertoires for 
optimization of PCR conditions [366], resequencing of samples using different primers for 
amplification [367], emulsion PCR [368] and barcoding techniques [1]) have been developed to 
overcome the problems of unequal amplifications with multiplex PCR. Because of its simplicity and 
because it allows to get maximum quality reads, we decided to use a barcoding approach similar to 
the one that has been published by Vollmers et al. [1]. By labelling cDNA molecules with individual 
barcodes at the reverse transcription step and avoiding multiplex PCR, we are able to reduce PCR 
amplification bias and sequencing errors. To minimize library preparation or sequencing Chip effects, 
we made sure to always handle control and acute patient samples in parallel for each step of the 
experiment – meaning from RNA extraction through to the final sequencing run. Stringent 
precautions were also applied to avoid cross-sample contaminations. To have a more or less random 
distribution among samples from the different groups and timepoints, we also made sure to rotate the 
MID barcodes between samples each time libraries were prepared. By reducing the number of PCR 
cycles and by employing a reverse transcription protocol for high GC content mRNA molecules, we 
were able to get rid of the disturbing large unwanted side-band mentioned before. Although we were 
able to use a lower number of PCR cycles (19 in our case) as compared to the protocol of Vollmer et 
al. [1] (which used 27), the limiting step was actually not the amount of library needed for sequencing, 
but quantification on the bioanalyzer instrument. PCR approaches allowing quantification from lower 
amounts of library material might allow to further go down with PCR cycles and thereby give us an 
even less biased view into the B cell repertoire. 
 
While manually generating phylogenetic trees of clones of interest including next generation 
sequencing data, we noticed that they still contained a large number of insertion and deletion errors. 
Those could be easily corrected by alignment to the single cell sequences. When assessing individual 
runs before and after cleanup, we were however able to see a reduction in errors, meaning that the 
used pipeline does its job. Insertion and deletion errors might persist in the final consensus sequences, 
because the Ion Torrent errors are not occurring randomly [369,370]. Since error correction with 
barcoding techniques is based on the most frequently occurring base at a certain position, systematic 




findings. Insertion and deletion errors can however be more easily identified and removed as 
compared to substitution errors and sequence assignments by IMGT [354] also takes these types of 
possible errors into account. With the present method, we are not able to control for errors occurring 
during the reverse transcription or second strand synthesis steps, nor are we be able to detect an error 
occurring in one of the very early cycles of the PCR used for amplification. 
 
In order to get an idea about sequencing depth, we compared CDR3 amino acid overlap between 
sequencing, library and biological replicates. We concluded, that biological replicates are more 
reliable to get a maximum of information from the data. The overlap between biological replicates 
observed in the present study is comparable to the extent of overlap observed in other studies[1,12], 
confirming previous statements that different methods give rise to comparable results [12,372]. By 
comparing V and J gene distributions obtained with our next generation sequencing approach with 
that one obtained by randomly sorted single B cells, we were able to exclude large amplification 
biases. Similar to previously published data [12,373], IGHV3-23 and IGHV3-30 V-genes and IGHJ4 
followed by IGHJ6 J-genes predominated within sequences obtained with both approaches. Although 
globally seen, there were no huge differences in the V and J gene usage in our datasets as compared 
to previously published ones slight discrepancies between the datasets were however observed. 
IGHV3-7 for example was more predominant in our datasets, while IGHJ6 was a bit less prominent 
as compared to those of other studies [12,373]. 
 
Since herein we analyzed a smaller number of sequences as compared to other studies [1,12], it makes 
sense that the degree of sample overlap observed here is closer to the range that they observe when 
only taking most abundant sequences into account. The ~20-30% CDR3 amino acid overlap between 
biological replicates indicates that our approach covers a significant part of the expanded repertoire. 
Also in line with what has previously been observed [12,14], we found that every donors’ repertoire 
is rather unique. While ~10-30% CDR3 amino acid overlap was observed between samples from 
different timepoints, overlap between donors was not exceeding an average of 0.2%. Since the focus 
of the present study was the portion of the repertoire that is expanded in response to infection, the 
employed method should be perfectly fine. In the course of the study, we however found that 
overlapping clones might not be as expanded as initially hypothesized. Sequencing depth was 
however enough to see a difference in inter-donor IgG cluster overlap between our two groups. We 




From our observations, we concluded that we are only sampling a snapshot of the bulk repertoire 
with deep sequencing but also only part of the antigen reacting B cell repertoire with the single cell 
approaches. Due to the heterogeneity and low level of Borrelia reactive B cells, future studies would 
need to extract sequences form much larger amounts of blood to be able to more closely assess clonal 
relatedness and evolution of Borrelia reactive B cells in the course of infection. As opposed to 
vaccination studies, in which flow cytometry [116], ELISPOT [67,135,136] and more recently also 
deep sequencing data [1,127,169,171,326,374] could confirm the plasmablast burst that generally 
occurs 6-7 days after the boost, the situation in acute or chronic infections might be more complicated. 
In addition to that, recent studies indicate that these largely expanded cells might not necessarily be 
the ones of interest for biomarker research, as lower level clones showed a higher degree of overlap 
between donors [171]. 
 
Our clustering analysis confirmed reports from other groups, who showed that it is possible to find a 
higher cluster overlap among individuals that encountered the same antigenic challenge 
[165,169,171,326]. These approaches allow to determine whether highly similar B cell clones are 
generated in different donors. We observed however, that very different B cell receptor sequences 
might interact with the same epitope and that the chance of finding similar B cell clones in the 
expanded repertoire of two different acute patients is rather low. Probably key residues and whole 
antibody structures rather than CDR3 sequences and common V and J genes are the determinants of 
antigen-binding. For this reason more sophisticated clustering approaches are required to extract 
sequences reactive with the same antigen. Bioinformatics tools that allow to extract common key 
mutated residues and structural features in a high throughput manner directly from deep sequencing 
data need to be developed. Due to the aforementioned problems with sample normalization, 
extraction of clones of an ongoing immune challenge will also be more reliable if general repertoire 
characteristics that could separate clones according to their time and mode of generation (like clonal 
expansions, mutation status, isotypes, phylogenetic tree structures, evolution of clones over the 
different timepoints, etc) are included into the analysis. The development of such a tool by far exceeds 
the capacities of this project. Publications of improved analysis pipelines for B cell repertoire data 
are exploding at the moment and probably some advanced tools will emerge soon. 
 
Isolation of memory B cells of different specificities by in vitro single cell stimulation allowed us to 




approaches to identify related sequences in deep sequencing data. At low identity thresholds, the 
degree of clustering of single cell CDR3 amino acid sequences with deep sequencing data was rather 
dependent on sequence composition and similar values were obtained for the different donors. This 
indicates, that the degree of clustering of a certain sequence can depend on its composition and might 
not necessarily be due to the presence of a higher amount of closer clones in the repertoire. At lower 
levels of identity, sequences rich in tyrosine residues showed a higher tendency to be found back in 
the deep sequencing data. B cell repertoire signatures identified for Dengue [165] and influenza [169] 
viruses also showed such polytyrosine residues, raising the question of how specific antibodies with 
such properties are for a certain antigen. The physicochemical properties of tyrosine allows it to 
interact with a large variety of amino acids on the surface of antigens, which explains its abundance 
in antigen binding sites of antibodies [80,83]. Because of the lower abundance in the heavy chain 
CDR3s of antigen-experienced B cell subsets [73,81], sequences with polytyrosine residues were 
thought to be rather polyspecific, a finding that could not be confirmed by more recent studies [82]. 
Although polytyrosine residues were found in the CDR3s of several of our isolated single cell 
sequences, antibodies produced by the isolated cells generally gave positive results only for one of 
the several antigens tested, meaning that they are rather specific. Only one sequence which had two 
adjacent tyrosine residues (CDR3: ARADDSPSYYVNAFDL) showed reactivity to both Borrelia and 
measles virus. Very likely tyrosine residues are frequently used to mediate antigen contacts, but their 
precise position within a certain context is probably determining the specificity of these residues. 
Since the tested individuals were from the same region and were probably exposed to similar immune 
challenges in the past, it might not be surprising to find similar CDR3 sequence distributions and 
clustering tendencies within their memory repertoires. The only antigen for which we were able to 
compare truly negative with seropositive or acute donors was VlsE-C6. Also with this one we were 
not able to reliably define one clustering threshold that would allow to clearly separate acute from 
control groups. This is confirming, that each donor rather generates unique sequences in response to 
an immune challenge and that the rather individual nature of each binding mechanism complicates 
the determination of a global clustering scheme applicable to all antibody-antigen interactions. 
Isolation of antigen-reactive single B cell receptors and characterization of individual antibody-
antigen interactions with x-ray crystallography remains the method of choice to better understand 
these phenomena. 
 
Generally, it is also difficult to extract antigen-specific B cell signatures from the low numbers of 




that reactive sequences can have very different V and J genes as well as CDR3 lengths. This makes 
them difficult to compare at the sequence level and more extensive analysis of the three dimensional 
antibody-antigen interactions would be required to completely understand which residues are 
important to determine antigen specificity. Mutation analysis of individual positions might be another 
strategy. The number of different clones per individual that are produced in response to a TT boost 
has for example been estimated to be in the range of 44-79 different clones per donor [116], a number 
that we are far from reaching with our single cell approach. When considering different donors, this 
number of possible interactions is expected to be even higher. We first need to determine the diversity 
and specificity of epitope reactive repertoires before being able to reliably answer the question of 
whether it is possible to use B cell repertoire signatures as diagnostic tools. In this regard, techniques 
combining single cell with deep sequencing approaches are crucial [123].  
 
5.3 Comparison of methods allowing to isolate and characterize antigen-
reactive B cells 
 
One major goal of this study was to characterize B cell receptor sequences of clones that are naturally 
induced by Borrelia infection. For this reason, we explored different methods that allow to isolate 
antigen-reactive B cells directly from patient samples. One possibility we considered was 
immortalization of B cells [375]. This allows to reuse the same sample for different experiments. One 
could for example use one part of the expanded cells for sorting VlsE peptide positive B cells and at 
a later timepoint reuse the same sample for sorting with other Borrelia antigens. This would allow to 
dissect the B cell repertoire of a patient in great depth without the need of many patient samples. On 
the other hand, this approach has also already been used successfully to stimulate single cells and to 
isolate antigen-reactive B cells from patients [376]. In our hands, EBV immortalized B cell lines were 
however not very stable when kept for prolonged times in culture, which is why we abandoned this 
method. More recent immortalization techniques [377] seem very interesting as they allow to expand 
B cells expressing the B cell receptor on their surface but at the same time also secrete the soluble 
form of the receptor. This would allow to screen supernatants of single sorted cells for specific 
antibodies but one would also have the option to sort antigen-reactive B cells with tetramer staining 





Another attractive approach we started to explore was in vitro antigen-specific memory B cell 
stimulation. The idea was to enrich samples in B cell receptor sequences of interest prior to library 
preparation. From initial pilot experiments, we however concluded, that in vitro stimulation is a 
complex process that could be influenced by the activation status of the patient´s immune cells, the 
genetic background of the donor, peripheral blood immune cell subset composition and many other 
factors that are difficult to control for. Approaches, that pre-sort B cell subsets of interest and 
stimulate single isolated cells to produce antibodies followed by direct screening of supernatants by 
ELISA are beneficial over more general stimulation conditions [378,379]. These methods have the 
big advantage, that one can directly screen for reactivity of the B cell receptor towards the antigen, 
without the need for tedious cloning and expression of the antibodies. In addition to that, an increased 
amount of starting material due to the expansion of the single B cells should enhance the likelihood 
of a positive PCR result. Single cell approaches have also the advantage that one can get information 
about the whole B cell receptor, including corresponding heavy and light chain sequences. The 
stimulation protocol used in this study [355] has the advantage, that it allows to dissect the human 
memory B cell repertoire at the single cell level without any bias from prior pre-enrichment of cell 
subsets of interest. Although we negatively selected for IgG class switched B cells, we did not enrich 
for any other B cell marker allowing to get an idea about the level of antigen-specific B cells in the 
untouched IgG repertoire. 
 
Combining in vitro single cell stimulation with screening against a whole group of antigens allows to 
determine antigen specificity of the single cells, thereby excluding the possibility of a positive ELISA 
result due to polyspecificity of the produced antibodies or other factors that might potentially 
influence ELISA results. Isolation of antigen-reactive memory B cells with tetramers [352] might be 
a less time consuming and cheaper approach, but setting the right gate is challenging especially if cell 
numbers are low and the amount of sample scarce. In addition to these problems, we also observed 
non-specific binding of the tetramers. It seems, that the Borrelia peptides bound to Neutravidin, but 
that not all the biotin binding sites of the tetramers were occupied. One possible explanation for this 
could be the presence of peptide aggregates. Some of the background noise could come from the 
binding of tetramers to CD43+ B cells that are labeled with CD43-biotin from the MACS kit that we 
used to negatively enrich for B cells. Double staining of unmanipulated PBMC samples  with peptide 
Streptavidin and Neutravidin tetramers in different colors will probably allow to reduce background 




reactive antibodies from non-specific ones. In theory, this step can be omitted when isolating antigen-
reactive single cells by in vitro stimulation. 
 
With the latter method, we were however only able to get a complete antibody sequence from a subset 
(40%) of positive wells. This was generally not due to the single cell PCR not amplifying all V genes, 
as 84% and 85% of the heavy and light chain PCRs were giving a PCR band visible on the gel. For 
11% we did not get any PCR product at all. We however noticed, that in 18% of the wells we got a 
PCR product for both kappa and lambda light chains. In addition to that, for one of the antibodies, 
we got two different light chain sequences associated with one heavy chain sequence. For this reason, 
we conclude that also for this method it might still be important to clone the antibodies to confirm 
specificity. Since cell seeding follows Poisson distribution, it could potentially be that more than one 
cell has been seeded per well, which could be the reason why the Sanger sequencing did not work in 
some cases. To avoid confusion and if the antibody sequences are of interest, it might be important 
to consider high precision single cell sorting directly into the 384 well plate with a FACS machine 
instead of manual seeding. Although the rest of the sequences requires confirmation by cloning, we 
are quite confident, that at least for the heavy chain, the Borrelia peptide reactive sequence (CDR3: 
ARGTRDGQNPEFDY) isolated twice from Lyme 8 binds VlsE-C6. 
 
Analysis of larger amounts of single cells are required to exclude that an insufficient sample coverage 
might be the reason for the low reproducibility between the two single cell isolation techniques finally 
used in this study. On the other hand, it is also possible that the two methods select for different B 
cell subsets. 
 
Previous studies have shown, that antibodies might interact with antigens in their membrane bound 
form but do not necessarily need to also bind to the same antigen in their soluble form [380]. This 
might be one explanation for why IgM sequences isolated with labeled antigens of interest might 
seem rather non-specific when confirming binding with ELISA approaches [114]. Confirmation of 
antigen binding might therefore in that case be more directly assessed by employing competition 
assays [171]. In vitro stimulation on the other hand might just activate specific B cell subsets thereby 
possibly not covering all Borrelia reactive B cells. Studies on hepatitis B vaccination also showed 
discrepancies between deep sequencing and ELISPOT data [126], which the authors explained by the 




ELISPOT assay. Deep sequencing on the other hand seemed sensitive enough to detect the B cell 
clones generated after the first vaccination boost. 
 
The low frequency of clustering between sequences from our peptide enriched dataset originating 
from different donors is in line with other studies that assessed the degree of sequence overlap 
between datasets containing antigen enriched sequences [127,160]. We were able to confirm 
heterogeneity of VlsE-C6 reactive B cell receptor sequences with two different methods further 
supporting this notion. 
 
5.4 Promises and challenges of studying the B cell repertoire of acute Lyme 
disease patients 
 
Although public B cell repertoire signatures reactive to specific antigens have been discovered 
[127,165,169,171,326], their detection and validation generally still requires combination with 
approaches to isolate antigen-specific B cells. As illustrated by studies on anti-HIV broadly 
neutralizing antibodies [160,381] for example, it is rather difficult to extract antigen-specific 
signatures directly from deep sequencing data. Earlier single cell studies even suggested that it is 
rather not possible. Next generation sequencing now allows a deeper analysis of the B cell repertoire 
with increasing reports of sequences with overlapping features between donors. The diversity of the 
B cell repertoire is at the same time its beauty but also a nightmare in a sense, that it tremendously 
complicates data analysis. In this regard, Lyme disease especially in the European setting is an even 
worse nightmare. Different circulating Borrelia species [265] might express antigens of different 
structure. In addition to that, Borrelia are masters in changing protein expression [382]. Depending 
on the stage in which the patient is, different antigens might be expressed and predominate the B cell 
immune response. Not to forget the heterogeneous timepoints of infection. 
Although upon acute infection, antibody secreting cell (ASC) numbers in peripheral blood also 
generally seem to peak around 7-8 days after onset of symptoms, responses can nevertheless vary 
greatly between donors [4]. Vaccination studies allow to analyze defined timepoints. Furthermore, 
individuals can be challenged with exactly the same antigen, leaving only the donors’ background as 
variable. But even under these more “controlled” conditions, isolation of common clones seems rather 




peripheral blood B cell immune response upon acute Lyme disease infection. The higher CDR3 
amino acid overlap between acute patient samples from different timepoints is indicative of an 
ongoing B cell immune response at both the IgM and IgG levels. Furthermore, sequence clustering 
revealed a higher percentage overlap among acute Lyme disease patients’ IgG repertoires as 
compared to those from healthy controls. 
 
Pevious reports from the Lyme disease field indicate, that this disease might be associated with low 
and heterogeneous B cell immune responses and might explain the difficulties we had to isolate true 
Borrelia reactive B cell receptor sequences from our samples. In contrast to some older studies that 
showed an increase in peripheral B-lymphocytes in other acute bacterial infections [142,143], Lyme 
disease does not seem to be associated with such changes [317,318]. A recent RNAseq study of acute 
patients PBMCs found differences in the induction of B cell developmental pathways and calcium-
induced T cell apoptosis by Borrelia as compared to other infectious agents [251]. These data 
generated further evidence for the involvement of a rather low proportion of B and T cells in 
peripheral blood in the acute Lyme disease condition as compared to other diseases. Analysis of 
immune factor levels within peripheral blood was able to separate acute patients into two groups, one 
with higher levels of T cell recruiting chemokine and inflammatory marker expression associated 
with lymphopenia and the development of antibodies against Borrelia and a second group in which 
B and T cell responses seem to be rather low [248], further supporting heterogeneous responses 
among patients and explaining possible different outcomes. Studies at the antibody level also 
described three different antibody responses towards Borrelia [304]. 
 
5.5 Possible effect of the tick bite on IgM expressing B cells 
 
Both our flow cytometry and the deep sequencing data indicate, that a subset of individuals develop 
a strong B cell immune response to the tick bite, a phenomenon, that we did not observe to such a 
drastic degree in the acute Lyme disease patients. As in three out of the five analyzed donors with a 
recent tick bite we observed a strong and long lasting perturbation at the level of IgM expressing B 
cells, we think it might be interesting to analyze larger cohorts of donors with a recent tick bite to 
confirm this effect. We can envisage two possible explanations for the absence in acute Lyme disease. 
It could be, that Borrelia counteract such strong B cell immune responses similar to the effects 




the tick to take an undisturbed meal. Since this effect seems to occur already before the general 
transmission of Borrelia [184,185], another more plausible explanation would be, that Borrelia are 
rather transmitted in individuals with weaker responses towards ticks [383]. It is maybe interesting 
to mention in this context, that the third tick bite donor, which did not contain largely expanded clones 
in its IgM repertoire, showed a very high IgG sequence overlap with acute patients. This indicates 
that the response in this donor might be closer to a response occurring upon acute Lyme disease 
infection. As it is unnaturally quick and long-lasting, the real existence of this effect needs further 
validation. The lower diversity of the two affected repertoires might not necessarily be due to a B cell 
expansion but could also be due to lower B cell numbers in these individuals. This would support the 
possibility that naïve B cells disappeared from the blood and that other cells might have predominated 
these PBMC samples. We think that it is highly unlikely, that merely by chance the same sequence 
was overamplified in the different samples from the same donor. Also the mutation status of these 
sequences indicated, that they are quite distant from the germline, while this was generally not true 
for related sequences found in other donors. These findings indicate, that these mutations are probably 
true mutations and were not solely present due to difficulties of the Ion Torrent to sequence reads of 
that particular composition. In the expanded clone from Tick2, replacement mutations were mainly 
concentrated in the CDR2 region, which would make biologically sense. 
 
5.6 Interesting individual cases 
 
Two (Lyme2 and Lyme8) of the twelve acute Lyme disease patients analyzed in this study showed 
an increase in VlsE-C6 IgG antibody titer as determined by our in house peptide ELISA. One of these 
donors (Lyme8) has been analyzed with in vitro single B cell stimulation. This was the only case for 
which we were able to isolate the same B cell sequence from two different wells, making us confident 
that this sequence is really Borrelia specific. Since this donor was showing a drastic increase in 
antibody production over the sampling period, we would expect to detect expanded plasmablasts in 
these peripheral blood samples. In accordance with an ongoing response, this donor showed a quite 
high CDR3 amino acid overlap between samples from the different timepoints (IgG: 
33%(T0)↔7%(T1), 6%(T1)↔8%(T2), 33%(T0)↔8%(T2) , IgM: 60%(T0)↔50%(T1), 
53%(T1)↔52%(T2), 58%(T0)↔51%(T2)). A large number (123) of sequences from the deep 
sequencing data could be assigned to the clone isolated by in vitro single cell stimulation, which was 




started 4 days before the first blood draw, indicating that she is still at a very early stage of the disease. 
When integrating this information with the results obtained from phylogenetic tree analysis, we 
concluded that this clone might have been generated from memory B cells. All sequences of that 
clone were of IgG isotype and this tree had a quite long tree trunk, indicating that this clone might 
have started from an already mutated B cell. Interestingly we had difficulties to isolate Borrelia 
reactive memory B cells from this donor with our tetramer staining approach. We managed to isolate 
two peptide reactive sequences from the first timepoint sample. One of these could be found back in 
the next generation sequencing data. This clone was predominated by IgM sequences that could be 
found in all three timepoints analyzed, but interestingly one IgG sequence was found in the last 
timepoint. Since the trunk of this tree is also rather long, this clone has probably been generated from 
an IgM memory B cell that switched isotype at later timepoints of infection. Together these data 
indicate that this donors B cell immune response started from pre-existing memory B cells and might 
therefore have been rather plasma cell than memory B cell driven. These findings indicate, that we 
are isolating different B cell subsets with our two single cell approaches. Single cell clonal analysis 
are however in line with next generation sequencing data, indicating that a short term expansion of 
IgG B cells occurred at the first timepoint of sampling, combined with a rather long term perturbation 
at the IgM level. More general phylogenetic tree analysis of the deep sequencing data [77,384,385] 
from our patients will allow to classify clones into different categories. Repertoire data harbour a 
tremendous amount of valuable information that would allow to determine the stage and the nature 
of individual B cell immune responses. The possibility of differentiating a primary from a secondary 
immune response based on B cell repertoire data can be very helpful to support correct interpretation 
of serological results. 
 
Although we cannot exclude, that Lyme4 was recently vaccinated against tetanus toxoid (TT), 
interestingly we detected a possible ongoing immune response against this antigen in this donor. This 
patient had problems to mount a robust class switched long term antibody response towards VlsE-
C6, as the IgG antibody titres were declining with treatment over time. Besides erythema migrans, 
this patient also reported to have suffered from additional symptoms which did not completely 
disappear within the one month period sampled. Although CDC [386] is warning that TT might be 
transferred by insect bites, I am not aware of any study directly showing infection by Clostridium 
tetani via tick bites. The possibility is however not to be excluded. Although this patient might have 
been infected via another route, it could very likely be, that ticks are contaminated with spores that 




outside in nature, where such spores could be present. This means, that it might be crucial to regularly 
check the TT immune status of risk cohorts - as should however theoretically anyhow be done – 
especially in the case of more elderly people [387]. Transmission via insect bites might also be one 
explanation for why tetanus infections are common in countries with high malaria incidences [388]. 
 
It might also be interesting to note, that Lyme6 had only symptoms for two weeks and stayed 
seronegative over the one month period of sampling. Quite some of the single cells isolated with 
tetramer staining from that donor could however be found back in the next generation sequencing 
data. Clones of both IgM and IgG isotypes could be retrieved in that way. The presence of memory 
B cells but absence of antibodies in this early stage patient is in line with mouse studies, that showed 
that the tick can have an effect on antibody production but not memory B cell formation [287,288]. 
This might be one explanation for the rather slow antibody response of patients towards Borrelia. 
Due to problems with non-specific binding, we can however not be completely sure that the isolated 
single cells are really VlsE-C6 reactive so that further confirmation of such a phenomenon is required. 
With in vitro single cell stimulation, we were however also able to identify VlsE-C6 reactive B cell 
clones in that donor, indicating that they might indeed be present in this repertoire. 
 
A similar phenomenon was also observed in donor SP2. This was the donor from the seropositive 
group that showed the brightest staining with peptide tetramers. Initially this donor was assigned to 
the seronegative group. When reanalyzing the immunoblot after having observed this bright signal 
induced by tetramer staining, we however observed a faint IgG band reactive with the VlsE-mix. This 
donor was probably categorized as being seronegative, because reactivity was not clearly more 
positive as compared to the cut-off control of the immunoblot. When reassessing the donors’ data 
sheets, we noticed that he reported to have had a tick bite with a red skin lesion 5 weeks before the 
blood draw. For these reasons, we shifted this donor later into the seropositive group. Interestingly, 
when preparing the B cells for the tetramer staining experiment, we observed an overnight 
proliferation of the B cells. The next morning way more cells were present in the tube as compared 
to the day before. This was however the only donor for which we observed such an effect. 
Interestingly 72% of the single sorted B cells from that donor were of IgA isotype, while this was the 
case for only 46% of the control cells. IgA anti-VlsE-C6 antibodies have been detected in early Lyme 
disease, but IgA only positive individuals have not been observed in that study[389]. Overall our 




however repeatedly observed a little bit more staining in seropositive as compared to seronegative 
donors. In a mouse study from our laboratory, the same approach (using a different antigen and 
peptide) confirmed a brighter staining of B cells from immunized as compared to non-immunized 
mice. From this, we concluded that at least some of the stained B cells should be peptide reactive. 
We did however not observe any correlation between antibody levels and memory B cell staining. 
The same was also observed in other studies [390], meaning that this approach cannot be used to 
confirm specificity. Competition experiments [171] should have been performed to more reliably 
confirm specificity of the approach. 
 
The last interesting case that we want to mention in this context is Lyme11. In this donor, we 
identified a CLL clone that interferred with our tetramer staining and that allowed us to understand 
some possible reasons for background noise in this type of assay. This donor showed a rather special 
response towards Borrelia, because the erythema migrans was present already for a whole year before 
Lyme disease was diagnosed and the patient entered our study. Although erythema migrans is thought 
to generally resolve even without antibiotics treatment, this seemed rather problematic in this patient. 
Upon antibiotics treatment, the erythema migrans however disappeared while other symptoms 
remained. This shows, that it might be important to consider other possible reasons – like a weakened 
immune response or other patient specific factors that might affect the immune response - than 
Borrelia themselves for the chronic course of Lyme disease. It was found, that patients with 
haematological malignancies for example more frequently required retreatment [218]. This indicates, 
that these patients might have more problems to combat the bacteria and would be in line with what 
we observed in this patient. It remains to be investigated whether the continuous symptoms in this 
case have been due to Borrelia or the underlying CLL condition. 
 




6 CONCLUSION AND PERSPECTIVES 
 
 
Own experiences with recruitment of patients confirmed, that problems with the diagnosis of acute 
Lyme disease are real. Although diagnosis might be easy for experts in the field, it might be rather 
problematic for general practitioners that only rarely encounter these patients. The rather personal 
nature of the B cell repertoire hampered the isolation of a clear Borrelia specific B cell repertoire 
signature. Our data however indicate that an ongoing B cell immune response is detectable in the 
peripheral blood of acute patients at both the IgM and IgG levels. The question to solve in future 
projects will be to determine in what exact way information contained in these data are useful to 
support diagnosis. With the present project, we are able to provide a first insight into the composition 
of B cell repertoires of acute Lyme disease patients. Since many different B cell receptors can interact 
with the same epitope, we came to the conclusion that we first need to determine the sizes, diversities 
and specificities of antigen-reactive repertoires before being able to reliably extract signatures from 
the deep sequencing data. Once candidate signatures are identified, quantitative real time PCR might 
be more sensitive to detect the clones of interest in patient samples than next generation sequencing. 
Based on our findings, we don’t expect individual well defined clones to overlap between different 
patients. The signatures that we are looking for seem way more complex than initially imagined. We 
expect that more extensive repertoire analysis will lead to the extraction of a list of well-defined 
Borrelia-reactive B cell clones that might be separated from clones of other reactivities by the 
presence of key mutations at certain residues. Due to the rather dynamic and private nature of the B 
cell repertoire, the presence of certain combinations of clones will probably be the signatures that we 
are looking for (Figure 55). We expect, that mutation levels and isotype compositions of individual 
clones present within the repertoire as well as their phylogenetic tree relationships [77,384,385] will 
allow to classify patients into different categories. We expect that a closer analysis of these parameters 
will allow to distinguish ongoing B cell immune responses from past infections and primary from 
secondary immune responses. We would for example expect more isotype mixed clones that are 
closer to the germline in a primary immune response as compared to a secondary one. If we manage 
to match precisely defined clones with certain antigens, we might use the B cell repertoire to 
distinguish chronic infections from autoimmune responses. This could be very helpful to understand 
the underlying causes of “chronic Lyme disease”. The B cell repertoire is a very attractive tool to be 
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explored in all cases for which direct detection of the pathogen within patient samples is not reliable. 
Due to its complex nature more extensive investigations are however required before we completely 
understand B cell immune responses at this level of detail. Bioinformatics and systems biology 
approaches are required to process the tremendous amount of information present in these data and 
will allow to extract only the relevant information. Before being able to develop sophisticated 
bioinformatics tools, one does however need to explore and understand the nature of these data. This 
is what we provide with the present project. Now will be the turn of the bioinformaticians to develop 
the necessary tools to more robustly validate our hypothesis (Figure 55). 
 
Figure 55: Schematic representation of how B cell repertoire data might be used in the future 
to support the diagnosis of acute Lyme disease. From our data, we concluded that there will be 
rather a large number of different Borrelia reactive clones and that only a subset of overlapping 
clones will occur in each patient. Of those, again only a subset will be sampled when taking blood. 
More extensive analysis of Borrelia reactive B cell repertoires will be required to extract specific 
clones of interest. Future diagnostic tests based on B cell repertoire data will determine the presence 
of these identified clones within the repertoires of patients. The polyspecific nature of the B cell 
repertoire will probably require the presence of more than one of these clones for the tests to be 
reliable. Primary, secondary, ongoing and past immune responses can be distinguished by 
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The questionnaires for high risk individuals have been setup by Anna L. Reye and the ones for the 
acute patients were adapted together with Josiane Kirpach. The ok from the ethics committee and 
data protection agency have already been obtained prior to the start of Josiane’s PhD. 
 
8.1.1 Fragebogen Risikogruppe „Neue Biomarker für Borreliose“ 
 
 
 männlich   weiblich     Geburtsjahr:.............................................................. 
Wohnort oder PLZ:...................................................       Beruf:.................................................................. 
 
Haben Sie bereits vorher an der Zeckenstudie der Abteilung für Immunologie des CRP-Santé teilgenommen?  
 
 Ja        Nein 
   
 
 
Berufsbedingt:...........................(Stunden pro Tag)   Privat: ...........................(Stunden pro Tag) 
 
 
 keine Zecke      1-5 Zecken      6-10 Zecken      11-20 Zecken      21-50 Zecken      51-100 Zecken      
>100 Zecken      
 
1. Allgemeine Angaben 
2. Durchschnittliche Aufenthaltsdauer im Freien von März bis Oktober (Zeckenaktivitätsperiode) 





 keine Zecke      1-5 Zecken      6-10 Zecken      11-20 Zecken      21-50 Zecken      51-100 Zecken      
>100 Zecken    
 
Wann stellten Sie den letzten Zeckenstich bei sich fest?..................................................................... ....................... 
   
 
 Zeckenabwehrmittel     Körperinspektion nach Aufenthalt in Zeckengebieten   
 Frühes Entfernen festgebissener Zecken    Kleidung als Schutz  
 Andere (genaue Angaben)......................................................................................................................................  
 
 
 Ja, für ca. ............. Tage     Nein 
 
 
 Ja  Nein 
 Erythema migrans (Wanderröte)    Neuroborreliose          Lyme Arthritis 
 Acrodermatitis chronica atrophicans    andere: ............................................................................... 
  
Wann wurde die Diagnose erstellt? ........................................................................................... ................................. 
 
 
 Vollständige Heilung  
 Keine vollständige Heilung, verbliebene Symptome sind...................................................................................... 
 Therapie schlug fehl, verbliebene Symptome sind................................................................................................. 
 
Weitere Kommentare: ................................................................................................................................................ 
 
8.1.2 Questionnaire groupe à risque „Nouveaux biomarqueurs pour la borréliose“ 
 
4. Wie viele Zeckenstiche stellen Sie jährlich an sich fest? 
5. Ergreifen Sie regelmäßig Präventionsmassnahmen? (Mehrfachnennungen möglich) 
6. Beobachten Sie die Einstichstelle nach Entfernung der Zecke? 
7. Wurde bei Ihnen bereits Lyme Borreliose diagnostiziert? Wenn ja, in welcher Manifestation? 





 masculin     féminin      Année de naissance : ................................. 
Domicile ou code postal : ...................................................  Profession : ............................................ 
 
Avez-vous déjà participé auparavant à l’étude sur les tiques du Département d’Immunologie du CRP-Santé? 
 




Raisons Professionnelles : ......................... (Heures/jour) et/ou       Privées : ................... (Heures/jour) 
 
 
 Aucune tique      1-5 tiques      6-10 tiques     11-20 tiques      21-50 tiques     51-100 tiques      
 >100 tiques 
   
 
 Aucune piqûre      1-5 piqûres      6-10 piqûres     11-20 piqûres      21-50 piqûres     51-100 piqûres      
 >100 piqûres     
   
Quand avez-vous remarqué votre dernière piqûre de tique ? .............................................................................. ....... 
 
 
 Utilisation de répulsifs à tiques                Inspection corporelle après un séjour en plein air 
 Enlèvement précoce des tiques fixées               Port de vêtements adaptés (couvrants)   
 Autres (indications précises) .................................................................................................................................. 
 
 
 Oui, pendant environ ............... jours     Non 
 
1. Données générales 
2.  Durée moyenne de séjour  à l’air libre pendant la période de mars – octobre (période d’activité des tiques) 
3.  Sur une période d’un an, combien de tiques avez-vous détecté sur votre corps ? (y compris les non fixées) 
4.  En moyenne, combien de piqûres de tiques avez-vous eu par an ? 
5.  Est-ce que vous adoptez régulièrement des mesures préventives ? (plusieurs réponses sont possibles) 





 Oui  Non 
 Érythème migrant      Neuroborréliose           
 Arthrite de Lyme      Acrodermatite chronique atrophiante (ACA) 
 Autres....................................................................................................................... ............................................... 
 
Quand avez-vous été diagnostiqué ? .......................................................................................................................... 
 
 
 Guérison complète 
 Guérison incomplète, les symptômes restants sont : .............................................................................................      
 La thérapie a échoué, les symptômes restants sont : ......................................................................... .................... 
 
Commentaires supplémentaires : ...............................................................................................................................  
 
8.1.3 Fragebogen bei Erstvorstellung 
 
 












 Wanderröte (Erythema migrans) 
 Bläulich-rote Verfärbungen der Haut 
 Schwellungen der Haut 
 Zigarettenpapierartig gefältete Haut 
 Ungewöhnlich dünne Haut 
 Durchschimmernde Gefässe 











 Aussergewöhnliche Müdigkeit 
 Schlafstörungen 











Sollten Sie an Hautveränderungen leiden, können Sie gerne ein Foto beilegen oder an unsere Emailadresse 
borreliose@crp-sante.lu schicken. 
7.   Avez-vous été diagnostiqué comme ayant la maladie de Lyme ? Si oui, sur la base de quelle(s) 
manisfestation(s)? 
8.  Avec quel succès a-t-on traité la borréliose de Lyme ? 









 Klinische Symptome  Serologie  Andere Tests: .................................................................................. 
 
 
Borrelia burgd. IgG: 
Borrelia burgd. IgG Index:  
Borrelia burgd. IgM:   





Bor. burgd. Blot IgG:  
 






Wenn möglich legen Sie bitte jetzt oder beim nächsten Termin eine Kopie Ihres serologischen Befundes bei. 
 
 
Medikament/Antibiotikum: ......................................... Therapiebeginn: .................  Dauer der Therapie: ................ 
 
 






 keine   1-5 Zecken   6-10 Zecken   11-20 Zecken   21-50 Zecken   51-100 Zecken  >100 Zecken      
 
 
 keine   1-5 Zecken   6-10 Zecken   11-20 Zecken   21-50 Zecken   51-100 Zecken  >100 Zecken      
 
2. Seit wann beobachten Sie die oben genannten Beschwerden? 
3. Wie wurde die Diagnose erstellt? 
4. Serologisches Ergebnis 
5. Therapie 
6. Durchschnittliche Aufenthaltsdauer im Freien von März bis Oktober (Zeckenaktivitätsperiode) 
7.  Bei welcher Beschäftigung haben Sie den meisten Kontakt zu Zecken? 
8. Wieviele Zecken sammeln Sie jährlich von sich ab? (inkl. noch nicht festgebissener Zecken) 




Wann stellten Sie den letzten Zeckenstich bei sich fest (ungefähr)?...................................................................... 
   
 
 Zeckenabwehrmittel     Körperinspektion nach Aufenthalt in Zeckengebieten   
 Frühes Entfernen festgebissener Zecken    Kleidung als Schutz  
 Andere (genaue Angaben)............................................................................................................................ .......... 
 
 















 Entzündungen des Gehirns 
 Lähmungserscheinungen 





 Wanderröte (Erythema migrans) 
 Bläulich-rote Verfärbungen der Haut 
 Schwellungen der Haut 
 Zigarettenpapierartig gefältete Haut 
 Ungewöhnlich dünne Haut 
 Durchschimmernde Gefässe 











 Aussergewöhnliche Müdigkeit 
 Schlafstörungen 












Sollten Sie an Hautveränderungen leiden, können Sie gerne ein Foto beilegen oder an unsere Emailadresse 
borreliose@crp-sante.lu schicken. 
 
10. Ergreifen Sie regelmäßig Präventionsmassnahmen? (Mehrfachnennungen möglich) 
11. Beobachten Sie die Einstichstelle nach Entfernung der Zecke? 
12. Hat Ihr Arzt bei Ihnen schon einmal eine Borreliose diagnostiziert? 


















Bitte beantworten Sie auch die folgenden Fragen, die im Rahmen einer anderen Studie der Abteilung für 
Immunologie von Bedeutung sind: 
 
 
 Ja und zwar ungefähr vor ..................... Jahren 
 Nein 
 Weiss nicht 
 
 
 Ja und zwar ungefähr vor ..................... Jahren 
 Nein 
 Weiss nicht 
 
8.1.5 Questionnaire première séance 
 
 
2. Seit wann treten die oben genannten Beschwerden auf? 
3. Therapie 
4. Weitere Kommentare 
5. Sind Sie schon einmal an Masern erkrankt? 
6.  Wurden Sie gegen Masern geimpft? 









 Inflammation du cerveau 
 Paralysie 
 Troubles sensoriels 
 
 
Manifestations sur la peau :  
 Érythème migrant 
 Décoloration rouge-bleuâtre 
 Enflure 
 Apparence craquelée rappelant un  
     papier de cigarette froissé 
 Peau anormalement mince 
 Vaisseaux sanguins transparaissant 




 Maux de tête 
 Symptômes grippaux 
 Raideur de la nuque 
 Troubles d’équilibre 
 Troubles de concentration 
 Troubles de la mémoire 
 Fatigue exceptionnelle 
 Insomnie 
 Changement de la personnalité,  


















 Symptômes cliniques  Sérologie  Autres tests: ...............................................................................................  
 
 
Borrelia burgd. IgG: 
Borrelia burgd. IgG index:  
Borrelia burgd. IgM:   





Bor. burgd. blot IgG:  
 










Médicament/Antibiotique: ................................... Début de la thérapie: ...................  Durée de la thérapie: ...................... 
2. Depuis quand observez-vous les symptômes susmentionnés? 
3. Comment la borréliose a-t-elle été diagnostiquée? 













 Aucune    1-5 tiques     6-10 tiques    11-20 tiques    21-50 tiques    51-100 tiques    >100 tiques   
  
 
 Aucune    1-5 tiques     6-10 tiques    11-20 tiques    21-50 tiques    51-100 tiques    >100 tiques   
   
Quand avez-vous remarqué votre dernière piqûre de tique (à peu près) ? ................................................................. ......... 
   
 
 Utilisation de répulsifs à tiques                Inspection corporelle après un séjour en plein air 
 Enlèvement précoce des tiques fixées               Port de vêtements adaptés (couvrants)   
 Autres (indications précises) ................................................................. ............................. ............................................ 
 
 





8.1.6 Questionnaire séances ultérieures 
 
 
6.  Durée moyenne de séjour à l’extérieur pendant la période de mars - octobre (période d’activité des tiques) 
7.   Durant quelle(s) activité(s) avez-vous plus de risque d’expositions aux tiques? 
8.  Sur une période d’un an, combien de tiques avez-vous détecté sur votre corps? (y compris les non fixées) 
9.  En moyenne, combien de piqûres de tiques complez-vous annuellement? 
10.  Est-ce que vous adoptez régulièrement des mesures préventives? (plusieurs réponses sont possibles) 
11.  Observez-vous l’endroit de piqûre après enlèvement de la tique? 
12. Est-ce que votre médecin a déjà diagnostiqué la borréliose chez vous dans le passé ? 









 Inflammation du cerveau 
 Paralysie 
 Troubles sensoriels 
 
 
Manifestations sur la peau :  
 Érythème migrant 
 Décoloration rouge-bleuâtre 
 Enflure 
 Apparence craquelée rappelant un  
     papier de cigarette froissé 
 Peau anormalement mince 
 Vaisseaux sanguins transparaissant 




 Maux de tête 
 Symptômes grippaux 
 Raideur de la nuque 
 Troubles d’équilibre 
 Manque de concentration 
 Troubles de la mémoire 
 Fatigue exceptionnelle 
 Insomnie 






























Veuillez répondre aussi aux questions suivantes, qui sont importantes pour une autre étude actuellement effectuée 
au Département d’Immunologie: 
 
 
2. Depuis quand observez-vous les symptômes susmentionnés? 
3. Thérapie 
4.  Commentaires supplémentaires 




 Oui, il y a environ ..................... an(s) 
 Non 
 Je ne sais pas 
 
 
 Oui, j’ai été vacciné il y a environ ..................... an(s) 
 Non 
 Je ne sais pas 
 
 
8.2 Conference participations 
 
11th - 12th September 2012 Life Sciences PhD days (Limperstberg, Luxembourg) 
Poster presentation: Exploring the Lymphocyte Repertoires of Lyme 
Borreliosis Patients as a Potential Tool for Epidemiology, 
Symptomatology and Diagnosis 
 
28th November 2012  SaarLorLux meeting (Nancy, France) 
Oral presentation: Exploring the Lymphocyte Repertoires of Lyme 
Borreliosis Patients 
 
15th - 16th November 2012 Antigen processing and presentation in health and disease 
(Dommeldange, Luxembourg) 
 
25th - 27th February 2013  AK B cell meeting (Schluchsee, Germany) 
 
13th - 14th June 2013  AK Vakzine Meeting (Freiburg, Germany) 
Oral presentation: Exploring the Lymphocyte Repertoires of Lyme 
Borreliosis Patients as a potential Tool for Epidemiology, 
Symptomatology and Diagnosis 
 
18th - 21st August 2013 13th International Conference on Lyme Borreliosis and Other 
Tick-Borne Diseases (Boston, USA) 
Poster presentation: From prevalence studies to the development of 
novel diagnostic tests for Lyme Disease 
 
02nd - 7th September 2013 ESF-EMBO Symposium with support from EFIS – B Cells from 
Bedside to Bench and Back Again (Pultusk, Poland) 
Poster presentation: Exploring the B cell Repertoires of Lyme 
Borreliosis Patients as a potential Tool for Epidemiology, 
Symptomatology and Diagnosis 
 
09th - 10th September 2013 Life Sciences PhD Days (Limpertsberg, Luxembourg) 




Oral presentation: Exploring the B cell Repertoires in Lyme Borreliosis 
Patients towards Personalized Medicine 
 
12th - 14th November 2013 13th Euroconference on Clinical Cell Analysis (Kirchberg, 
Luxembourg) 
Poster presentation: Exploring the B cell Repertoires in Lyme 
Borreliosis Patients towards Personalized Medicine 
 
22nd - 28th March 2014 Gordon Research Conference - Antibody Biology & Engineering" 
and "Antibody Biology & Engineering Gordon-Merck Research 
Seminar" (Lucca, Italy) 
Poster presentation: Evaluation of Borrelia specific CDR3 sequences 
as potential biomarker for acute Lyme Borreliosis 
 
11th September 2014  17th Saar-Lor-Lux workshop (Nancy, France) 
Oral presentation: Combining flow cytometry with next-
generationsequencing for identification of antigen-specific B cells in 
Lyme Borreliosis patients 
 
15th - 16th September 2014 Life Sciences PhD Days (Luxembourg, Luxembourg) 
Oral presentation: Combining flow cytometry with next-
generationsequencing for identification of antigen-specific B cells in 
Lyme Borreliosis patients 
 
17th - 20th September 2014 DGfI meeting (Bonn, Germany) 
Poster presentation: What can we read from the B cell repertoires of 
Lyme Borreliosis patients? 
 
27th - 30th September 2015 14th International Conference on Lyme Borreliosis and other tick 
borne diseases (Vienna, Austria) 
Poster presentation: The promises and challenges of analyzing the B 
cell repertoire of acute Lyme disease patients 
 
15th - 16th October 2015  AK Vakzine Meeting (Freiburg, Germany) 
Oral presentation: The promises and challenges of analyzing the B cell 
repertoire of acute Lyme disease patients 
 
12th - 13th November 2015 7th Annual Next Generation Sequencing Congress & 3rd Single Cell 
Analysis Congress (London, United Kindom) 
 
21st - 22nd September 2015 Life Sciences PhD Days (Belval, Luxembourg) 
Poster: Dissecting the B cell repertoire of acute Lyme disease patients 
 
25th - 27th April 2016 PhD School Luxembourg (COST Action FA1207) (Esch-sur-Alzette, 
Luxembourg) 









Update of bookchapter: Josiane Kirpach, Claude P. Muller (2015), Epitopes. Encyclopedia of Life 
Sciences 
 
Sally Cutler, Nataliia Rudenko, Marina Golovchenko, Wibke J. Cramaro, Josiane Kirpach, Sara 
Savic, Iva Christova, Ana Amaro (2016), Diagnosing Borreliosis. Vector Borne Zoonotic Dis. 
 
 
Currently we have three manuscripts in preparation to which Josiane Kirpach has contributed and 
where she will be among the first few authors. Please find below the current running titles of the 
concerned manuscripts: 
 
Detection of a low level and heterogeneous B cell immune response in peripheral blood of acute 
Lyme disease patients with next generation sequencing. Kirpach et al. in preparation. 
 
Using in vitro stimulation to isolate memory B cell receptor sequences reactive towards common 
antigens and determination of their levels in B cell repertoire deep sequencing data. Kirpach et al. in 
peparation. 
 
Next generation sequencing reveals a constrained viral quasispecies evolution under crossreactive 
antibody pressure. Kirpach et al. in preparation. 
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